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Background: Fatigue is a complex, multifactorial and multidimensional phenomenon, which has 
been described as a persistent overwhelming sense of tiredness, weakness, or exhaustion. It is the 
third most common concern for patients with inflammatory bowel disease (IBD), experienced by 
44-86% of patients with active disease and 22-41% of patients in remission. Fatigue can have a 
significant negative impact on patients’ quality of life (QoL). The aetiology of fatigue is not well 
understood. Interventions for IBD-fatigue are scarce, demonstrating limited benefit, and have not 
been implemented into clinical practice. The development of a theoretically-driven intervention 
to improve fatigue is a primary need for this population. 
 
Methods: The overall aim of the study was to develop a complex intervention for the management 
of IBD-fatigue and test its feasibility and potential efficacy. Guided by self-regulation theory and 
the Medical Research Council framework for development, feasibility and piloting phases, four 
steps were conducted in an iterative process. A systematic review study (Paper 1), identified 
aetiological modifiable factors which had already been or could be targeted by health 
interventions to improve IBD-fatigue. A quantitative cross-sectional study (n = 182) (Paper 2), 
evaluated the potential relationship between the identified modifiable cognitive-behavioural 
factors and IBD-fatigue. Patient and public involvement activities informed the adaptation of a 
cognitive-behavioural therapy (CBT) intervention for multiple-sclerosis fatigue to IBD-fatigue. 
Lastly, a two-arm pilot randomised controlled trial (RCT) with a nested qualitative study (Papers 
3 and 4) assessed the feasibility and initial estimates of efficacy of a CBT manual with 8, weekly 
therapist telephone session (n = 15) vs. a fatigue information sheet without help (n = 16).  
 
Results: Initial estimates of efficacy with per protocol analysis showed a reduction in fatigue 
scores and an improvement in QoL scores at 3-months post-randomisation. The difference in 
change in scores between groups was significant for impact of fatigue. The intervention was 
acceptable to participants and feasible for therapists to deliver. Healthcare professionals working 
with IBD patients reported that the intervention would be broadly applicable but time, finance 
and training constraints may limit its implementation in routine clinical care. 
 
Conclusions: CBT for IBD-fatigue is feasible and has a potential for improvement of the impact 
of fatigue on daily activities. A large-scale RCT is needed to investigate the size and longevity of 
treatment gains and the cost-effectiveness of the therapy. Incorporating changes to the protocol 
and developing an online intervention may be an effective way to overcome the barriers to 
implementation identified by healthcare professionals and test the generalisability of the 
intervention to IBD-clinical practice.  
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1. Introduction  
1.1. Background to inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD) mainly encompasses two related but distinct conditions of the 
gastrointestinal tract, ulcerative colitis (UC) and Crohn’s disease (CD) (Silverberg et al., 2005). 
UC is characterised by diffuse mucosal inflammation limited to the rectum and colon. Disease 
extent can be broadly divided into distal and more extensive disease. Distal disease refers to colitis 
limited to the rectum (proctitis) or rectum and sigmoid colon (proctosigmoiditis). More extensive 
disease includes left-sided colitis (up to the splenic flexure), extensive colitis (up to the hepatic 
flexure), and pancolitis (affecting the whole colon) (Dignass et al., 2012). CD is characterised by 
patchy, transmural inflammation, affecting any part of the gastrointestinal tract from the mouth 
to the anus. It may be defined by pattern of disease (inflammatory, fistulating, or stricturing) or 
by location (terminal ileal, colonic, ileocolic, upper gastrointestinal) (Van Assche et al., 2010, 
Baumgart and Sandborn, 2016). Lastly, inflammatory bowel disease unclassified (IBDU) is a 
diagnosis/classification for patients for whom the endoscopy is inconclusive and histology reveals 
chronic inflammation with absence of definite diagnostic features of either CD or UC (Silverberg 
et al., 2005). For most patients, IBDU represents a temporary diagnosis, as it has been estimated 
that 80% of them will be reclassified to either CD or UC within eight years (Meucci et al., 1999).  
 
1.1.1 Clinical features of IBD 
The cardinal symptom of UC is bloody diarrhoea, associated at times with abdominal pain, 
urgency, tenesmus and fatigue (Stange et al., 2008, Dignass et al., 2012). Its clinical course is 
marked by exacerbation and remission. About 10% of patients need a colectomy at some point in 
the disease trajectory (Solberg et al., 2009). Symptoms of CD are more heterogeneous, and 
usually include abdominal pain, diarrhoea and weight loss. Extra-intestinal symptoms such as 
fever, malaise, anorexia and fatigue are also more common. Furthermore, CD may lead to 
intestinal obstruction due to fistulae, strictures or abscesses, which may need to be addressed 
surgically to minimise the disease (Baumgart and Sandborn, 2016). Although the risk of surgery 
1, 5, and 10 years after diagnosis has decreased significantly over the past half a century (Frolkis 
et al., 2013), 70-80% of patients with CD may still require surgery within their lifetime, depending 
on disease severity and location (Burisch et al., 2013).  
 
1.1.2 Diagnostic investigations  
A single diagnostic instrument for the diagnosis of IBD is not available. The diagnosis is 
confirmed by clinical evaluation and a combination of radiological, endoscopic, histological, 
16 
and/or biochemical investigations, and the absence of alternative diagnoses (Hanauer and 
Sandborn, 2001, Kornbluth and Sachar, 2010). Imaging studies have a limited use in establishing 
diagnosis; computerised tomography and magnetic resonance imaging might show alterations in 
the small bowel but are not specific or sensitive enough to be diagnostic tools (Panes et al., 2013). 
Markers of inflammation such as erythrocyte sedimentation rate and C-reactive protein can be 
elevated or normal in patients with IBD (Menees et al., 2015). Faecal calprotectin, a protein 
detectable in stool that correlates with increased neutrophils in the intestine, can be utilised in 
ruling out a diagnosis, since patients with low faecal calprotectin have a less than 1% chance of 
having IBD (Sands, 2015). This biomarker has also been shown to predict persistent inflammation 
(Cerrillo et al., 2015, Yamaguchi et al., 2016) and risk of relapse (Molander et al., 2015, Ferreiro-
Iglesias et al., 2016). A full endoscopy with biopsies examined for histological features of IBD is 
the only way to establish the diagnosis of IBD with certainty (Annese et al., 2013). 
 
1.1.3 Disease activity vs. disease severity assessment  
Disease activity and disease severity in IBD refer to two distinct yet overlapping concepts. 
Disease activity reflects a cross-sectional assessment of inflammatory activity, whereas overall 
disease severity may include longitudinal and historical factors which give a more complete 
picture of the global burden of disease (Siegel et al., 2016b). Patients may have severe disease 
warranting aggressive therapies even if their disease activity is not severe at that point in time. 
However, placing a value on disease activity and severity is inherently difficult in IBD and is 
hampered by a lack of validated instruments with discrete thresholds. This is particularly 
problematic when considering that most treatment algorithms in IBD begin with classifying 
patients according to disease severity, and most therapies with regulatory approval are for use 
according to a patient’s disease severity at a particular point in time (Peyrin-Biroulet et al., 2013).  
 
No single IBD biomarker can accurately measure disease severity in IBD (Siegel et al., 2016a). 
Disease activity indices (DAIs) are therefore generally employed to quantify disease activity, 
clinical remission and response to treatment (Bojic et al., 2016). Numerous DAIs exist, but the 
most commonly used are the Mayo score (Schroeder et al., 1987) and the Simple Clinical Colitis 
Activity Index (SCCAI) (Walmsley et al., 1998) for UC and the Crohn’s Disease Activity Index 
(CDAI) (Best et al., 1979) and the Harvey Bradshaw Index (HBAI) (Harvey and Bradshaw, 1980) 
for CD. However, the relationship between gastro-intestinal (GI) symptom reporting and disease 
activity defined using objective measures of mucosal inflammation is poor. DAIs reflect symptom 
reporting behaviour rather than disease activity per se (Targownik et al., 2015, Gracie et al., 
2016). Furthermore, DAIs have been criticised for a lack of objectivity (Bojic et al., 2016), a low 
specificity and sensitivity of symptoms included, and for failing to capture the impact of disease 
from the patient’s perspective (Bodger et al., 2014).  
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Intestinal damage begins soon after onset of inflammation, sometimes in the absence of 
significant symptoms captured by DAIs. Moreover, IBD can have a significant impact on patients 
even when they are not experiencing symptoms, which are usually associated with active disease. 
There is hence the need to think beyond current clinical symptoms to include other factors 
important to the patient (Peyrin-Biroulet et al., 2016a). The development of validated and 
reproducible measures of IBD severity, accounting for current disease activity, assessment of 
cumulative bowel damage and quality of life (QoL) is essential (Peyrin-Biroulet et al., 2016b).  
Measuring disease severity using composite criteria that incorporate (a) impact of disease on 
patient (clinical symptoms, QoL, fatigue and disability); (b) inflammatory burden (disease 
activity and extent); and (c) disease course (structural damage, surgery, number of flares, and 
extraintestinal manifestations) (Levesque et al., 2015, Siegel et al., 2016b) may therefore be the 
most promising way forward.  
 
1.1.4 Epidemiology of IBD 
IBD is a lifelong condition, presenting in adolescence in 25% of the IBD population (mean age 
range at diagnosis is between 33.4 and 45 years; median age at diagnosis is 29.5 years) and follows 
an unpredictable relapsing and remitting course (Loftus et al., 2002). CD and UC have classically 
been thought to demonstrate a bimodal age distribution (i.e. with an incidence peak in the second 
and third decades of life followed by a second, smaller peak in the later decades), however recent 
epidemiologic studies (Jeuring et al., 2016, Sturm et al., 2016) have not uniformly found the same 
results. It may be suggested that these differences in age distribution are a representation of 
variations in diagnostic criteria and/or classification (Loftus, 2004).  
 
IBD occurs across the world but with considerable variations in both incidence and prevalence, 
both within and between geographic regions (Burisch and Munkholm, 2015). The highest 
incidence rates are found in Northern Europe (Burisch et al., 2013, 2014) and North America 
(Bernstein et al., 2006a, Loftus et al., 2007), with the illness being more common in industrialised 
than non-industrialised countries. IBD affects an estimated 2.2 million people in Europe (Cosnes 
et al., 2011). The overall prevalence of IBD in the United Kingdom (UK) is about 300 000, with 
incidence ranging between 8.8 to 14.3 UC and 5.6 to 8.6 CD patients per 100 000 population per 
year (Bardhan et al., 2010). Overall the incidence of IBD has considerably increased between the 
1950s and the 1980s (Logan, 1998, Loftus et al., 2007) and has subsequently continued to increase 
at a slower rate (Gunesh et al., 2008, Molodecky et al., 2012). To date the increase in incidence 
of both CD and UC in North America and Europe is fairly stable, however the prevalence of IBD 
is expected to increase further due to early age of onset and low mortality rates (Molodecky et al., 
18 
2012, Ng et al., 2017, Burisch et al., 2013). Conversely, since 1990, incidence has been rising in 
newly industrialised countries in Africa, Asia and South America (Ng et al., 2017).  
 
Several important diagnostic changes have been introduced in recent years, which may contribute 
to an apparent increase in IBD incidence. These include: advances in imaging techniques, changes 
in mode of diagnosis, optimisation of general practitioner (GP) referral routines and growth in 
awareness of disease (van den Heuvel et al., 2017). However, a recent retrospective study in Italy 
(Cantoro et al., 2017) has shown that although there has been a decrease in the proportion of 
patients with a diagnostic delay over 24 months, there has been no change in the median 
diagnostic delay of IBD in the last six decades. The median diagnostic delay was significantly 
longer in CD than UC, with more than one-third of patients with CD being misdiagnosed as 
irritable bowel syndrome (IBS). As a delay in the diagnosis of IBD has been found to be a risk 
factor for the development of complications and surgery (Schoepfer et al., 2013, Li et al., 2015), 
efforts should be spent to develop effective pathways for early detection of IBD.  
 
1.1.5 Risk factors for IBD 
The precise aetiology of CD and UC is not presently known (Lees et al., 2011). The chronic 
intestinal inflammation that characterises IBD results from a complex interplay between the 
immune system, the host genotype, and the intestinal microbiota. However, the currently 
identified susceptibility genes only account for a fraction of disease risk, with genetics explaining 
only 7.5% of disease variance (Jostins et al., 2012). This and the rising incidence of IBD 
worldwide underline the effect of environmental factors such as smoking which influence disease 
onset and progression. It is suggested that everyone is born with a certain genetic susceptibility 
for IBD and exposure to environmental factors in the Western lifestyle and living environment 
can reach a certain threshold, after which IBD is developed (van der Sloot et al., 2017). Identifying 
modifiable environmental factors is challenging, and whereas the summation of environmental 
factors may be crucial, each individual factor may confer only a modest risk (Maaser et al., 2017). 
Indeed, no single factor alone is sufficient for development of disease (Parkes et al., 2014, 
Ananthakrishnan, 2015, 2018). Furthermore, risk factors for IBD vary across countries. For 
instance, certain risk factors that are significant in developed countries may not have the same 
effect in developing Asian or Middle Eastern populations (Ng et al., 2014).   
 
Women and men are diagnosed in more or less equal numbers (Rubin et al., 2000, Ponder and 
Long, 2013). However, incidence is influenced by race and ethnicity. The risk of IBD is three-
fold higher in the Jewish population than in the non-Jewish population (Bernstein et al. 2006b), 
with Ashkenazi Jews being at particularly high risk. However, this could be an inflated incidence 
resulted from methodological issues in the prevalence study designs (Ekbom, 2004). Twin and 
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genetic studies have suggested a key heritable component for both CD and UC (Ananthakrishnan, 
2015). Between 2% and 14% of patients with CD, report a family history of the condition whereas 
a small proportion of CD patients will have a family history of UC. A similar proportion, 8–14%, 
of patients with UC will have a family history of IBD, more commonly UC. Consequently, the 
relative risk of developing IBD for first-degree relatives of a patient with CD is estimated to be 
around 5% in non-Jewish and 8% in Jewish patients, with the corresponding risk of UC being 
1.6% and 5.2%, respectively (Yang et al., 1993). If both parents were affected, the risk of the 
offspring developing IBD before the age of 30 years is estimated to be as high as one-in-three 
(Halme et al., 2006). In the future, results of studies such as the Genetic Environmental Microbial 
Project, following healthy individuals who are at a higher risk of developing disease over time, 
will aid in determining possible causes for CD.  
 
Meta-analytic data have quantified the increase in risk associated with smoking to be twofold for 
CD (Maaser et al., 2017, Mahid et al., 2006, To et al., 2016a). Since the 1980s, it has been 
established that cigarette smokers may be less likely to develop UC than non-smokers (Harries et 
al., 1982). However, the suggestion that smoking may improve the natural history of UC has 
recently been questioned. Smoking, when compared to non-smoking, does not appear to have any 
positive effect on colectomy rates, reduction in the rates of flare of disease activity, proximal 
disease extension, or the development of pouchitis in patients with UC included in a systematic 
review (To et al., 2016b). Given the high morbidity and mortality associated with smoking, it may 
therefore be a risk to advise patients on the benefits of smoking on disease outcomes in UC. For 
a large number of environmental factors possibly in IBD, meta-analyses are not available yet and 
the level of evidence provided by individual studies remains low. Therefore more studies are 
needed before firm conclusions and recommendations concerning adaptation of lifestyle and 
living environments to prevent and/or treat IBD can be given (van der Sloot et al., 2017).  
 
1.1.6 Societal and economic impact of IBD 
The impact of IBD on society is disproportionately high (Carter et al., 2004), with a hospital 
serving a population of 300 000 typically seeing 45–90 new cases per annum and having 500 
under follow up (Loftus, 2004). There is a small increase in mortality for both UC (hazard ratio 
[HR] 1.44, 95% confidence intervals [CI] 1.31 to 1.58) and CD (HR 1.73, CI 1.54 to 1.96), largely 
dependent on age and distribution of disease (Card et al., 2003). CD and UC cause substantial 
economic burden on the healthcare system, including both direct and indirect expenditures. IBD 
ranks as the first of the five most expensive GI disorders, despite being the lowest in prevalence 
(Stone, 2012). Direct medical costs include expenses for hospitalisations, physician services, 
prescription medicines, diagnostic procedures and specialised nursing care (Kappelman et al., 
2008). Indirect costs are the value of lost earnings or productivity; they may include the value of 
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leisure or time lost. Indeed, employed patients with IBD, even when in complete clinical 
remission, report experiencing decreased productivity significantly more frequently compared to 
controls (Zand et al., 2015). Furthermore, the cost of IBD has increased over the past decade due 
to the changing cost-drivers of disease management. The evolution of treatment for CD and UC 
with the approval of the more effective but more costly tumour necrosis factor (TNF) inhibitors 
has changed the landscape of treatment and cost for IBD (Mehta, 2016). Whereas anti-TNFs have 
decreased acute care costs, including hospitalisations and emergency visits, they have 
substantially increased pharmacy utilisation costs (Park et al., 2016).  
 
The high manufacturing costs and long duration of development have been identified as the main 
contributors to the high cost of biological medicines. For this reason there has been a recent switch 
from originator biological medicines to biosimilars, which are usually priced 15-30% below their 
reference products in Europe. A biosimilar is a biological medicine that enters the market after 
the expiration of the patient of an original reference product and shows no clinically meaningful 
differences in terms of quality, safety and efficacy when compared to the reference product 
(Gecse et al., 2013). Two infliximab biosimilars are currently approved in Europe for use in both 
CD and UD. The increasing use of these drugs and the possible addition of further biosimilars in 
the future may likely change the landscape of biologic agents in IBD and the consequent cost 
expenditure in IBD (Danese et al., 2015).  
 
1.1.7 Overview of drugs for the management of IBD  
Over the last decade, several new drugs have been introduced for the treatment of UC and CD. 
Therapy for IBD is a rapidly evolving field, with many new biological agents under investigation 
that are likely to change therapeutic strategies radically in the next few years (Mowat et al., 2011). 
UC is conventionally managed with a step-up algorithm that considers disease activity and 
response to treatment. 5-aminosalicytic acid compounds (5-ASAs) comprise the base of the 
therapeutic pyramid followed in sequence by corticosteroids, immunosuppressives and biologics 
(Chande et al., 2015a). Similarly, current guidelines for CD recommend a step-up strategy 
consisting of progressive intensification as disease severity increases. Less toxic drugs are used 
in mild disease, whereas more efficacious but more toxic drugs are employed in severe disease or 
in patients who are not responsive to first-line therapy.  
 
However, with the advent of biologics, a reversal of the traditional therapeutic pyramid (bottom-
up approach), with an early introduction of more aggressive drugs for CD has been advocated by 
some (Spurio et al., 2012). Conventional management of CD following a sequence of treatment 
from corticosteroids, to immunomodulators to biologics might not adequately control the 
underlying inflammation and could delay the start of the most effective treatment (Khanna et al., 
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2015a). The top-down approach aims to do more than just controlling symptoms (Colombel and 
Mahadevan, 2017). Indeed, symptoms are not necessarily indicative of endoscopic status in CD 
patients and may not be adequate criteria to guide adjustment of treatment to control mucosal 
inflammation (Colombel et al., 2017). Nonetheless, although the use of biologics as first line 
treatment may be ‘disease-modifying’, if patients fail to respond to biologics, it will be less likely 
for them to achieve remission with a second biologic agent or another drug, leaving fewer 
therapeutic options (Rogler, 2013). Overall, rather than applying a universal treatment strategy to 
all patients, severity of disease at presentation and/or biomarkers (Colombel et al., 2017) may 
ultimately guide therapy in newly diagnosed CD patients (Rutgeerts, 2012). A brief overview of 
the major drug options for IBD, following a therapeutic treatment pyramid (Figure 1) is presented 
below.  
 
Figure 1: Therapeutic pyramid for IBD management.  
Taken from Aloi, M., et al. 2014. Advances in the medical management of paediatric IBD. Nature Reviews 
Gastroenterology & Hepatology, 11(2), 99-108. 
Abbreviations: 5-ASA, 5-aminosalicylate; 6-MP, 6-mercaptopurine; AZA, azathioprine; MTX, 
methotrexate 
 
1.1.7.1 First line therapy (5-ASAs) 
5-ASAs can be delivered by oral tablets or as topical agents in the form of liquid or foam enemas 
or suppositories. They act on the gut epithelial cells by a variety of mechanisms to moderate the 
release of lipid mediators, inflammatory cells, cytokines and reactive oxygen species. The main 
role for 5-ASAs is maintenance of remission of UC (Sandborn and Hanauer, 2003). 
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1.1.7.2 Second-line therapy (Corticosteroids) 
Corticosteroids are potent anti-inflammatory agents for moderate to severe relapses of both UC 
and CD. They have no role in maintenance therapy for both diseases and act through inhibition 
of several inflammatory pathways. The efficacy of steroids should be balanced against the 
potentially severe side effects (Hanauer, 2002). However, the treatment of IBD active disease 
with steroids is often ultimately appreciated by the patients because it can relieve them rapidly 
from challenging symptoms (Schiro and Stein, 2015). Three broad groups of side effects can be 
identified: i) effects due to supra-physiological doses such as cosmetic, sleep and mood 
disturbance, dyspepsia or glucose intolerance; ii) effects due to prolonged use such as cataracts, 
osteoporosis, osteonecrosis, myopathy, sepsis and susceptibility to infection; iii) effects due to 
withdrawal such as adrenal insufficiency, myalgia, malaise and arthralgia. Enteral nutrition is 
increasingly used for remission induction in children with CD, to minimise the use of steroids 
(Connors et al., 2017).  
 
1.1.7.3 Third-line therapy (Immunomodulators) 
The main immunomodulators utilised in IBD are thiopurines and methotrexate. Thiopurines are 
designed to suppress the normal activity of the body’s immune system. They are widely used in 
IBD as adjunctive therapy and as corticosteroid-sparing therapies, although their slow onset of 
action precludes usage as sole therapy for active disease. Thiopurines are effective in steroid 
dependent UC, they are also effective maintenance therapy for patients who require repeated 
courses of steroids (Timmer et al., 2016). In CD, thiopurines are effective in both induction and 
maintenance of remission (Chande et al., 2015b). Nonetheless, adverse events occur in about 20% 
of patients taking thiopurines. The most common are allergic reactions, which occur soon after 
induction and cease rapidly subsequent to the drug being withdrawn. Leucopenia, bone marrow 
toxicity, hepatotoxicity, pancreatitis are rare (Derijks et al., 2006). Frequency of malignancies are 
reported in other patient populations on thiopurines (Buell et al., 2005), however these findings 
are not confirmed in patients with IBD (Ariyaratnam and Subramanian, 2014, Jess et al., 2014). 
Recently, thiopurine metabolite measurement can provide guidance when an adequate response 
is not reached, including if nonadherence is at issue (Dubinsky, 2004).  
 
Methotrexate is a folic acid antagonist which inhibits purine synthesis, deoxyribonucleic acid and 
ribonucleic acid formation, and suppresses inflammation in chronic inflammatory conditions 
through a complicated cascade (Alfadhli et al., 2004, Chande et al., 2014). Methotrexate is mainly 
utilised in CD and it is contraindicated in pregnancy because of the potential teratogenicity. 
Currently, it is recommended that females and males stop methotrexate therapy 3 months before 
planned pregnancy, and that methotrexate should not be used during pregnancy or breast feeding 
(Feagins and Kane, 2009). Methotrexate has been found to be superior to placebo for the 
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maintenance of remission at 40 weeks (Patel et al., 2014). While 25mg/week of intramuscular 
methotrexate provides benefit for induction of remission and complete withdrawal from steroids, 
lower dose oral methotrexate does not appear to provide any significant benefit relative to placebo 
or active comparator for CD (McDonald et al., 2012).  
 
1.1.7.4 Fourth-line therapy (Biologics)  
Biological therapies are designed to block or neutralise pro-inflammatory cytokines, which play 
a major role in the pathogenesis of IBD. The initial biologics licensed in the UK (infliximab, 
adalimumab and golimumab [UC only]) have been monoclonal antibodies against TNF. 
Infliximab is given as intravenous infusions; adalimumab and golimumab are given as a sub-
cutaneous injection. Two infliximab biosimilars are also approved in Europe (Danese et al., 
2015). Meta-analytic results have shown that both anti-TNF agents (infliximab and adalimumab) 
result in a higher likelihood of induction of remission and response compared to placebo in CD 
(Stidham et al., 2014a). Likewise, all anti-TNF agents (infliximab, adalimumab and golimumab) 
result in higher likelihood of induction of remission and response compared to placebo in UC 
(Stidham et al., 2014b). Currently, the choice of a biologic agent for the treatment of IBD is 
therefore primarily empiric and based on patient and physician preferences (Figure 2). In absence 
of comparative, head to head studies it is unclear whether any of these agents is more effective 












Figure 2: Biologic agents in IBD: a proposed algorithm for practice. 
Taken from Danese, S., et al. 2015. Biologic agents for IBD: practical insights. Nature Reviews of 
Gastroenterology Hepatology 12(9), 537-545. 
 
Abbreviations: anti-TNF, anti-tumour necrosis factor; IBD, inflammatory bowel disease  
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Despite established efficacy and safety of anti-TNF agents, they are not effective in one-fifth of 
individuals in whom they are administered (primary non-response) (Allez et al., 2010, Chowers 
et al., 2010). An additional one-third will eventually fail therapy (secondary loss of response) 
(Gisbert and Panés, 2009). Indeed, most of the current evidence does not give an indication of the 
expected efficacy of anti-TNF agents beyond one year. Findings have shown that 30.6% of 229 
UC patients had discontinued infliximab at three years due to adverse events or lack of effect 
(Reinisch et al., 2012). Similarly, sustained clinical benefit for adalimumab was observed only in 
61.5% of 168 CD patients during a median follow-up of 20 months (Karmiris et al., 2009). The 
overall risk of relapse after discontinuation of anti-TNF therapy has been found to be 44% for CD 
(912 patients) and 38% for UC (266 patients) (Gisbert et al., 2016). Unfortunately, no definite 
criteria that can predict response with these agents have been discerned to date, however assays 
are emerging that can reliably measure both antibodies to anti-TNF and circulating drug levels 
(Bernstein, 2015). Therapeutic drug monitoring makes it possible to determine if modifications 
to the drug regimen are required to increase concentrations or whether the patient should be 
switched to another treatment (Chaparro et al., 2011).  
Anti-TNF therapies share a similar profile of adverse events, including increased risk of infections 
from intracellular pathogens, most notably, tuberculosis, other opportunistic infections, 
autoimmunity, infusion reactions, and other more rare side effects. This should be balanced with 
the potential curative option of surgery in UC (Singh et al., 2011a, Mowat et al., 2011). In the 
future, biological therapies for both CD and UC will be used selectively based on personalised 
benefit/risk assessment and will be optimised throughout the course of treatment. Choice of 
therapy will depend on individual patient profiles, determined through reliable biomarkers and 
tissue signatures. Drug monitoring will be part of treatment optimisation (D'Haens et al., 2014).  
Vedolizumab is a gut-selective α4β7 integrin antagonist, which has recently been approved for 
use in IBD patients. It has a longer effect compared to anti-TNF agents. Results from the GEMINI 
clinical trials have demonstrated that vedolizumab met primary endpoints for improvement in 
clinical response at 6 weeks and for clinical remission at 52 weeks (Feagan et al., 2013, Sandborn 
et al., 2013). Specifically among patients who had previously failed anti-TNF, although efficacy 
rates were lower than when vedolizumab was used as first-line therapy, a higher proportion of the 
population given vedolizumab was in remission (26.6%) at 10 weeks than those given placebo 
(12.1%) (Sands et al., 2014). This suggests that vedolizumab could be considered an added 
therapeutic option in the treatment pyramid for patients who have failed other therapies. However, 
currently the lack of comparative efficacy studies, makes the efficacy-to-safety ratio difficult to 
establish (Regueiro et al., 2016). 
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Ustekinumab is a monoclonal antibody that neutralizes both IL-12 and -23. Ustekinumab has 
recently been approved by the National Institute for Health and Clinical Excellence in July 2017 
for the treatment of moderately to severely active CD, for adults who have had an inadequate 
response with, lost response to, or were intolerant to other therapies. Evidence from a Cochrane 
review (Khanna et al., 2015b) suggests that ustekinumab may be effective for induction of clinical 
improvement in CD. Since the publication of the Cochrane review, ustekinumab was tested in 
two induction trials, UNITI-1 and UNITI-2 (Feagan et al., 2016). Patients with moderately to 
severe CD receiving intravenous ustekinumab had a significantly higher rate of response than did 
those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a 
clinical response to induction therapy. Nonetheless, it remains unclear whether ustekinumab is an 
effective agent for induction of remission. Further longitudinal data are required to determine the 
long-term efficacy and safety of ustekinumab over time.  
 
1.1.8 Impact of IBD on patients’ lives 
In addition to taxing patients with a number of symptoms, IBD can exert a substantial impact on 
patients’ daily life, affecting work, personal relationships and education (O'Connor et al., 2013). 
Disease flares can be intense and the related physical symptoms, such as diarrhoea, abdominal 
pain and fatigue can significantly affect daily functioning. For most IBD patients, life-long 
pharmacological treatment is required, which is accompanied by side effects, which can be severe 
(Gearry et al., 2004, Stallmach et al., 2010, Schiro and Stein, 2015). Moreover, many patients 
require surgery, sometimes leading to a permanent ileostomy or colostomy. Finally, chronic 
immune suppression increases the risk of haematological malignancies and colitis is associated 
with an increased risk of colorectal cancer (Lukas, 2010). Thus, IBD affects patients' daily life 
due to physical impairments, lifelong surveillance, treatment side effects, its unpredictable course, 
and the risk of malignancy (Annese et al., 2015). 
 
Due to the severity of IBD, emotional burden and psychological distress is also common (Keeton 
et al., 2015), with prevalence of symptoms of depression and anxiety around 22% and 35% 
respectively (Neuendorf et al., 2016). Utilising self-report assessment, lifetime prevalence of 
depression and anxiety has been found to be about twice as high in IBD patients as in the general 
population (Walker et al., 2008). The aetiology of mood disorders in IBD appears to be 
multifactorial, with complex “brain-gut” interactions (Alarhayem et al., 2015). Studies typically 
report higher levels of depression and anxiety for those who have active disease compared to 
those in remission (Calvet et al., 2006, Ben et al., 2012, Gandhi et al., 2014, Panara et al., 2014). 
It is suggested that the symptomatic phase of IBD is associated with increased depression and 
anxiety together with increased intestinal expression of inflammatory cytokines. This supports 
the hypothesis that raised inflammatory cytokines may be responsible for the increased risk of 
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depression and/or anxiety-related symptoms (Martin-Subero et al., 2016, Abautret-Daly et al., 
2017). Furthermore, anti-TNF (Horst et al., 2015) and vedolizumab (Stevens et al., 2017) therapy 
have been found to lead to a reduction in disease activity scores and psychological symptom 
scores in patients with IBD. Conversely, patients on corticosteroids are more likely to experience 
adverse psychiatric effects (Fardet et al., 2007).  
 
Overall psychological disturbances have been associated with poor coping, more disease flare-
ups and non-adherence to medication (Goodhand et al., 2012, 2013). Likewise, depression and 
anxiety are associated with decreased health related QoL in IBD patients (Hyphantis et al., 2010, 
Iglesias-Rey et al., 2014). However, to date less than 40% of IBD patients with high levels of 
psychological comorbidities receive treatment for these mental health disorders (Evertsz et al., 
2012). As of 2014, only 24% of IBD services in the UK have access to a dedicated clinical 
psychologist (IBD Standards Working Group, 2013). Existing models of care for IBD rarely 
specifically address the psychosocial aspects of the disease, typically operating within the 
biomedical model, where physical and psychological services are run independently of each other 
rather than being integrated into comprehensive care to recognise the complex patient needs 
(Mikocka‐Walus et al., 2009, 2014).  
 
1.1.9 Implications for treatment of IBD 
Looking at data from large surveys in IBD, the most important treatment objectives from the 
patient perspective have been found to be improving QoL (40.2%) and completely resolving the 
symptoms (33.3%), followed by avoiding surgery, preventing relapses, and avoiding stomas 
(20.5%) (Casellas et al., 2016). Overall, patients’ main expectation was for symptoms to be 
relieved by the treatment (Casellas et al., 2014). However, to assess the primary treatment 
objectives in IBD clinical trials, clinical or endoscopic indices are usually used and measures of 
QoL and symptom resolution based on patient reported outcomes are rarely considered 
(Hindryckx et al., 2015). In order to make treatment more effective it is therefore important to 
reconcile patient and clinician priorities. 
 
As IBD has an early life onset, a chronic nature and does not generally shorten lifespan, 
addressing how patients deal with their disease is an important aspect of care (Graff et al., 2009). 
Indeed, in line with the international expert consensus of the recent Therapeutic Targets in 
Inflammatory Bowel Disease (STRIDE) initiative (Peyrin-Biroulet et al., 2015) on appropriate 
evidence-based treatment targets for IBD, the ultimate goal of treatment is not only to achieve 
endoscopic remission but also to improve patients’ QoL. Manifestation of IBD cannot be fully 
accounted for by pathophysiology and it is important to have a biopsychosocial understanding of 
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illness where clinical outcome and disease exacerbation influence, and are strongly influenced by 
both biological and psychosocial factors (Bonaz and Bernstein, 2013). The simple management 
of inflammation does not necessarily impact upon the symptoms prioritised by the patients. As 
such, health-care professionals (HCPs) managing patients with IBD should aim to evaluate patient 
reported outcomes such as QoL, fatigue, work productivity, anxiety and depression, with the 
ultimate goal of improving patients’ lives (Williet et al., 2016).  
1.2 Fatigue in inflammatory bowel disease  
In addition to diarrhoea, IBD burdens patients with a number of other symptoms (Singh et al., 
2011b). The main symptoms that most patients consider to be a priority are: abdominal pain, 
bowel movement urgency and diarrhoea, fatigue, rectal bleeding and IBS symptoms of pain, 
constipation and bloating (Casellas et al., 2016). Fatigue is the third most predominant concern 
for patients with IBD, experienced by 44- 86% of patients with active disease and 22-41% of 
patients in remission (Czuber-Dochan, 2013a). The IBD priority setting partnership between the 
James Lind Alliance and the British Society of Gastroenterology 
(http://www.jla.nihr.ac.uk/priority-setting-partnerships/inflammatory-bowel-disease) (Hart et al., 
2016) has therefore highlighted IBD fatigue as a top 10 UK research priority. Likewise, the 
development of fatigue management interventions has been identified as one of the top five 
research priorities in IBD nursing research in Europe (Dibley et al., 2017). Fatigue can have a 
significant negative impact on patients’ QoL (Cohen et al., 2014, Kappelman et al., 2014, 
Minderhoud et al., 2007, Norton et al., 2015). Symptoms of fatigue limit individuals in their 
everyday lives, both physically and socially (Beck et al., 2013). Although fatigue understandably 
increases during periods of inflammation, for some patients it persists when disease is in clinical 
and endoscopic remission (Kreijne et al., 2015).  
 
1.2.1 Definitions and assessment of IBD-fatigue  
An accepted and sufficiently accurate definition of fatigue would be the first step towards 
achieving the further aims of detecting fatigue and increasing the available means of managing 
it. However, so far such definitions have proven elusive (Shen et al., 2006). Fatigue is often 
experienced in the general population (van’t Leven et al., 2010); it is usually transient and can be 
caused by a lack of sleep or high stress levels (Kant et al., 2003). In patients with chronic 
conditions fatigue is a complex, multifactorial and multidimensional phenomenon, which has 
been described as a persistent overwhelming sense of tiredness, weakness, or exhaustion (Dittner 
et al., 2004), that can be mental, physical or both (Arnett and Clark, 2012). Unlike everyday 
tiredness, fatigue is often unrelieved by adequate sleep or rest (Cella et al., 1998). 
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Despite the pervasiveness of fatigue as a chief complaint in IBD patients, it is often only identified 
and treated in a relatively small proportion of those affected. Several factors may contribute to 
this tendency. Fatigue is typically underreported and IBD patients who do report fatigue 
symptoms often feel unsupported, with their reports of fatigue being ignored (Czuber-Dochan et 
al., 2013b). Fatigue is ultimately a subjective experience, and thus difficult to measure (Dittner et 
al., 2004). There is no objective ‘gold standard’ to measure fatigue (Shen et al., 2006). In a 
systematic review of the literature looking at fatigue in IBD (Czuber-Dochan et al., 2013a), the 
18 studies included in the review attempted to measure fatigue utilising nine different scales, with 
many employing more than one scale. The Multidimensional Fatigue Inventory (MFI) and the 
Fatigue Impact Scale were the most frequently utilised scales. However, no rationale for using 
these was provided by study authors and both these assessment scales were developed in other 
chronic conditions and not specifically for patients with IBD. To date, only one scale, the 
Inflammatory Bowel Disease-Fatigue (IBD-F) has been developed and psychometrically tested 
specifically for this population (Czuber-Dochan et al., 2014a). Although it has been tested in only 
one study so far, condition specific tools reflect the needs and problems identified by patients 
themselves thereby potentially making findings more applicable to clinical practice (Norton et 
al., 2015). 
 
1.2.2 Impact of fatigue on patients’ life 
Although people with IBD report higher levels of fatigue when their disease is active, people 
describe struggling with fatigue even when in remission (Matini and Ogden, 2016). In a large 
scale European survey (Lönnfors et al., 2014), 50% of the respondents felt tired every day of the 
week during their last or current flare-up, and 95% at least one day a week. Between flare-ups, 
83% of respondents felt tired at least one day a week, 20% daily. Likewise, fatigue was the most 
common reason for being absent from work due to IBD. Fatigue can have a negative impact on 
the personal and social life, on the work and employment and the ability to think clearly of people 
with IBD. People report limiting or missing activities, social events and travel due to their fatigue 
(Czuber-Dochan et al., 2013b). They also have to put their life on hold and cancel holidays 
(Schoultz et al., 2016). Ultimately, fatigue can lead people to give up hobbies and activities 
completely. As people feel tired, they lose their willingness to go out and socialise with others 
(Wilburn et al., 2017). This can result in them being isolated with very little energy to form or 
keep up relationships (Schoultz et al., 2016). Fatigue has also been associated with impaired 
sexual activity, including both sexual function and desire (Rivière et al., 2017). At home people 
with IBD-fatigue can depend heavily on family support and at work they often require short 
breaks or naps in order to get them through the day. Their lack of energy can also influence their 
decision-making. For instance some people report deciding not to have any more children for the 
feeling of not being able to parent properly. For others their fatigue influences their decision not 
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to work, take an early retirement or change jobs. Additionally, fatigue can cause people to make 
mistakes both at work and in their personal lives and to struggle to cope with parental 
responsibility (Czuber-Dochan et al., 2013b). Indeed, some people report not being able to think 
as clearly and sharply as they wanted to a lot of the time (Woodward et al., 2016). 
 
Fatigue can impact people in different ways. For children and adolescents with IBD, fatigue can 
lead them to perceive themselves negatively, different to their peers. Their involvement with 
friends can lessen because of symptoms of fatigue (Nicholas et al., 2007). They also report 
absences from school during flares due to their fatigue (Devlen et al., 2014). Moreover, young 
people with IBD may feel compelled to disclose their illness to their friends due to a change in 
their social behaviour. Indeed, their lack of energy may result in a change in their behaviour that 
could not be otherwise explained (Barned et al., 2016). Women report feeling significantly more 
concerned by symptoms of fatigue compared to men (Pittet et al., 2017). For women with IBD, 
fatigue can limit them in their everyday life, socially, physically and at work. Fatigue makes it 
difficult to maintain the same level of social life as previously, hence often leading them to reduce 
their social networks to the closest family and friends. In terms of physical limitations, fatigue 
can contribute to women deliberately choosing not to exercise and avoiding physical housework 
activities such as cleaning and gardening. Women report concentration to be an essential problem 
which affects their work efficiency and their choice of tasks. Ultimately, fatigue can lead to 
feelings of anger, frustration, sadness, self-pity, worry, and grief. Furthermore, fatigue is often 
connected with feelings of a guilty conscience and powerlessness (Beck et al., 2013).  
 
In addition to causing distress as a symptom itself, people’s distress also stems from their 
perception that their fatigue is not taken seriously by HCPs (Czuber-Dochan et al. 2013b). People 
rarely have the opportunity to talk to their HCPs about their fatigue and during consultations the 
focus is mostly on bowel functioning and not on the impact of IBD on their QoL. Indeed patients 
report that they are made to feel as if their fatigue had to be accepted as an inevitable aspect of 
their IBD and there was nothing that could be done to change it (Czuber-Dochan et al. 2013b). 
People perceive that their fatigue is under estimated and no strategies to manage fatigue are 
offered by the UK National Health Service (NHS). Consequently, some report that NHS care 
would be improved by a holistic approach which incorporates also non bowel-related symptoms 





2. Critical analysis of methodology  
 
This chapter presents the methodology of this PhD project. An overall rationale for the study and 
the research questions that have been addressed is presented. A background on the current status 
in the methodology of complex interventions is subsequently provided. This sets the scene, 
explaining how the PhD project fits within the current field of complex intervention development. 
By purposively explicating known strengths and limitations in complex intervention design, the 
first part of this chapter justifies how the design of the PhD intervention resulted from an attempt 
to build upon these strengths and overcome these limitations. Subsequently, the second part of 
this chapter outlines the practical application of this knowledge to the methodological design of 
the study phases. As this is a methodology chapter and not a methods chapter, the specific 
methods of each phase of the study are not presented here but are described in the Methods section 
of each of the published four papers. As word count constraints imposed by published journals 
prevents an exhaustive explanation of the study processes, a more detailed account of the methods 
involved in each phase, together with justifications for their choice is presented at the end of each 
of the published papers. The intervention development process is presented at the beginning of 
Chapter 5, prior to the intervention protocol, published as Paper 3.  
2.1 Rationale for the study  
Evidence presented in Chapter 1 demonstrates that fatigue is a prevalent and predominant concern 
in patients with IBD and it has a significant impact on patients’ QoL. The aetiology of fatigue is 
not well understood by patients or HCPs, with evident implications for its management. To date 
interventions for IBD-fatigue are scarce, demonstrating limited short-term or no benefit, and have 
not been implemented into clinical practice. The development of a robust theoretically-driven 
intervention to improve fatigue is therefore a primary concern for this population. 
 
The overall aim of the study was to develop a complex intervention for the management of fatigue 
and test its feasibility and potential efficacy in patients with IBD. To achieve the overall study 
aim, a series of questions were posed.   
2.2 Research questions  
• Which potentially modifiable physical and psychosocial factors are associated with 
fatigue in patients with IBD?  
• Which available interventions for the management of fatigue have been identified and 
previously tested in patients with IBD?  
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• Which mechanisms of change are relevant, acceptable and useful when developing an 
intervention for the management of fatigue to patients with IBD? 
• What is the feasibility of an intervention for the management of fatigue in patients with 
IBD?  
• What is the feasibility of a trial protocol for delivering a full pragmatic randomised 
controlled trial (RCT) of an intervention for the management of fatigue in patients with 
IBD?  
• What are the initial estimates of efficacy of an intervention for the management of 
fatigue in patients with IBD?  
2.3 Methodological rigour in intervention development  
Although the importance of methodological rigour at the early stage of intervention development 
is now widely recognised (Craig et al., 2008), it has been suggested that there is continuous waste 
of research by developing interventions that never impact on healthcare (Chalmers et al., 2014). 
Much healthcare research is currently wasted because findings are unusable by clinicians for 
patients’ care (Glasziou et al., 2008, Chalmers and Glasziou, 2009) or to inform public health 
policy (Ahmad et al., 2010). Interventions shown to be efficacious at the trial stage, often prove 
to have diminished effectiveness when disseminated into the real world (Glasgow et al., 2012). 
Similarly, findings from studies that could be important for clinical practice are subsequently 
found impossible to replicate (Glasziou et al., 2008). This could signify suboptimal health 
outcome, poor return on investment and significant opportunity costs (Neta et al., 2015).  
 
The potential reasons that could explain these phenomena may relate to: a scarcity of interventions 
based on theories (Michie et al., 2005), a limited understanding of the causal assumptions about 
how interventions work (Moore et al., 2015), an inadequate reporting of intervention development 
(Hoffmann et al., 2014b, Hoddinott, 2015), and an insufficient use of intervention development 
frameworks for the development, testing, evaluation and implementation of interventions  
(Campbell et al., 2000). Summary of these problems and how they were overcome in this PhD 
project design in order to improve methodological rigour is summarised in Table 1 and further 
explained in this chapter.  
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Table 1: Issues compromising methodological rigour and proposed resolutions for the 
methodological design of the intervention. 
Identified problem  Proposed solution  
2.3.1 Scarcity of interventions based on 
theories 
Use of theory in intervention development   
2.3.2 Limited understanding of the causal 
assumptions about how interventions work 
Use of logic models  
2.3.3 Inadequate reporting of intervention 
development 
Use of reporting guidelines to report 
intervention development  
2.3.4 Insufficient use of intervention 
development frameworks   
Use of an intervention development 
framework   
 
2.3.1 Theory in interventions 
A theory is defined as a coherent and non-contradictory set of statements, concepts, or ideas that 
organises, predicts, and explains phenomena, events, and behaviour. Theories are useful in 
intervention development because they specify determinants of behaviour that are potentially 
amenable to change. Thus, theories inform us which variables should be targeted by interventions, 
namely – which variables should be manipulated in order to produce the desired change in 
behaviour (Eccles et al., 2005). The application of theory is advocated as an integral step in 
intervention design and evaluation and in evidence synthesis (Davis et al., 2015).  The 
development of interventions should be informed by a theory, and both intervention development 
and evaluation require a strong theoretical foundation with empirical support (Hardeman et al., 
2005, Michie et al., 2005). The intentional testing of theory in research helps to expand the 
knowledge base (Johnston and Dixon, 2008). The use of theory may help to explain how the 
intervention works (Glasgow and Emmons, 2007). Development and evaluation of complex 
interventions is challenging as a result of problems in identifying and separately assessing the 
effects of various components of the intervention (Blackwood, 2006). As such, by utilising a 
theory in the development process, interventions may target specific mechanisms of change, 
facilitating an understanding of what works across different contexts and clinical populations 
(Michie et al., 2008). Furthermore, theoretically identified mechanisms of action can be 
investigated to gain further understanding of how the intervention brings about its effects (Michie 
and Abraham, 2004, Rothman et al., 2004). Addressing these issues may ultimately improve the 
translation of research into practice (Michie et al., 2011). 
 
Specifically, the use of theory is recommended by the UK Medical Research Council (MRC)  
(Campbell et al., 2000) to provide hypotheses of specific mechanisms and interactions in complex 
interventions (Noar and Zimmerman, 2005, Siemonsma et al., 2010, Coryn et al., 2011) during 
the first phase of the development of interventions  (Campbell et al., 2000). This is particularly 
useful in interventions for long-term conditions that encompass several interacting management 
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strategies, which are difficult to evaluate and reproduce (Tougas et al., 2015). Indeed, evidence 
from long-term conditions, including diabetes (Zhao et al., 2016), cancer (Avery et al., 2013) and 
acquired immune deficiency syndrome (Protogerou and Johnson, 2014) shows that trials making 
use of theory tend to have better medical and psychological outcomes than those that did not. The 
use of theory assisted in the identification of theoretical constructs to target in the intervention 
and which participants to include in the study (Ayling et al., 2015). It also enabled the 
measurement of theoretical constructs pre and post intervention, allowing researchers to 
determine the intervention’s mechanism of action which can then help with further refinement of 
the theory (Michie and Prestwich, 2010).  
 
Nonetheless, it is difficult to define ‘use of theory’ and ‘theory informed’ interventions, because 
‘theory-based’ interventions could employ techniques that are not consistent with the underlying 
theory or use only parts of the theory. Furthermore, several reviews assessing the effect of the use 
of theory fail to consider how theory informed the intervention. These reviews only compare 
effect sizes between studies that explicitly report the theoretical grounding of the intervention 
versus those that do not. Guidelines for the transparent reporting of the use or non-use of theory 
would make it easier to unravel the extent of the problem. Overall, evidence regarding the 
association between the use of theory to develop interventions and resultant better outcomes is 
mixed (Prestwich et al., 2015). However, theory should still be used to aid in understanding 
complex mechanisms and interactions between components of interventions (Noar and 
Zimmerman, 2005, Siemonsma et al., 2010, Coryn et al., 2011). 
 
There are multiple theories available to develop interventions. A recent scoping review of theories 
of behaviour and behaviour change (Davis et al., 2015) identified 82 theories spanning across a 
myriad of behaviours (e.g. increasing physical activity, safe sex practices, smoking cessation). 
Another systematic review of behavioural theories (Kwasnicka et al., 2016) identified 100 
theories encompassing five main themes: motives, self-regulation, habits, resources and 
contextual factors. However, in the health behaviour literature (Davies et al., 2010, Glanz and 
Bishop, 2010, Prestwich et al., 2014, Davis et al., 2015), only some interventions describe using 
any theoretical framework or theory components to guide their development. The limited use of 
theory may be due to the fact that researchers do not consider the application of theory helpful or 
they may lack the skills to select or apply theory, especially given the lack of guidance in the area 
(Gainforth et al., 2015). Current recommendations to use theory early in the design of 
interventions do not specifically describe how to incorporate theory into the development process 
(Tougas et al., 2015). Moreover, there is heterogeneity in the distribution of frequency of, and 
approaches to, theory use (Davis et al., 2015). Processes by which theories are selected and the 
methods for measuring theoretical constructs are not well developed in the literature. Researchers 
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may “use” theory to varying degrees along a continuum, ranging from studies that are simply 
informed by theory, to those that apply or test theory more explicitly, to those that build and/or 
extend theory (Painter et al., 2008). More studies evaluating theory-based interventions are 
therefore required and encouraged (Avery et al., 2013). In order to overcome the limitations of 
interventions without a theoretical basis, theory was incorporated in the design of the PhD 
intervention. Further description of the chosen theory and the rationale for this choice is provided 
in Section 2.6.3 Step 2b: Identifying the appropriate theory.  
 
2.3.2 Logic models in interventions  
In addition to the use of theory in interventions, the UK MRC framework guidance for complex 
interventions (Moore et al., 2015) advises the use of logic models in order to clarify causal 
assumptions of the intervention. However, the use of logic models has only recently been 
recommended and is still relatively rare (Hawe, 2015).  A logic model can be defined as a graphic 
description of a system designed to identify important elements and relationships within that 
system (Anderson et al., 2011). This includes a graphical representation of the pathways from 
problem to intervention or individual intervention components to anticipated outcomes (Rehfuess 
et al., 2017). Logic models can help to conceptualise and handle intervention design complexity 
by i) making underlying theories of change explicit, including assumptions about causal pathways 
between the intervention and multiple outcomes, ii) depicting intervention components and the 
relationships between them, and iii) displaying interactions between the intervention and the 
system, within which it is implemented (Rohwer et al., 2017). Logic models add to theories of 
change in that they are used to outline programme components and check whether they are 
plausible in relation to the outcomes; they do not require the underlying assumptions to be 
specified (Clark and Anderson, 2004). Indeed, although it is useful for interventions to draw 
explicitly on existing theories, sometimes an intervention development can be driven also by other 
factors such as experience or common sense. Logic models can therefore allow researchers to be 
clear about what these additional assumptions are and how they fit alongside the chosen theory 
of change (Moore et al., 2015). In order to further strengthen the intervention design, a logic 
model for the intervention was included in the PhD project. A description of the model is provided 
in Section 2.6.4 Step 3: Modelling processes and outcomes (Figure 6, p. 58).  
 
2.3.3 Reporting of interventions  
To comprehend the results of an RCT, its design conduct, analysis, and interpretation has to be 
understood by the reader. This goal can be achieved only through total transparency from authors 
(Moher et al., 2001). Guidelines and checklists help individuals meet certain standards by 
providing sets of rules or principles that guide towards the best behaviour in a particular area. 
They are successfully and routinely used, often on a compulsory basis, in many areas of human 
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activity to prevent errors and omissions. Reporting guidelines have been developed to provide 
structured advice on how to report research studies in order to improve the accuracy and 
transparency of publications. They complement advice on scientific writing and journals’ 
instructions to authors, with some journals requiring the authors to adhere to the relevant selected 
guideline when submitting their manuscripts (Simera et al., 2010). In June 2008, the UK NHS 
provided funds to set up the EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research), an international initiative that promotes transparency and accurate reporting of health 
research studies. EQUATOR provides resources, education and training to facilitate good 
research reporting (Moher et al., 2008). Attempting to bring all available reporting guidelines 
under one roof to allow their easy identification and use, the EQUATOR website lists over 90 
reporting guidelines developed with the objective of improving the reporting of research studies 
relating to health. However, there are major differences in the scope, content and development 
processes of individual guidelines and there is currently no available tool for the evaluation of 
reporting guidelines (Moher et al., 2009). Despite, the extensive availability of these guidelines, 
a systematic choice of a guideline taking into account its characteristics, development process and 
robustness in their use in the editorial process is therefore still difficult.  
 
The two most utilised reporting guidelines for RCTs are the Consolidated Standards of Reporting 
Trials (CONSORT) statement (Moher et al., 2001) and the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) checklist (Chan et al., 2013). The 
CONSORT statement is an evidence-based minimum set of recommendations, consisting of a 
checklist, flow diagram and descriptive text, intended to facilitate the complete and transparent 
reporting of RCTs and subsequently aid in their critical appraisal and interpretation (Turner et al., 
2012).  Evidence suggests that use of the CONSORT guidelines is associated with an increase in 
the completeness of reporting of clinical trial full-texts (Turner et al., 2011, 2012) and abstracts 
(Mbuagbaw et al., 2014). The uptake of CONSORT is reflected in a number of metrics. 
Combined, the 1996 (Begg et al., 1996), 2001 (Moher et al., 2001) and 2010 (Schulz et al., 2010) 
publications of the CONSORT Statement and Explanation and Elaboration documents (Altman 
et al., 2001) have been cited more than 12,000 times (according to Scopus, May 2015), making 
CONSORT among the most highly cited biomedical publications of all time. Also an indicative 
measure of CONSORT uptake, is the support from major editorial organisations and its 
endorsement by more than 63% of high impact journals in medical specialties and general 
medicine (Shamseer et al., 2016). This includes a  large group of rehabilitation medicine Editors 
who signed up collectively to mandate the use of reporting guidelines in their journals in 2014 
(Chan et al., 2014b). 
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The SPIRIT checklist is a 33-item checklist of minimum recommended protocol items, which is 
intended to be used as a guide when preparing a protocol for a clinical trial. Similarly to 
CONSORT, the SPIRIT was developed to address unclear description of trial methodology in 
protocols (Chan et al., 2013). To date, a large number of groups have endorsed the SPIRIT 2013 
Statement including more than 50 journals, academic institutions, industry, trial groups and 
patient groups (Sarkis-Onofre et al., 2015). Most recently, the Template for Intervention 
Description and Replication (TIDieR) initiative has also introduced a checklist extension to 
SPIRIT and CONSORT to help researchers to more fully describe interventions, with the ultimate 
aim of improving their replicability (Hoffmann et al., 2014c). The TIDieR guide acknowledges 
that providing complete intervention descriptions may increase the word count and offers 
suggestions for how authors may manage this, including providing details in published protocols 
and online supplementary materials – which 75% of journals now have the capacity to host 
(Hoffmann et al., 2014a). Indeed, the study protocol can provide detailed information that is not 
available in the main published text. Its availability can therefore help to clarify unclear reporting 
and identify selective reporting within publications, as well as inform clinical practice and future 
research (Wieseler et al., 2013).  
 
Despite these promising findings relating to the use of reporting guidelines, adequate reporting of 
interventions is still not consistent across journals and the implementation of guidelines is still far 
from standardised (Shamseer et al., 2016). A systematic scoping review of adherence to reporting 
guidelines in healthcare literature reported that 43 of 50 reviews found that levels of adherence to 
reporting guidelines were suboptimal (Samaan et al., 2013). Likewise, a systematic review of 
studies investigating reporting improvements as a consequence of endorsement by journals of 
reporting guidelines other than CONSORT (Stevens et al., 2014), found that insufficient evidence 
exists to determine the relation between journals’ endorsement of reporting guidelines and the 
completeness of reporting in published health research reports. As CONSORT is the most 
extensively used reporting guideline, this may suggest there could be a significant variation in 
reporting according to the chosen guideline. Indeed, there is still wide variability in the 
information contained on journal websites on what to include in reports of trial methods, 
especially in relation to the intervention used or details of participants (Moher et al., 2016). 
Published reports of interventions often remain brief and vague (Tate et al., 2016), and focus only 
on results (Riley et al., 2008, Hoffmann et al., 2014b), with important processes and decision-
making in the early stages of intervention development being confined to grant proposals and 
PhD theses (Hoddinott, 2015). Some editors typically require only limited information on the 
theoretical basis of the intervention, and space constraints of published papers preclude a thorough 
description of the intervention components. When replicating or modifying existing interventions, 
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researchers and practitioners are therefore sometimes left guessing about the key components that 
made an intervention successful or unsuccessful (Tate et al., 2016).  
 
Additionally, despite their importance, protocols are not always publicly accessible (Chan et al., 
2014a). Some fields, such as psychology, document standardised interventions in treatment 
manuals. Treatment manuals describe the intervention theory, goals, and strategies, including how 
a programme should be organised and delivered, and the role and responsibilities of 
interventionists (Bond et al., 2000). However, a recent review of non-pharmacological RCTs 
found that such materials are infrequently (47%) published (Hoffmann et al., 2013). Alternatively, 
even when intervention manuals are available they vary greatly in the level of detail and style 
(Michie and Abraham, 2008). When interventions are complex, indicating they are built up from 
a number of components which may act both independently and interdependently (Campbell et 
al., 2000), reporting of intervention development involves more than enumerating a list of 
ingredients. The components, frequency, monitoring and mode of delivery may all influence 
efficacy. Thus, for research to be replicated and reliability adopted by HCPs and patients, a 
detailed description of the decision-making processes and a justification for the inclusion of each 
component of the intervention according to theoretically predicted mechanisms of action should 
be provided. Not only should the description of the intervention elucidate what works, but also 
how and ultimately why the intervention components interact to achieve the proposed change 
(Michie et al., 2011, Hoffmann et al., 2013, 2014b). In order to overcome limitations in 
intervention reporting, the protocol of the intervention was published (Artom et al., 2017; Paper 
3) and a justification of the inclusion of the intervention components following a framework for 
the development of complex interventions is described in Section 2.5 Application of the MRC 
framework to this PhD project.  
 
2.3.4 Intervention development frameworks  
Having identified the relevant components of the intervention using a theory, the next step is to 
develop an appropriate intervention. Indeed, problems often arise in the evaluation and 
implementation of complex interventions because researchers have not fully defined and 
developed the intervention (Campbell et al., 2000). The use of an intervention development 
framework can aid in this process. Frameworks are systems of concepts, assumptions, and 
theories organised graphically or narratively (Eccles et al., 2005) and in the context of 
unexplained heterogeneity of outcomes of trials of complex interventions, thorough attention to 
the different phases of intervention development can help researchers consider the causal 
assumptions of their intervention before initiating an RCT (Jonkman et al., 2017). However, not 
many intervention development frameworks have been published and confusion remains as to 
which framework to follow and which intervention development methods are more likely to be 
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most suitable for different types of interventions (Levati et al., 2016). As such, intervention 
development frameworks are not always used and definitive RCTs of complex interventions do 
not always undergo all the phases of development. Interventions are built instead on investigator’s 
interpretation of other empirical studies (Grimshaw et al., 2005).  
 
Developing an intervention without an intervention development framework is akin to exploring 
the clinical role of a drug, without understanding its pharmacology, the physiology of the patient 
being treated or the pathophysiology of the patients’ problem. It could be argued that this is an 
expensive version of trial-and-error with no system in place to anticipate success of the 
intervention and a low likelihood of being able to replicate the success of the intervention, if it is 
achieved (Eccles et al., 2005). Although going through the phases of a framework may seem like 
a lengthy and costly process, early observational and piloting studies require significantly less 
resources compared to the cost of multi-centre RCTs (Sturt et al., 2006). Full-scale trials may 
provide convincing evidence for the introduction of interventions in clinical practice. Ultimately, 
however, the interventions may prove to be inadequately prepared to be implemented in real-
world healthcare systems (Rowlands et al., 2005). In order to overcome the limitations of 
developing complex interventions without an intervention development framework, the 
development of the PhD intervention was guided by the use of a framework for complex 
interventions. Further description of the justification for the choice of the framework is descripted 
in Sections 2.4.4 and 2.4.5, further explanation of its application to this PhD project is described 
in Section 2.5. Application of the MRC framework to this PhD project.  
 
2.4 The Medical Research Council Framework for the development of complex 
interventions 
2.4.1 First version of the MRC framework  
The MRC framework was firstly published in 2000 (Campbell et al., 2000). This guidance was 
published in response to the difficulties faced by those attempting to develop multiple-component 
interventions and evaluate their impact (Datta and Petticrew, 2013). The first version (Figure 3) 
of the MRC framework (Campbell et al., 2000) presented a step-wise approach in five phases: 
pre-clinical (theory), modelling, exploratory, definitive RCT and long-term implementation 
phases. The pre-clinical (theory) phase aims to explore relevant theory to ensure best choice of 
intervention and hypothesis and to predict major confounders and strategic design issues. 
Evidence from the literature should be explored, for instance this may take the form of a review. 
It may also involve qualitative testing using interviews, surveys or observational studies with 
patients, HCPs and stakeholders about the studied problem. The modelling phase aims to identify 
the components of the intervention, how they fit together and the underlying mechanisms by 
which they will influence outcomes.  The exploratory phase is where the evidence gathered thus 
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far is put to the test, the recruitment procedures and intervention itself are piloted in practice, and 
the suitability of the outcome measures is assessed. Based on the results of the exploratory phase, 
a definitive RCT then evaluates the effectiveness of the complex intervention. This is then 
evaluated in the process evaluation phase, in order to explain discrepancies between expected and 
observed outcomes in the real world, to understand how context influences outcomes, and to 
provide insights to aid implementation of the intervention into clinical practice.  
 
Figure 3: Original Medical Research Council Framework for the development of complex 
interventions (Campbell et al. 2000). 
Despite its usefulness, the first version of the framework was criticised for a number of reasons 
including: neglecting the early phases of development and modelling work (Hardeman et al., 
2005), adopting a linear model of evaluation process and omitting to consider the context of the 
intervention when assessing efficacy in RCTs (Campbell et al., 2007). Firstly, although the 2000 
framework emphasises the importance of the phases of development and modelling, it lacks 
details on how these phases should be conducted (Hardeman et al., 2005). Specifically, 
researchers may encounter challenges when theories do not exist to guide intervention 
development or where the evidence or theory underpinning the intervention may need to be 
refined through the modelling phase itself (Corry et al., 2013). Secondly, using a linear stepwise 
approach, where phases of the intervention development are conducted sequentially, may not 
neatly lend itself to complex interventions involving multiple components and methods of 
enquiry. Indeed, in complex interventions there may be an overlap in certain processes, making 
it difficult to pre-determine a set order of phases (Massoud et al., 2016). Finally, the context of 
the intervention cannot be omitted. Understanding context is crucial both when designing 
interventions and when assessing whether an intervention that was effective in one setting might 
work in others. The context includes the wider socio-economic background, the health service 
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system, the characteristics of the population, the prevalence or severity of the condition studied 
and how these change over time. If the context is not taken into account, it is difficult to determine 
whether it is the intervention that did not work or whether it was applied to an inappropriate 
context (Craig and Petticrew, 2013, Campbell et al., 2007). The MRC framework in its 2000 
version advocates the use of RCTs as the primary method of enquiry. RCTs assess the efficacy 
of interventions within a particular context. By advocating the use of RCTs as a gold standard, 
the framework thus fails to determine whether outcomes would be transferrable and effective in 
other contexts outside the ones defined by the RCT (Blackwood et al., 2010). 
 
2.4.2 Second version of the MRC framework  
An updated version of the MRC framework (Figure 4), aiming to address previous limitations 
was published in 2008 (Craig et al., 2008). Attempting to address the issue of linearity, the 2008 
framework has a more flexible approach and conducts the first three phases simultaneously in an 
iterative process, to better understand the problem, the intervention and the evaluation (Massoud 
et al., 2016). Nonetheless, an order in the phases is still suggested. For instance, modeling and 
pilot testing of the intervention, should still precede the evaluation phase, to ensure the 
intervention has been developed to a point where it is expected to have a worthwhile effect and 
where the mechanisms by which this effect is generated are reasonably understood (Haji et al., 
2014). Likewise, in effort to resolve the issue of context, the new version of the framework 
proposed to supplement RCTs with other methodological approaches, including the use of 
qualitative research strategies (Blackwood et al., 2010). Qualitative strategies, utilised at various 
phases of the framework can help understand the role of contextual factors in producing outcomes 
(Nelson et al., 2015).  
 
Broadening its conceptualisation of complexity, the new version of the MRC framework 
conceptualises it as: i) the number of interacting components within the experimental and control 
interventions, ii) the number and difficulty of behaviours required by those delivering or receiving 
the intervention, iii) the number of groups or organisational levels targeted by the intervention, 
iv) the number and variability of outcomes, and v) the degree of flexibility or tailoring of the 
intervention permitted (Noyes et al., 2013). The framework therefore aims to guide researchers 
through these aspects of complexity in order to more effectively design and evaluate complex 
interventions (Blackwood et al., 2010).  
 
The updated MRC framework includes four phases: development, feasibility and piloting, 
evaluation and implementation. The current version of the MRC framework advises an iterative, 
stepped, structured and mixed-method approach rather than a linear approach. The intervention 
development phase of the framework involves the development of the intervention’s theoretical 
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rationale. This phase aims to identify underpinning active ingredients and how these are expected 
to interact with one another and with the context of delivery to generate outcomes. It includes 
identifying the evidence-base, identifying or developing theory, and modelling processes and 
outcomes. The feasibility and piloting phase includes testing the feasibility and acceptability of 
the proposed intervention and its evaluation methods. Further refinements may be made to the 
intervention theory after this phase to optimise the intervention design, logic model and the 
proposed evaluation design prior to testing effectiveness and cost-effectiveness. Once a well-
theorised intervention has been developed and feasibility questions addressed, RCTs are 
recommended in the evaluation phase to examine their effectiveness (and cost-effectiveness) 
whenever randomisation is practicable. Finally, in the implementation phase, studies are needed 
to address the scale-up of interventions into routine practice and whether they are still effective 
in the real world. The cumulative effect of these processes should be the generation of a strong 
theoretically-grounded intervention, providing greater confidence that outcomes observed during 
trials can be replicated in real-world settings, and which supports the ongoing cycle of developing 
and evaluation of complex interventions (Blackwood et al., 2010, Bonell et al., 2014, Fletcher et 
al., 2016).  
 
2.4.3 Ongoing limitations of the MRC framework  
Despite the MRC framework’s refined version published in 2008 (Craig et al., 2008), it is still not 
without limitations. The main criticism remains around the issue of context. Although the new 
version of the framework takes context more into account, questions remain concerning the 
demonstration of efficacy and effectiveness. The MRC in its 2008 version still makes no mention 
of considerations of context when discussing intervention development, and only brief mention 
of the role of contextual factors in modifying intervention’s effects (Moore and Evans, 2017). It 
is unclear if the health evaluation research should be studying the effect of the intervention per 
Figure 4: Revised Medical Research Council Framework for the development of complex 
interventions (Craig et al. 2008).  
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se, or the contextual factors that promote or inhibit its effectiveness, or both. While the MRC 
acknowledges that trials on their own may not be able to provide comprehensively definitive 
information, it still maintains the traditional assumption that interventions work or do not work 
based on their inherent quality, notwithstanding the context in which they are operationalised. 
There is thus the assumption that the reliability of the intervention is the key factor in its success 
or failure in everyday settings (Blackwood et al., 2010). Furthermore, the MRC’s definition of 
complexity (i.e. including several components), may not take context enough into account and 
may therefore be criticised for not necessarily being comprehensive. Indeed, it can be claimed 
that complexity is a characteristic of the system within which an intervention acts as well as being 
an inherent characteristic of an intervention itself.  
 
The issue of overlooking context is particularly relevant in the implementation phase of the MRC 
framework. The effectiveness of complex interventions, together with their success in reaching 
all its target populations, is significantly influenced by their implementation in a given context 
(Waters et al., 2011, Wells et al., 2012). Understanding whether such an intervention really makes 
a difference requires a conceptualisation of the intervention within its context of implementation 
(Pfadenhauer et al., 2017). Implementers of interventions are challenged by two conflicting 
demands: on the one hand, universal interventions are to be implemented with fidelity, on the 
other hand, these must be adapted to local needs and circumstances (Shortell et al., 2004). If 
interventions are conceptualised as attempts to disrupt mechanisms which perpetuate and sustain 
a problem in a given time and place, they cannot be understood in isolation from the systems 
whose functioning they attempt to change. Stakeholders therefore need to be continually involved 
in the development of complex interventions through intervention coproduction, ensuring that 
pertinent contextual influences can be sufficiently accommodated within theories of change, and 
that theories still retain their integrity in light of this context (Moore and Evans, 2017). In order 
to overcome the issue of overlooking context stakeholders, both patients and HCPs were involved 
throughout all stages of the intervention development and piloting. Further description of how 
this involvement was conducted is provided in Section 2.6.4 Modelling processes and outcomes 
and Section 2.7.1 Testing procedures.   
 
2.4.4 Comparing the MRC framework with other intervention development frameworks  
The main intervention development frameworks preceding the year 2000 included: Intervention 
Mapping (IM; Bartholomew et al., 1998), the PRECEDE-PROCEED model (Green and Kreuter, 
1999) and the RE-AIM framework (Glasgow et al., 1999). However, they tended to be oriented 
towards an individual behaviour change, provided little specific detail on intervention 
development or required great technical skills and resources (Wight et al., 2015). The PRECEDE-
PROCEED model, for instance, specified phases of needs assessment that mapped onto the first 
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phase of the MRC framework yet it does not cover the successive steps of modelling and piloting 
which are required to obtain the finished intervention product. Furthermore, despite providing a 
framework for programming behavioural changes, these changes may not be as straightforward 
when applied to symptom management in long-term conditions (Hardeman et al., 2005). 
Although useful, the RE-AIM framework is an evaluation model not an intervention development 
model (Glasgow et al., 1999). It hence focuses on phases 3 to 5 of the MRC framework 
(Hardeman et al., 2005), which go beyond the scope of the PhD project.  
 
Of the above frameworks, IM was possibly the most fitting for the needs of this project. IM was 
innovative at its advent as it provided a system for the integration of theory, empirical findings 
from the literature, and information from the target population in a systematic way. It has a visual 
component, including diagrams and matrices and iterative steps. Each step requires performance 
of several specific tasks leading to a product that provides the basis for the subsequent steps. The 
five key steps of the IM process are: i) creating matrices of proximal programme objectives from 
performance objectives and determinants of behaviour and environmental conditions, ii) selecting 
theory-based intervention methods and practical strategies, iii) designing and organising 
programmes, iv) specifying adoption and implementation plans, and v) generating an evaluation 
plan . IM originated in response to questions on how to use theory in intervention development 
(Kok et al., 2016). The MRC framework has been criticised for not providing detailed guidance 
on designing an implementation intervention (French et al., 2012). Some have therefore utilised 
the detailed guidance provided by IM in order to fulfil the criteria stipulated by the framework 
(Taylor et al., 2013). However, the creation of the matrices of change objectives can be time-
consuming and at times the information requires a large amount of reviewing, revising and 
refining (Pittson and Wallace1, 2011). For this reason, IM is typically applied to unidimensional 
behaviours, such as weight gain prevention and physical activity modification (Kwak et al., 2007). 
Moreover, IM originated in primary care prevention (van Oostrom et al., 2007). Its use was 
therefore deemed inappropriate to guide the development of an intervention addressing a 
multidimensional and multifactorial symptom like fatigue.  
 
2.4.5 Rationale for choosing the MRC framework for this PhD project  
To date the MRC framework is the most widely used guideline for the development of complex 
interventions (Corry et al., 2013). In a systematic review aiming to identify guidelines for 
intervention development and to examine how researchers have used guidelines when developing 
interventions (Corry et al., 2013), the only guideline reported to have been used in the 
development of interventions is the MRC framework with 9 of 14 papers that describe the 
development of an intervention reporting the use of this guideline. Five papers reporting the 
development of interventions did not refer to the MRC framework or specify the use of any other 
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framework to guide the development of the intervention. Similarly, in a UK scoping review 
aiming to identify and synthesise the available evidence relating to strategies and methods utilised 
to optimise complex interventions at the pre-trial stage (Levati et al., 2016), 17 of the 27 studies 
used the MRC framework. The studies used the 2000 framework, the updated 2008 version or a 
combination of the two. Conversely, the use of other frameworks is rare and heterogeneous, with 
no other framework utilised consistently for the development of complex health interventions.  
 
The choice of the MRC framework has likely become popular as its strength lies in its emphasis 
on modelling complex interventions based on theory, pilot testing active ingredients, and the 
iterative nature of the research process, which are essential in developing complex interventions 
(Haji et al., 2014). Although it does not guarantee success, the MRC framework sets standards 
for theoretical and methodological development within an RCT that could ultimately improve the 
intervention and it proposes developing the best intervention and the best evaluation methods at 
each step (Reelick, 2011, Redfern et al., 2006). The aim of the guidance was to draw attention to 
methods which are known to work, and make recommendations that could be supported by 
practical examples (Craig and Petticrew, 2013). In both its versions the MRC framework is clearly 
not perfect but there are currently no other frameworks for the development of complex 
interventions which provide such comprehensive, yet flexible guidance for researchers. For 
example, identifying the evidence base can help to ensure that the best choices are made regarding 
the intervention and proposed hypothesis, and highlights strategic design issues. The 
identification or development of the appropriate theory may lead to changes in the hypothesis and 
the identification of potentially useful structural organisations or components of the intervention 
prior to its development. Modelling may identify the potential vulnerabilities of an intervention 
and by testing out processes and outcomes researchers can overcome these vulnerabilities before 
a large-scale RCT (Reelick, 2011). In conclusion, whilst taking its limitations into account, it was 
therefore decided to utilise the MRC framework to guide this PhD project.  
 
2.5 Application of the MRC framework to this PhD project  
This PhD project stems from a body of work related to fatigue in inflammatory bowel disease 
(IBD) developed by researchers at King’s College London, University College London and 
Addenbrookes’ NHS Trust. A large, four-year study, conducted for Crohn’s and Colitis United 
Kingdom (CCUK) charity and funded by the Big Lottery Fund was undertaken between 2010 and 
2014. The project set out to examine the causes and nature of fatigue, pilot a fatigue assessment 
tool and explore interventions to improve its management in IBD. Prior to the beginning of this 
PhD project, the research team already completed: interviews with patients about their experience 
and management of IBD-fatigue (Czuber-Dochan et al., 2013b), interviews with HCPs to explore 
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their perceptions of IBD-fatigue and its impact on everyday life of people with IBD (Czuber-
Dochan et al., 2014b), a review of description and management of IBD-fatigue (Czuber-Dochan 
et al., 2013a) and the development (Czuber-Dochan et al., 2014a) and testing (Norton et al., 2015) 
of an IBD-specific fatigue assessment tool. An in-depth description of this work is beyond the 
scope of this chapter. However, the completion of these studies was crucial to the development 
of this PhD and it should therefore be taken into account when evaluating the choices made in 
this PhD. Specifically, in the first step of the process (identifying existing evidence), the bulk of 
knowledge about fatigue produced by these previous studies by members of the supervisory team 
made a significant contribution in shaping the starting point of this PhD. A clear distinction will 
be made between the work already completed prior to this PhD, the work that forms part of this 












Due to the previously discussed limitations of the first version of the MRC framework (Campbell 
et al., 2000), the second version of the framework was utilised to guide this PhD project. The 
revised version of the MRC framework (Craig et al., 2008) characterises the process of 
development through to implementation in phases which do not necessarily follow a linear 
sequence. This PhD project covers the first two phases: the development phase and the feasibility 
and piloting phase (Figure 5). Although, not strictly defined this way in the MRC framework 
original document, for the purpose of clarity, each phase has been sub-divided into steps. Utilising 
the MRC guidance as a starting point, the application of each step of the process to this PhD has 
been described in detail in this chapter. This included: the specific project aims associated with 
each step, the research questions answered by each step, the research methods chosen to answer 
the research questions in each step, the publication output/s associated with each step and the 
ways in which the outcomes produced by each step informed the other steps of the research 












(STEPS 1, 2 & 3) 
PILOT & FEASIBILITY PHASE 
(STEP 4) 
PAPER  1    PAPER 2       PAPER 3                       PAPER 4 
Figure 5: Overview of PhD project phases. 
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As this is a Methodology chapter, full results of the study steps will not be presented here. Results 
will be in the Results sections of the individual published papers. Only results which are relevant 
in feeding in to the next step of intervention development are reported. As the MRC framework 
has been criticised for sometimes lacking detailed direction on the design process (French et al., 
2012), when gaps in the framework guidance were identified, an effort was made to integrate it 
with information from other resources that could be of use. In order to guarantee transparency 
and allow for better development of future interventions, where issues with utilising the MRC 
framework to guide the development process that could not be resolved, these were highlighted 
and further discussed in the Discussion chapter of this PhD thesis.
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Table 2: Contribution of the stages of the MRC framework to the development of the intervention. 
 DEVELOPMENT PHASE FEASIBILITY AND PILOTING PHASE 
MRC steps  Step 1: Identifying the evidence-base  Step 2 a & b: Identifying components 
of the intervention and identifying 
appropriate theory  
Step 3: Modelling processes and 
outcomes  
Step 4: Testing procedures and 
estimating recruitment and retention 
Aims  
 
-To identify the evidence-base on 
interventions for fatigue in IBD  
 
-To use the theory to identify components 
of the intervention  
-To identify an appropriate underlying 
theory for the development of an 
intervention for fatigue in IBD  
 
- To use patient and HCPs 
perspectives to inform the adaptation 
of an intervention for MS-fatigue to 
IBD-fatigue  
 
- To test procedures of an intervention for 
the management of fatigue in patients with 
IBD 
- To estimate recruitment and retention of 
an intervention for the management of 
fatigue in patients with IBD  
Research 
questions 
-Which available interventions for the 
management of fatigue have been 
identified and previously tested in 
patients with IBD?  
-Which potentially modifiable physical 
and psychosocial factors are associated 
with fatigue in patients with IBD?  
 
-Which potentially modifiable physical 
and psychosocial factors are associated 
with fatigue in patients with IBD?  
 
-Which mechanisms of change are 
relevant, acceptable and useful when 
developing an intervention for the 
management of fatigue to patients 
with IBD? 
-What is the feasibility of an intervention 
for the management of fatigue in patients 
with IBD? 
-What is the feasibility of a trial protocol 
for delivering a full pragmatic RCT of an 
intervention for the management of fatigue 
in patients with IBD? 
- What are the initial estimates of efficacy 
of an intervention for the management of 
fatigue in patients with IBD? 
Methods  Systematic review  Quantitative cross-sectional study  
 
Patient and public involvement 
activity 
Pilot intervention testing with nested 
qualitative component  
Output  PhD Paper 1 PhD Paper 2 PhD Paper 3 PhD Paper 4 
Results   -Lack of psychosocial interventions for 
fatigue in IBD with long-term effects  
-Consistent significant associations 
between fatigue and disease activity, 
depression, anxiety and sleep difficulties  
-Lack of longitudinal studies exploring 
modifiable predictors of fatigue in IBD 
 
-Significant associations between fatigue 
in IBD and emotional, cognitive and 
behavioural factors drawn from self-
regulation theory  
- Significant associations between fatigue 
in IBD and emotional, cognitive and 
behavioural factors associated with 
fatigue in other long-term conditions  
-Intervention content acceptable and 
relevant to patients with IBD-fatigue  
- Need for IBD-specific examples 
- High readability level scores  
- Plain formatting  
- Completeness of outcome data measures, 
feasibility of delivery and acceptability of 
the intervention progression criteria were 
met 
- Recruitment and retention progression 
criteria were not fully met  
- HCPs found the intervention broadly 
applicable but identified time, finance and 
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training constraints in the implementation 
of the intervention  
- There was a significant difference in 
change of fatigue impact scores between 




- Need for further exploration of 
cognitive and behavioural factors 
associated with fatigue in IBD which 
could be targeted in interventions  
-Applicability of an intervention manual 
for fatigue in MS to patients with fatigue 
in IBD 
- Keep MS intervention manual 
content and structure, adding 
examples relevant to IBD 
- Lower readability level scores 
- Make formatting more acceptable 
to patients  
- Progression to large-scale effectiveness 
RCT with changes to the protocol  
- Need to include strategies to improve 
recruitment, withdrawal and loss to 
follow-up rates  
- Consider online interventions to reduce 
barriers to implementation  
Key: HCP – healthcare professional, IBD – inflammatory bowel disease, MRC – Medical Research Council, MS – multiple sclerosis, RCT – randomised controlled trial
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2.6 Development Phase  
The MRC guidelines advise substantial development work prior to the testing of the intervention. 
Indeed in the development phase of the MRC framework it is stated that before a full evaluation 
is conducted the intervention must be developed up to a point where a worthwhile effect can be 
expected. For the development phase the MRC advises to: identify the evidence-base, identify or 
develop theory and model processes and outcomes. Conducting a systematic review of what is 
already known about similar interventions and the methods that have been used to evaluate them 
is advised if there is no recent, high quality review available. Findings from this phase should 
then form the theoretical and empirical basis for developing an intervention.  
 
2.6.1 Step 1: Identifying the evidence-base - Paper 1 (Chapter 3) 
2.6.1.1 Existing systematic review evidence 
In order to identify the evidence-base for the intervention, the development process was 
commenced by: defining and understanding the problem and its causes, and clarifying which 
causal or contextual factors related to the problem are malleable and have greatest scope for 
change. Indeed, it is important to look at previous evidence and use relevant information to inform 
new trials (Sutton et al., 2009) and a recent review found that 94% of the trials funded by the 
National Institute for Health Research Health Technology Assessment programme used a 
systematic review to inform a new trial design (Bhurke et al., 2015). As such, existing systematic 
reviews on the topic of fatigue and IBD were firstly sought to define the problem and its causes. 
Systematic reviews aim to collate all empirical evidence fitting a pre-specified eligibility criteria 
in order to answer a specific research question. They use systematic and explicit methods with 
the purpose of minimising bias, hence providing more reliable findings that can lead to 
conclusions being drawn and decisions made. Systematic reviews can be used to explore 
variations in practice, confirm the appropriateness of current practice or highlight a need for future 
research (Higgins and Green, 2011). Identifying systematic reviews on fatigue and IBD was 
therefore considered an effective way to define the problem of fatigue in patients with IBD, 
understand the causes of fatigue in patients with IBD and appraise current intervention practice 
for the management of fatigue in patients with IBD. Two published systematic reviews were 
found (Czuber-Dochan et al., 2013a, Van Langenberg and Gibson, 2010). 
 
The first review by Van Langenberg and Gibson (2010) set out to examine the literature and 
determine the prevalence of fatigue in IBD patients. Ten studies were included in the review. 
Quantifying IBD-fatigue as a common problem that needs to be addressed, the review reported a 
prevalence of fatigue ranging from 28% to 41% in IBD in remission and up to 86% in moderate 
to severely active CD. All studies in the review were published between 2002 and 2009, showing 
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a recent rising interest in this symptom. The increase in publications also possibly suggested a 
growing recognition of the importance of its understanding and management for patients. 
Nonetheless, of the studies included in this first review, only one assessed fatigue in IBD patients 
as the primary outcome and in the rest the focus of fatigue was secondary to the main findings of 
the study. This indicated the need for the undertaking of more studies with fatigue as a primary 
outcome in order to have a greater understanding of the symptom. A significant positive 
relationship between fatigue and disease activity, and a significant negative relationship between 
fatigue and health related QoL were identified. These relationships highlight both the need to 
effectively manage disease activity in order to potentially improve fatigue and the need to 
effectively manage fatigue in order to potentially improve QoL in patients with IBD. Finally, the 
review discussed the central but incomplete association between inflammation and fatigue, and 
the need to look beyond inflammation to other factors in order to gain a full understanding of 
fatigue.  
 
The subsequent review (Czuber-Dochan et al., 2013a) aimed to establish what is known about 
how people with IBD describe their experience of fatigue, how it is managed and what factors are 
associated with the presence and severity of IBD-fatigue. It included 28 studies. The review 
reported a similarly high prevalence of fatigue in new studies since the publication of the previous 
review. The steady rise in prevalence of IBD-fatigue confirmed the need for fatigue-management 
interventions to be developed. Fatigue assessment with 9 different non-IBD specific scales, 
highlighted to need to design studies utilising IBD-fatigue specific scales in the future. The review 
reported multiple physical, psychological and situational factors associated with IBD-fatigue. 
These associations strengthened the view of fatigue as a multifactorial phenomenon which should 
be targeted through multidimensional interventions. Lastly, the review summarised the results of 
three pharmacological and two non-pharmacological interventions for the management of fatigue. 
Including the same pharmacological studies included in 2010 which did not utilise fatigue as a 
primary outcome, the review did not provide further information on pharmacological 
management for fatigue. Likewise, the small samples and effect sizes, and short term effects of 
the non-pharmacological trials provided no definitive conclusions on which non-pharmacological 
interventions should be pursued.     
 
2.6.1.2 The need for another review 
The two existing systematic reviews were helpful in defining and quantifying the problem by 
recognising the prevalence of IBD-fatigue, its significant negative effect of QoL and the 
consequent need to develop effective interventions for its management. The reviews recognised 
fatigue as a multidimensional and multifactorial phenomenon with physical, psychological and 
situational causal underpinnings and the need to address these though the combination of different 
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therapeutic approaches. Additionally, the sparsity of interventions for IBD-fatigue management 
with significant and long-term effects and the need to design more interventions for fatigue 
specifically was a clear outcome of both reviews. Nonetheless, some questions remained 
unanswered that raised the need for another systematic review to be conducted. The existing 
reviews identified multiple causal factors for fatigue. However, they did not differentiate between 
associated factors which were amenable to interventional modification and those which were not. 
Additionally, taking into account the growth in the number of studies between the first review 
search on June 30th 2009 (Van Langenberg and Gibson, 2010) and the second review search on  
August 3rd 2012, a search for new studies published after then was deemed necessary. Indeed, the 
value of a systematic review is optimised when it is kept up to date and evidence is continually 
evolving as new research becomes available (Moher and Tsertsvadze, 2006).  
 
A systematic review (Artom et al. 2016a; PhD Paper 1) aiming to systematically search and 
synthesise available evidence on potentially modifiable factors contributing to IBD-fatigue and 
what advances in the management of fatigue in individuals with IBD had been made was therefore 
undertaken. The review attempted to answer the following questions: i) What are the modifiable 
factors associated with presence and severity of IBD-fatigue? and ii) What are the modifiable 
factors, which have been previously targeted by interventions for the management of IBD-
fatigue? A systematic search for new studies published since the search of the previous review 
(Czuber-Dochan et al., 2013a) in August 2012 [n = 21] and a reselection of papers [n = 28] 
included in the previous review according to the aims of the current review were conducted in 
April 2015. The search included quantitative observational designs [case control, cohort, or cross-
sectional studies] and experimental studies (RCTs, quasi-experimental RCTs, non-RCTs, and 
pilot and feasibility studies). Following the MRC guidelines for the development phase of 
complex intervention development (Campbell et al., 2007), the present systematic review was 
therefore specifically designed to identify opportunities for intervention in fatigue research that 
could result in meaningful improvements in IBD-fatigue.  
 
As the aim of the overall PhD project was to develop an intervention for the management of 
fatigue in IBD, the identification of opportunities for intervention in the existing literature was 
considered a necessary step in order progress to the next step of identifying components of the 
intervention. Structuring the review into modifiable and non-modifiable physical and 
psychosocial factors provided a practical means to identify factors not amenable to interventional 
modification and factors to be potentially included in interventions to improve IBD-fatigue. 
Furthermore, it was thought to aid in establishing potential components of the intervention 
according to its modality (pharmacological or non-pharmacological). The inclusion in the review 
of IBD-fatigue management interventions aided the identification of existing therapeutic 
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strategies for fatigue which could be drawn on when developing the intervention. Lastly, it 
facilitated the detection of factors which had not been previously explored by existing studies but 
could be included in the intervention. A justification of how part of the results of the systematic 
review informed the next steps of intervention development is presented in Section 2.6.2. 
Identifying components of the intervention, however full results of the systematic review are 
presented in Paper 1 (Chapter 3) of this PhD thesis.  
 
2.6.2 Step 2a: Identifying components of the intervention - Paper 2 (Chapter 4) 
2.6.2.1 Using the systematic review results to identify components of the intervention 
The systematic review (Artom et al. 2016a) was utilised to feed into the Step 2a of the MRC 
framework and identifying components of the intervention. Indeed in order to obtain clear 
outcomes on the efficacy of the intervention, the rationale for inclusion of each component should 
be justified (Knowles et al., 2013a). Overall, the review showed an undue focus of existing IBD-
fatigue research on the relationship between IBD-fatigue and non-modifiable situational and 
physical factors. The majority of studies concentrated on factors including female gender, 
unemployment, disease type and surgery. Although they were less explored, the review 
encouragingly identified a number of modifiable physical and psychosocial targets for the 
development of the intervention. Chiefly, consistent significant positive associations were found 
between IBD-fatigue and emotional factors such as depression, anxiety and behavioural factors 
such as sleep difficulties. People who displayed higher levels of depression, anxiety, stress and 
sleep difficulties reported significantly greater levels of fatigue. Furthermore, the strong evidence 
to support association between fatigue and disease activity substantiated pharmacological 
treatment of underlying disease activity as the first line strategy for the management for IBD-
fatigue. In view of these findings, depression, anxiety, stress and sleep difficulties were selected 
as potential interventional targets of the intervention and were carried forward in the intervention 
development process. These were seen as particularly relevant in light of the systematic review 
evidence (Knowles et al., 2013a, McCombie et al., 2013, Gracie et al., 2017) to support the 
beneficial effects of psychological therapy on emotional and behavioural factors. Despite its 
importance, the medical management of disease activity was beyond the scope of this PhD 
project. The causal link between disease activity and fatigue was therefore taken into account in 
the next steps of the development process but did not form a part of the intervention. Patients who 
were experiencing an active flare of their IBD were not considered eligible for the intervention 
until treated.  
 
Adding to the observational data on modifiable psychosocial factors associated with fatigue, 
initial findings from studies of IBD-fatigue specific non-pharmacological interventions included 
in the systematic review suggested promising effects for solution-focused therapy following pilot 
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testing (Vogelaar et al., 2011) and at 6 months’ follow-up in a full-scale RCT (Vogelaar et al., 
2014). After the 7-sessions solution-focused therapy course focusing on coping styles for fatigue, 
participants showed a greater reduction in fatigue and improvement of QoL compared to the care 
as usual group. Yet, the effect was not maintained at 9 months. Small reductions of fatigue were 
also shown with individualised exercise behavioural advice (McNelly et al., 2016). Participants 
who received an individual 15-minute consultation with a personal trainer providing advice to 
initiate in physical activity levels had lower fatigue levels measured by the Inflammatory Bowel 
Disease-Fatigue (IBD-F) scale (Czuber-Dochan et al., 2014a)  compared to those receiving 
exercise placebo at end of treatment. However, there were no reductions in fatigue following 
exercise advice when using the Functional Assessment of Chronic Illness Therapy-Fatigue scale 
(Yellen et al., 1997), suggesting either limitations in the trial design and/or differential effects 
according to the specificity of the scale used. Together the mixed results from the above 
intervention studies (McNelly et al., 2016, Vogelaar et al., 2011, 2014) warranted further 
exploration of a psychosocial and/or behavioural intervention using more rigorous trial designs. 
The decision to develop a psychosocial intervention was therefore made.   
 
2.6.3 Step 2b: Identifying appropriate theory - Paper 2 (Chapter 4) 
2.6.3.1 Using the systematic review results to identify an appropriate theory for the intervention 
Once the decision was made to develop a psychosocial intervention including the emotional 
(depression, anxiety, stress) and behavioural (sleep difficulties) factors identified in the review, 
Step 2b was undertaken to identify an appropriate theory. The incorporation of a theory is 
recommended by the MRC guidelines (Craig et al., 2008). Advantages of using theory in 
developing complex interventions have been previously described in Section 2.3.1. Nonetheless, 
aside from advising to undertake a systematic review of existing interventions the MRC 
framework does not provide practical procedures to assist researchers in identifying appropriate 
theory (Wight et al., 2015). The choice of the theory is left to the expertise of the investigators, 
their research questions and their disciplinary perspective (Hawe, 2015). In order to overcome 
this barrier in choosing an appropriate theory, specific attention was thus given to theories which 
have been utilised for the development of psychosocial interventions for fatigue in other long-
term conditions. Drawing from interventions in other conditions can enhance the process of 
intervention development based on theory, without ‘reinventing the wheel’ (Lippke and 
Ziegelmann, 2008).  
 
Quantitative (Jones et al., 2009, Kwakkenbos et al., 2015) and qualitative studies (Czuber-Dochan 
et al., 2013b, 2015), and systematic reviews (Artom et al. 2016a) have shown similarities between 
the perceived experience of fatigue between different disease groups. Although physiological 
triggers may be different, similar physical and psychosocial factors appear to be exacerbating and 
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maintaining fatigue across long-term conditions (Czuber-Dochan, 2015). Likewise cognitive and 
behavioural responses to symptoms of fatigue, such as avoidance of activity and focussing on 
symptoms (Deary et al., 2007, Spence and Moss-Morris, 2007), are common across medically 
unexplained symptoms (i.e. pain, headaches, constipation). Lastly, there is growing evidence for 
transdiagnostic approaches for treating mental health symptoms related to fatigue, such as 
depression and anxiety (Newby et al., 2015). Utilising a transdiagnostic approach to fatigue 
management, where interventions are based on the same underlying theories, may therefore be a 
viable option to address common processes in the perpetuation of fatigue while still addressing 
issues specific to the individual conditions. Once perpetuating factors of fatigue across conditions 
have been identified, the individual predisposing and precipitating aetiological factors underlying 
the specific condition can be addressed (Chalder and Willis, 2017).  
 
2.6.3.2 Self-regulation theory (Leventhal et al., 1980) 
Many of psychosocial interventions for fatigue conditions which included emotional and 
behavioural factors in other long-term conditions (Gielissen et al., 2006, Hewlett et al., 2011, van 
Kessel et al., 2008) are based on self-regulation theory (Leventhal et al., 1980). Self-regulation 
theory provides a framework for describing and understanding processes relative to the initiation 
and maintenance of behaviours for the self-management of illness threats (Leventhal et al., 2016). 
Self-regulation theory states that the way people think about their illness can have a significant 
impact on the way they behave in relation to their illness and its associated symptoms. Self-
regulation theory proposes that patients develop illness perceptions in order to understand health 
threat. Illness perceptions can be subdivided into five core dimensions. Perceptions of i) the 
identity of the illness consisting of the label as well as the symptoms that are associated with the 
illness, ii) the causes of the illness, iii) the consequences of the illness, iv) the extent the illness 
can be controlled and v) the course of the illness and the duration of the symptoms (Leventhal et 
al., 2003). According to this theory, these illness perceptions then determine how people cope 
with their illness and therefore which emotions they experience and which cognitive and 
behavioural strategies they use to deal with their illness and associated symptoms. If people have 
more positive perceptions of their illness and their symptoms, they will cope better, experience 
more positive emotions and utilise more positive cognitive and behavioural strategies to deal with 
them. If people have more negative perceptions, they will not cope as well, they will experience 
more negative emotions and utilise more negative cognitive and behavioural strategies to deal 
with their illness (Hagger and Orbell, 2003). 
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2.6.3.3. Application of self-regulation theory in other long-term conditions 
Drawing from an example of a long-term condition which is similar to IBD in its inflammatory 
and relapsing and remitting nature, a model was developed to explain and improve fatigue in 
multiple sclerosis (MS) utilising self-regulation theory (Van Kessel and Moss-Morris, 2006). In 
the model, symptoms of fatigue activate perceptions of fatigue and a representation of the 
individual’s present condition is formed by integrating current fatigue symptoms and contextual 
information with these pre-existing beliefs. This representation guides the selection of coping 
behaviours (e.g. avoidance/resting, all-or-nothing behaviour). At the same time, the symptoms or 
cues trigger activation of emotional responses and awareness of these emotional responses 
prompts the selection and use of strategies for controlling these emotions. When the model was 
applied to an intervention for the management of fatigue, patients who undertook cognitive 
behavioural therapy (CBT) to modify fatigue-related negative cognitions and behaviours had 
significantly higher levels of fatigue reduction compared to patients doing relaxation therapy (van 
Kessel et al., 2008). Specifically, mediation analysis conducted after the trial (Knoop et al., 2012) 
confirmed that change in negative perceptions of fatigue mediated the change in fatigue as a result 
of the CBT. Thus, having more positive views about fatigue was closely related to the reduction 
of fatigue severity.  
 
2.6.3.4 Application of self-regulation theory in IBD 
Although self-regulation theory has never been applied for the understanding of IBD-fatigue 
specifically, an extensive evidence base exists to show that illness perceptions play a major role 
in the coping and adjustment of patients with IBD. Illness perceptions have been found to be 
associated with both general (Rochelle and Fidler, 2013) and disease-specific (Han et al., 2005) 
QoL. Patients who believe IBD would have serious consequences, those who do not perceive 
themselves to have control over their illness and those who think their illness will last for a longer 
time, display lower QoL scores (Rochelle and Fidler, 2013). Likewise, patients who perceive 
more symptoms to be part of their IBD have significantly worse IBD-related QoL (Han et al., 
2005). Disability has also been found to have a relationship with illness perceptions, with illness 
perceptions accounting for a significant percentage of the explained variance in IBD disability in 
addition to demographic and clinical characteristics (Dorrian et al., 2009, van der Have et al., 
2015). Furthermore, illness perceptions have shown to have a significant direct influence on 
depression, anxiety and family functioning (Knowles et al., 2011, 2013b). More negative illness 
perceptions are associated with the decreasing of activity, which in turn is related to lower levels 
of mental  and physical health, and greater activity and work impairment (van Erp et al., 2017). 
Lastly, illness perceptions have been associated with non-adherence to anti-TNF therapy. Patients 
who perceived their IBD to have a shorter duration and perceived fewer of their symptoms to be 
a consequence of their IBD displayed lower adherence (van der Have et al., 2016). Based on 
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evidence to support its use in the understanding of management of fatigue in other long-term 
conditions (Gielissen et al., 2006, van Kessel et al., 2008, Hewlett et al., 2011) and its previous 
application in the understanding of other IBD-related outcomes, a decision was therefore made 
on the use of self-regulation theory (Leventhal et al., 1980) for the PhD intervention. 
 
2.6.3.5 The need for a quantitative study 
Although quantitative evidence showed a consistent association between fatigue, emotional 
(depression, anxiety and stress) and behavioural factors (sleep difficulties), no quantitative study 
previously explored the association between fatigue and cognitive factors in IBD. Key elements 
of self-regulation theory applied to fatigue have therefore not been tested in the IBD population. 
Prior to proceeding to Step 3 (modelling) and developing the intervention utilising self-regulation 
theory, it was therefore crucial to establish the relationship between fatigue and cognitive and 
behavioural factors as demonstrated by self-regulation theory through a quantitative study. Given 
that altering unhelpful illness perceptions and cognitions can improve clinical and psychosocial 
outcomes in long-term conditions (Broadbent et al., 2009, Seyyedrasooli et al., 2013, Yan et al., 
2014), determining how cognitive-behavioural factors interrelated with those emotional, clinical 
and socio-demographic factors already known to predict fatigue in IBD, was considered the best 
way to test self-regulation theory and ultimately translate this research into an IBD-fatigue 
intervention.  
 
The MRC framework states that in order to understand what changes are expected and how 
change is achieved because of the intervention, a theoretical understanding of the processes of 
change is needed. If the available evidence is insufficient, this can be done by supplementing it 
with new primary research. New primary research was therefore undertaken to determine which 
cognitions, emotions and behaviours should be targeted in the intervention. A quantitative cross-
sectional study assessing factors associated with fatigue in patients with IBD was conducted 
(Artom et al. 2016b). Quantitative studies have been found to be important in designing trials to 
provide information on anticipated incidence in control groups, standard deviations when 
assessing continuous outcomes and choice of baseline characteristics for adjustment analysis 
(Djurisic et al., 2017). The overall aim of the study was to identify which physical and 
psychosocial factors were associated with fatigue in patients with IBD. The study included the 
physical and psychosocial variables associated with fatigue in the PhD systematic review (Artom 
et al. 2016a). Furthermore, the study included cognitive and behavioural factors which had been 
found to be associated with fatigue in other long-term conditions where interventions were 
available (Matcham et al., 2015, Chilcot et al., 2016, Skerrett and Moss-Morris, 2006), yet had 
never been previously explored in IBD. Specifically the study hypothesised that i) cognitive 
factors (illness perceptions and symptom beliefs) would be associated with IBD-fatigue 
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symptoms and IBD-specific QoL, ii) behavioural factors (resting behaviours, all-or-nothing 
behaviour, and daytime sleepiness) would be associated with IBD-fatigue symptoms and IBD-
specific QoL and c) emotional factors (depression, anxiety, stress and distress) would be 
associated with IBD-fatigue symptoms and IBD-specific QoL. Full results of the quantitative 
cross-sectional study are presented in Paper 2 (Chapter 4) of this thesis.  
 
2.6.4 Step 3: Modelling processes and outcomes – Paper 3 (Chapter 5) 
2.6.4.1 Using the cross-sectional study to model processes and outcomes of the 
intervention  
The cross-sectional study (Artom et al. 2016b; PhD Paper 2) was utilised to confirm that cognitive 
(illness perceptions and symptom beliefs), behavioural (resting behaviours, all-or-nothing 
behaviour, and daytime sleepiness) and emotional (depression, anxiety, stress and distress) factors 
associated with fatigue in other long-term conditions, were also associated with IBD-fatigue. One 
hundred and eighty-two participants were included in the study. In a hierarchical regression 
model, more negative fatigue perceptions were significantly associated with severity of fatigue. 
Likewise, more negative fatigue perceptions, all-or-nothing and avoidance behaviours were 
significantly associated with greater impact of fatigue on daily activities. Cognitive, behavioural 
and emotional factors explained an added 41% of the variance in impact of fatigue in addition to 
socio-demographic and clinical factors alone. As such, the overlap of cognitive and behavioural 
factors associated with fatigue between IBD and other long-term conditions suggested that self-
regulation theory could effectively be utilised for the understanding of IBD-fatigue and for the 
development of an intervention for its management.  
 
Based on the models using self-regulation theory in other long-term conditions (Skerrett and 
Moss-Morris, 2006, Deary et al., 2007) a cognitive behavioural model for breaking vicious cycles 
related to IBD-fatigue was developed (Figure 6). The logic model describes the inputs that the 
intervention involves, the processes that these initiate, and the mechanisms via which these are 
intended to realise positive outcomes. However, in attempt to develop a logic model it was found 
that the literature providing guidance on their development largely ignores how implementation 
and causal pathways may vary by context (Fletcher et al., 2016). Contextual factors are 
acknowledged in the model but the ways in which they interact with the rest of the factors remains 
unclear. A full description of intervention development is presented at the beginning of Chapter 
5 of this thesis.  
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2.6.4.2 The need for a Patient and Public Involvement activity   
In the MRC framework there is significant ambiguity about the optimal way to conduct the 
modelling phase. The proposed intervention has to be evidence-based and patient centred (i.e. in 
line with patient needs) (Vogelaar et al., 2011), yet there are no specific guidelines as to which 
theories should be utilised and/or how to collect patients’ views. A Patient and Public 
Involvement activity involving patients with IBD, researchers and HCPs working with patients 
with IBD was therefore conducted in order to design the intervention manual. Full details of how 
the intervention manual was developed are provided at the beginning of Chapter 5.  
 
2.7 Feasibility and piloting phase  
2.7.1 Step 4 – Testing procedures 
2.7.1.1 The need for a pilot study  
As evaluations are often undermined by problems of acceptability, compliance, delivery of the 
intervention, recruitment and retention and smaller than expected effect sizes, the MRC 
framework advises a piloting phase prior to the testing of a large-scale trial (Craig et al., 2008). 
Before rolling out a new intervention across a wide range of settings, intervention procedures 
should be evaluated for their acceptability, feasibility and efficacy. Depending on the results, 
further work may then be required to progressively refine the design of the intervention, before 
embarking on a full-scale evaluation. Beyond evaluative methodology, a pilot study can help the 
investigator examine the key uncertainties identified during the development of an intervention 
(Craig and Petticrew, 2013). A pilot study that clarifies aspects of the intervention’s instructional 
Figure 6: Proposed logic model for breaking vicious cycle of fatigue with intervention. 
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design can provide valuable data that the authors and other researchers in the field can use to test 
the proposed intervention components and mechanisms. Conducting a pilot study can reduce the 
proportion of failed trials and allow the progression of projects for which feasibility has been 
demonstrated and quantified (Leon et al., 2011). As such, the PhD intervention was tested in a 
pilot study prior to full-scale evaluation.  
 
The protocol for the pilot study was published as PhD Paper 3 (Artom et al., 2017). It is recognised 
that this departs from traditional views of “publishable” work (Haji et al., 2014); however, well-
constructed, articulate reports from pilot and feasibility phases are now viewed as worthwhile 
contributions by journal editors and other leaders in the field. Indeed, pilot data can be of practical 
utility for the PhD but also benefit the larger scientific community. Sharing pilot work experience, 
may provide solutions to problems that other investigators encounter as they pursue their 
respective research projects (Conn et al., 2010). Furthermore, publishing the protocol for the pilot 
study increases the transparency of the research process by providing a complete and detailed 
description of the intervention and how it was conducted. Making protocols publically available 
can allow a better appraisal of the quality of the study and ultimately reduce biased reporting 
(Chan et al., 2004).  
 
2.7.1.2. The need for a randomised controlled trial  
An RCT is recognised in the health and medical sectors as a gold standard for demonstrating the 
causal link between an intervention and an effect (Rychetnik et al., 2002). A clinical trial is indeed 
considered the method with the strongest internal validity, as well as the strongest scientific 
inference, minimising the risk of bias. Given that there is an inverse relation between internal and 
external validity, the superiority of clinical trial over any other design is based on the premise of 
the superiority of internal validity over external validity. The use of RCTs is not to represent ‘real 
situations’, but rather because experimental conditions are better able to generate definitive 
evidence. Neutralising external factors represents both the key strength of experimental design – 
scientific rigour being a matter of controlling elements – and its key limitation – as it does not 
aim to explain real-life effects (Tarquinio et al., 2015).  
 
The limitation of experimental design is precisely that it minimises contextual factors that may, 
in fact, be essential to the success of the intervention (Tarquinio et al., 2015).  This raises the issue 
of the transferability of results. Transferability has been defined as the extent to which the 
measured efficacy of an intervention could be achieved in another setting (Wang et al., 2006). 
Many factors – related to experimental conditions – could influence the transferability of results 
of health behaviour complex interventions, either directly (outcomes are not transferable because 
the terms and conditions for implementing the intervention are different) or indirectly (for the 
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same implementation modalities, different outcomes are obtained). These elements may include 
population characteristics, the environment in which the intervention takes place, the quality of 
the relationship between intervention participants, and the adaptations to the intervention made 
on the ground by the caregiver. Thus, challenges remain in measuring the effect of contextual 
elements to ensure that the studied intervention would produce the same results when 
implemented in another context (Cambon et al., 2012, Victora et al., 2004). 
 
To overcome the limitations of RCTs, some authors have proposed adaptations to RCTs to bring 
this design closer to real-life conditions. These adaptations make it possible to test interventions 
in conditions closer to real life, i.e. to test the effectiveness of interventions and thereby maximise 
their transferability (Cambon et al., 2012). A second category of ‘adjustments’ to RCTs includes 
evaluation models using qualitative or mixed methods that aim to understand why a specific result 
was obtained and what could have contributed to it. Adapted models incorporate the analysis of 
process, components and mechanisms into evaluation models (Tarquinio et al., 2015). An adapted 
model, evaluating patients’ experience of the intervention using qualitative methods was chosen 
for the PhD intervention study.  
 
   2.7.1.3. The need for a nested qualitative study  
Qualitative methods are viewed as particularly helpful at this early stage as they can respond 
flexibly to issues as they emerge (O’Cathain et al., 2015) and encourage an iterative approach to 
intervention development (O’Cathain et al., 2014). Qualitative methods can contribute in several 
ways to the design and refinement of an intervention by identifying intervention components in 
need of further refinement, barriers or facilitators to implementing an intervention and involving 
users in the development process (Lewin et al., 2009). A qualitative study can also inform changes 
to the intervention logic model, in advance a full-scale RCT (Figure 6, p. 58). There is the need 
to link data on outcomes with qualitative methods to tackle the questions of “how” and “why”. 
This shifts the focus from what works to which preconditions make certain outcomes more likely, 
for which people, and in which context. A simple binary of success or failure is not always helpful, 
especially if it precludes learning from multiple sources (Lamont et al., 2016). For these reasons, 
a nested qualitative study was included in the pilot study. Full details of the pilot study methods 
are presented in Paper 3 (Chapter 5). Full results at the intervention 3-months’ follow-up are 
presented in Paper 4 (Chapter 6) of this thesis.  
 
2.8 Methodological conclusions  
The overall aim of the study was to develop a complex intervention for the management of fatigue 
and test its feasibility and potential efficacy in patients with IBD. The methodological choices 
taken to achieve this aim were taken in attempt to avoid research waste and develop an 
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intervention that could be utilised by clinicians to improve IBD patients’ care. Self-regulation 
theory (Leventhal et al., 1980) was utilised in the intervention development to identify which 
variables were to be changed by the PhD intervention in order to produce a significant change in 
fatigue and QoL. A logic model for the intervention was developed so as to improve the 
understanding of the causal assumptions of how the PhD intervention worked (Figure 6, p. 58). 
Reporting guidelines were followed in order to improve the accuracy and improve transparency 
of information. The SPIRIT checklist was utilised to guide the reporting of the intervention 
development in the published protocol for the intervention (Paper 3). The CONSORT statement 
was utilised to guide the report of the intervention results (Paper 4). Lastly, the MRC framework 
for the development of complex interventions (Craig et al., 2008) was utilised to guide each step 






3 Paper 1 - Targets for health interventions for inflammatory bowel disease-
fatigue: a systematic review  
 
This chapter presents an additional description and justification for the methods utilised for the 
systematic review (Artom et al., 2016a) published as Paper 1 of this PhD thesis. The published 
paper included Supplementary Table 1 (Appendix I) and Supplementary Table 2 (Appendix II). 
This includes a justification for the databases used and for the search terms and filters chosen for 
the systematic search. A statement of the contribution of the PhD student to this paper appears at 
the end of the paper on Page 81. Amendments to the published paper uggested by the PhD 




























3.1 Justification for databases 
The main characteristics of a systematic review are: clearly stated objectives, an explicit and 
reproducible methodology, pre-defined eligibility criteria for studies, a systematic search, an 
assessment of the validity of the findings of the included studies, and a systematic presentation of 
the characteristics and findings of the included studies (Higgins and Green, 2011). Conducting a 
thorough and well-documented search is one of the main distinctions between a systematic review 
and a literature review, and is a vital part of ensuring that the systematic review provides a 
rigorous and comprehensive summary of research evidence (Sackett et al., 1996). The ability to 
retrieve relevant material in a systematic review search depends on different of factors including: 
expertise of the searcher (Havill et al., 2014), the quality of the database indexing (Papaioannou 
et al., 2010), the integrity of the software (Havill et al., 2014) and the content of the databases 
(Papaioannou et al., 2010). Searching the correct databases is hence important so as to ensure that 
as high a proportion as possible of relevant studies are identified (Suarez-Almazor et al., 2000). 
Likewise, those involved in reviewing the literature should be aware of how databases compare, 
so that gaps in coverage between databases can be identified and duplication of effort involved in 
searching multiple databases is kept to a minimum (McDonald et al., 1999). The majority of 
relevant papers appear in a limited number of databases and the choice of databases is topic-
specific (Hartling et al., 2016). Furthermore, searches are often time-consuming and costly; 
therefore, there has been a growing interest in the trade-off between timeliness and exhaustiveness 
when preparing reviews (Peters et al., 2015).  
 
MEDLINE was chosen as the first-choice database because it provides access to a broad range of 
biomedical literature coverage including nursing, and clinical and experimental medicine. It was 
thus considered an appropriate database for the search of articles related to IBD. EMBASE 
searches complement MEDLINE in several ways, by providing greater coverage of European and 
non-English-language publications and broader coverage of key topics such as pharmaceuticals 
and psychology, both of which were relevant in the present review (Wong et al., 2006). The 
overlap of EMBASE and MEDLINE is estimated to be 10% to 87%, depending on the topic 
(Royle et al., 2005). CINAHL was selected for its focus on nursing and allied health literature. 
This focus was considered helpful in capturing interventions for the management of fatigue 
delivered by nurses and allied health professionals (Brazier and Begley, 1996, Gargon et al., 
2015). Similarly, the British Nursing Index was selected as it may be a source of choice for British 
nurses (Griffiths and Riddington, 2001). PsycINFO, which is a bibliographic psychological 
database, was used for the retrieval of articles related to psychological factors associated with 
IBD. Indeed, although it has some overlap with MEDLINE, its content area pertains to 
behavioural aspects of care and behavioural treatments for physical illness (Eady et al., 2008). 
The Cochrane Library was included as it provides enhanced access to reports of trials (Lefebvre 
85 
et al., 2008) and its use has been found to increase the search yield of conference proceedings and 
abstracts (Slobogean et al., 2009). Finally, Web of Science was utilised due to the 
multidisciplinary topic of the review (IBD and psychology) (Löhönen et al., 2010).  
 
3.2 Justification for search terms and filters  
The full search strategy for each database is presented in Appendix III. The search terms were 
identified replicating the rigorous methodology utilised by the previous review by Czuber-
Dochan and colleagues (2013a). A major challenge of conducting a systematic review is to 
identify a tentative start set of search terms (Kitchenham, 2004). Using the same search terms as 
a previous related systematic review in the field can therefore aid in overcoming this problem. It 
has been suggested that replicating the searches conducted in a systematic review can strengthen 
the claims made by the original review, and build confidence about the validity of the systematic 
review methodology (Staples and Niazi, 2007). There is some evidence from a Cochrane review 
to support the use of checking reference lists for locating studies in systematic reviews (Horsley 
et al., 2011). The process was therefore incorporated in order to maximise citation retrieval. The 
choice of filters was more challenging, requiring the evaluation of pros and cons related to each 
filter. Systematic bias due to the selection of studies in a particular language is called a language 
bias (Egger et al., 2002). Bias may lead to an over or underestimation of an intervention’s 
effectiveness, and ultimately, to inappropriate health policy decisions or patient care (Grégoire et 
al., 1995). It is consequently recognised that having relied exclusively on English-language 
studies may have missed important evidence on health interventions. However, the top 
international medical journals, by Journal Citation Reports impact factor, are English-language 
publications (Morrison et al., 2012). Furthermore, in a systematic review of use of language 
restrictions in systematic reviews and meta-analyses in conventional medicine (Morrison et al., 
2012), no evidence was found of systematic bias for systematic reviews including only English-
















4 Paper 2 - The contribution of clinical and psychosocial factors to fatigue in 182 
patients with inflammatory bowel disease: a cross‐sectional study 
This chapter presents an additional description and justification for the methods utilised for the 
cross-sectional study (Artom et al. 2016b) published as Paper 2 of this PhD thesis. This includes 
a justification for the cross-sectional study design and for the choice of the study questionnaires. 
The published paper included Supplementary Table 1 (Appendix IV), Supplementary Table 2 
(Appendix V) and Supplementary Table 3 (Appendix VI). Eligible patients were provided with a 
Patient Information Sheet (Appendix VII) explaining the nature and aims of the study. Patients 
had the opportunity to take the questionnaires home and return them by post to fully consider 
their participation in the study and what participation in the study involved. A signed Patient 
Consent Form (Appendix VIII) was returned with the questionnaires by post.  
 
The study was approved by the United Kingdom National Research Ethics Service – London 
Bridge Committee (15/LO/1081, Appendix IX). At the time of ethical approval, permission was 
granted also for clinical and questionnaire data collection at 12 and 24-months’ follow-up points. 
Due to the limited time-frame of this PhD project, only the baseline results of the quantitative 
study were analysed and reported in this thesis. The main advantage of longitudinal studies is that 
participants are observed at more than one time point, thereby allowing trends in an outcome to 
be monitored over time (Sedgwick, 2014). However, the requirement for participants to commit 
to multiple data collection time points may have influenced their decision to participate or not 
and hence the sample that resulted (Payne and Hendrix, 2010, Albrecht and Taylor, 2013). A 
statement of the contribution of the PhD student to this paper appears at the end of the paper on 
Page 97.  
 
Amendments to the published paper suggested by the PhD examiners following the oral 
examination are presented in Appendix XIX. Following the oral examination, analysis was 
conducted on the 12-month follow-up fatigue data. Findings of the additional analysis are 
























4.1 Cross-sectional study design  
In observational studies, the investigator observes and evaluates the results that occur without an 
intervention and does not allocate or control the exposure. The main types of observational studies 
are cross-sectional, cohort, case-control and case report studies (DiPietro, 2010). Cross-sectional 
studies are carried out at one time point or over a limited period in order to provide a snapshot of 
the outcome and the characteristics associated with it (Levin, 2006). They are a type of descriptive 
observational study which is commonly utilised either to determine prevalence or consider 
possible associations between exposure and outcome. In the latter case, independent and 
dependent variables are identified in a given population and then the associations between them 
are determined. Cross-sectional studies are a useful way of identifying associations that can 
subsequently be more rigorously tested in an analytic design such as an RCT. Advantages of 
cross-sectional studies are that they are relatively quick and as there is no follow-up fewer 
resources are required to run the study. Furthermore, although data are collected only once, 
multiple outcomes can be studied at the same time (Mann, 2003). Additionally, compared to 
longitudinal studies where loss to follow-up is common, this is not a problem in cross-sectional 
study design (Levin, 2006). For the purposes of this PhD project, the use of a cross-sectional study 
allowed for the assessment of fatigue and its association with multiple clinical and psychosocial 
outcomes at one point in time and yielded data needed to inform the intervention development.  
 
4.2 Study questionnaires  
Numerous questionnaires were selected to measure a number of clinical and psychosocial factors 
possibly linked to IBD-fatigue. The study questionnaires were presented to participants grouped 
in a booklet (Appendix X).  
 
4.2.1 IBD-Fatigue Scale (IBD-F)  
The IBD-F Scale (Czuber-Dochan et al., 2014a) aims to assess IBD-specific fatigue. The 
questionnaire has three sections. Section I consists of five questions assessing frequency and 
severity of fatigue; section II  consists of 30 questions rating the experience and impact of fatigue; 
and section III is a free-text section asking for patients’ comments and additional issues related 
to fatigue. Higher scores reflect higher levels of fatigue. Initial validation of the measure 
suggested that the questionnaire had good face and content validity, acceptable to excellent test–
retest stability and a high degree of internal consistency (Czuber-Dochan et al., 2014a). Both 
sections of the IBD-F have been found to be significantly correlated with widely utilised fatigue 
scales in IBD (Norton et al., 2015). To date, the scale has been translated into a number of 
languages: Danish (Bager et al., 2017), Polish, Spanish, American English, Greek , Chinese, and 
is currently being tested in tertiary referral centres in different countries.  
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The scale was chosen for the current study as it was developed by conducting in-depth interviews 
with participants with IBD, in order to gain insight into their experience. The use of an IBD-
specific scale can be utilised to represent issues of specific importance to people with IBD-fatigue. 
Indeed, the different manifestations and the wide range of mechanisms underlying fatigue make 
it difficult for one scale to be appropriate for measuring fatigue in all disease groups (Dittner et 
al., 2004). Furthermore, aside from measuring frequency and severity of fatigue, IBD-F allowed 
for the understanding of the effects of fatigue on patients’ lives, hence assessing the problems that 
they attribute to fatigue. The perception of the impact of fatigue can vary greatly from person to 
person. As fatigue and QoL are subjective states, it may be critical to select an instrument that 
measures not only fatigue, but fatigue in the context of other dimensions of well-being, such as 
physical, functional, social, and emotional well-being (Yellen et al., 1997). Additionally, the IBD-
F asks patients about the fatigue experienced in the “past two weeks”. Fatigue experienced “in 
the past week” was most commonly used by other scales. This is a longer timeframe compared to 
most fatigue scales utilised in studies of non-cancer gastrointestinal disorders (Han et al., 2016), 
thus allowing for a more extensive view of the patients’ experience to be captured. Likewise, it 
can be hypothesised that a longer timeframe may reflect a general state of fatigue rather than acute 
episodes that may not be representative of patients in remission (Stover et al., 2013). 
The IBD-F has been criticised for being too long to be used in clinical practice. Lengthy measures 
are likely to be difficult to implement consistently in clinical practice and in RCTs, for which 
parsimony is a desirable property (Ju et al., 2017). Nonetheless, strong correlations between 
sections I and II suggest that section I may be used as a screening tool alone (Vestergaard et al., 
2017). Following guidance by Whitehead (2009), for the purposes of this study, the final choice 
of using the whole scale represented a compromise between the detail required and the practical 
issues of completion. As Patient and Public Involvement responses indicated that the 
questionnaire was acceptable to patients, both sections were utilised in order to gather valuable 
information on the severity and impact of IBD-fatigue on patients’ daily activities. Furthermore, 
it is possible that the longer time-frame of the scale may increase the levels of recall bias that are 
inherent to self-report questionnaires (Heine et al., 2016). Indeed, individuals have been found to 
focus on the high levels of a phenomenon when assessed using recall questionnaires (Stone et al., 
2005). As such, findings from the IBD-F should be interpreted in light of these limitations.  
4.2.2 Multidimensional Fatigue Inventory (MFI)   
The MFI (Smets et al., 1995) is the most commonly used scale to measure fatigue in IBD (Czuber-
Dochan et al., 2013a). It is a 20-item self-assessment instrument designed to measure five 
dimensions of fatigue (physical fatigue, mental fatigue, general fatigue, reduced activity and 
motivation). Each dimension comprises four questions with scores ranging from 4 to 20 per 
dimension, with higher scores indicating greater fatigue. The “general fatigue” subscale is 
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commonly referenced as the primary fatigue descriptor, as opposed to using a total MFI scale 
score. Different cut-off points for fatigue have been adopted to delineate high or problematic 
fatigue in IBD. Most studies have utilised a cut-off of 13 (Goldenberg et al., 2013) on the basis 
of the ninth percentile of the score in a healthy control group (Graff et al., 2013). The MFI has 
shown good psychometric properties in patients with long-term conditions such as cancer (Tian 
and Hong, 2013) and it has recently been validated with patients with IBD (Norton et al., 2015).  
 
The MFI was chosen to be used in conjunction with the more recently developed IBD-F as the 
latter is an IBD-specific instrument. The MFI can assess different aspects of fatigue and it enables 
a comparison with healthy controls and other conditions. Having a common metric for fatigue 
across chronic health conditions can enhance the interpretability of fatigue across clinical research 
studies (Cella et al., 2016). The IBD-F is a relatively recently developed scale, hence currently 
data on its use is not extensive. Therefore the addition of a scale which has been used extensively 
both in IBD (Czuber-Dochan et al., 2013a) and other long-term conditions (Ballesio et al., 2017) 
can aid in avoiding information biases that might lead to incorrect interpretation of the data 
(Anthoine et al., 2014). It was decided that a multidimensional fatigue-specific instrument would 
help to better characterise fatigue in the study sample. Fatigue is a generic concept and it was not 
specifically constructed with a particular diagnosis in mind (Lerdal and Kottorp, 2011). Indeed, 
generic instruments can provide a useful brief index of fatigue in the context of broader health 
outcome (Dittner et al., 2004). They can also facilitate the documentation of commonalities and 
differences in relation to the severity and impact of fatigue across conditions (Hjollund et al., 
2007, Whitehead et al., 2016).  
 
4.2.3 United Kingdom Inflammatory Bowel Disease Questionnaire (UK IBDQ) 
The IBDQ (Cheung et al., 2000) is the British version of the McMaster IBDQ (Guyatt et al., 
1989). It has 30 items, each scored in the range 1 to 4, with a summary score between 30 and 120. 
A low score indicates poor QoL. Initial findings have supported the reliability, validity, 
reproducibility and responsiveness of the UK version of the questionnaire. The questionnaire has 
been found acceptable to patients in the UK. It enhances the precision of some of the questions 
in the McMaster IBDQ, improves the readability of the questionnaire, removes items that do not 
provide useful information and simplifies the response categories. The IBDQ was tested and 
validated for the first time in 1994 in a multicentre clinical trial that reported a correlation between 
the IBDQ and disease activity (Irvine et al., 1994). Findings have supported its validity, reliability 
and its acceptability to patients with IBD cross-culturally across several cultural and linguistic 
milieus (Lopez-Vivancos et al., 1999, Masachs et al., 2007, Ren et al., 2007, Ciccocioppo et al., 
2011, Maleki et al., 2015). The IBDQ is now the most established QoL measure in the IBD 
literature (Alrubaiy et al., 2015).  
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The IBDQ was chosen as it was developed with patients with IBD, it therefore reflects the 
concerns of the patients themselves about the impact of their disease on their life-style and QoL. 
Members of our Patient and Public Involvement group voted 15:2 in favour of the UK version 
when compared with the original version, stating “choices are more straightforward”. As fatigue 
has been found to be strongly associated with poor QoL in IBD (Cohen et al., 2014), exploring 
the association between modifiable factors and QoL was deemed as an important aspect to 
consider in the study. Indeed, the identification of factors associated with both fatigue and QoL 
could ultimately lead to the development of interventions that could improve both fatigue and 
QoL in patients with IBD.  
4.2.4 Hospital Anxiety and Depression Scale (HADS) 
The HADS (Zigmond and Snaith, 1983) is a widely used self-report instrument for assessing 
depression and anxiety in patients with medical illnesses. It has two subscales, anxiety and 
depression, each consisting of seven items. The two subscales are scored separately and higher 
scores indicate higher anxiety and depression respectively. The HADS was chosen for the current 
study because, as opposed to other measures, it was originally developed for physically ill patients 
and no items assessing somatic symptoms are included. In studies across different conditions 
(Bjelland et al., 2002) and in IBD-specifically (Kjærgaard et al., 2014) its internal consistency 
has been found to be high. For the HADS-total the optimal cut-off was found to be ≥ 9 (sensitivity 
85%, specificity 81%) and for HADS-A (anxiety) and the HADS- D (depression), the optimal 
cut-off were at ≥ 4 (sensitivity 85%, specificity 79%) (Kjærgaard et al., 2014). The HADS it is 
the most common measurement tool for the measurement of anxiety and depression in IBD  
(Neuendorf et al., 2016). 
 
However, the HADS has not yet been validated specifically for use in the IBD population. 
Moreover, the scale contains a number of symptom items including feeling slowed down, 
abdominal sensations and worry, which are commonly experienced by patients with IBD as part 
of their core IBD symptoms and as a normal psychological adjustment to such a diagnosis (Farrell 
et al., 2015a). There may hence be a risk of criterion contamination between IBD symptomology 
with anxiety and depressive symptoms measured by the HADS (Hopkins, 2017). Findings of the 
HADS in patients with IBD should thus be interpreted with caution and validation of its 
psychometric properties with the IBD population is warranted. Despite these limitations the 
HADS was chosen for the present study as it has been extensively utilised in both standard 
medical practice and health-related research and it performs better than other scales in patients 
from non-psychiatric hospital clinics (Bjelland et al., 2002). Furthermore, the scale only takes 2 
to 5 minutes to complete and it has been shown to be acceptable to the population for which it is 
designed (Snaith, 2003).  
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4.2.5 Epworth Sleepiness Scale (ESS) 
The ESS (Johns, 1991) is utilised to measure a subject’s level of daytime sleepiness and provides 
a practical assessment of interference during the day (Johns, 2000). From a clinical point of view, 
this is relevant in that it helps to determine the presence of pathology or simply predict whether 
sleep onset is likely to occur at inappropriate times (Shen et al., 2006). The questionnaire asks 
subjects to rate their chance of falling asleep or dozing on a scale of 0 to 3 in eight soporific 
situations, ranging from ‘Lying down to rest in the afternoon when circumstances permit’ to ‘in 
a car while stopped for a few minutes in traffic’. A total score from 0 to 24 is determined, with 
values over 10/11 indicating abnormal or pathological sleepiness. The ESS is a major instrument 
for measuring sleep outcomes in RCTs (Giles et al., 2006) and it is one of the most widely used 
tools for the assessment of sleepiness. It also has the advantages of being easy to use, cost-
effective (Chervin, 2003) and able to quickly summarise events occurring over a long period (Ali 
and Orr, 2014).  
 
The ESS has been criticised for being a subjective rating of sleep propensity in daily life and only 
covering one specific aspect of the multi-dimensional concept of sleepiness. The questionnaire 
has a single factor structure and it contains only one item relating to each situation where patients 
could fall asleep (Cluydts et al., 2002, Smith et al., 2008, Olaithe et al., 2013). However, there is 
no gold standard for the measurement of outcomes in sleep and sleep-related conditions due to 
the heterogeneous impacts of these conditions on QoL (Kaambwa et al., 2016). Due to the huge 
body of findings on the ESS and the knowledge of its strengths and limitations, utilising the ESS 
as an assessment tool for evaluating sleepiness has thus been advised to be an appropriate 
approach. Indeed, utilising the results of this observational study as a basis for fatigue-
management intervention development, identifying the presence of daytime sleepiness can guide 
diagnostic evaluations with respect to comorbid sleep disorders, allowing potential treatment by 
effective countermeasures for sleepiness (Popp et al., 2017).   
 
4.2.6 Brief Illness Perceptions Questionnaire (BIPQ) 
The BIPQ (Broadbent et al., 2006) uses a single-item scale approach to assess illness perceptions. 
It is a shorter version of the original Illness Perception Questionnaire (Weinman et al., 1996) 
which is utilised  to assess five dimensions within a cognitive representation of illness. The brief 
version consists of seven items: five of the items assess cognitive illness representations 
(consequences, timeline, personal control, treatment control and identity) and two of them assess 
emotional representation (concern and emotions). Each item (e.g. “How concerned are you about 
your fatigue?”) is rated using a response scale of 0 to 10; in which higher scores represent more 
threatening views of fatigue. The total scoring ranges from 0 to 70, with a higher score reflecting 
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a more threatening view of illness. The psychometric properties of this measure have been 
assessed using samples from several illness groups in 26 languages from 36 countries. Findings 
show that the BIPQ good concurrent and predictive validity (Broadbent et al., 2015). The BIPQ 
has been utilised with IBD cohorts to assess the relationship between IBD illness perceptions, 
health status and disability (van der Have et al., 2015); however there are no normative data for 
patients with IBD. As suggested by the authors (Broadbent et al., 2006), to make the questionnaire 
more relevant to the studied patient group, the more general word ‘illnesses’ was be replaced by 
the word ‘fatigue’.  
 
4.2.7 Cognitive Behavioural Response to Symptoms Questionnaire (CBSQ) 
The CBSQ has been used to measure patients’ cognitive and behavioural responses to their 
symptoms (fatigue) in patients different conditions including, MS (Casey et al., 2016, Skerrett 
and Moss-Morris, 2006, Knoop et al., 2012), IBS (Chilcot and Moss-Morris, 2013), renal disease 
(Chilcot et al., 2016) and chronic fatigue syndrome (Wearden and Emsley, 2013). The 
questionnaire consists of 42 items in the form of statements. It includes five cognitive subscales; 
fear avoidance, embarrassment avoidance, catastrophising about symptoms, beliefs that 
symptoms are a signal damage to the body (damage beliefs), and symptom focus. There are also 
two behavioural subscales, resting and avoidance of activity and all-or-nothing behaviour. All 
items are scored on a five-point frequency scale ranging from never (0) to all the time (4). Item 
scores are added from each subscale to obtain a total score. The questionnaire has shown 
acceptable internal reliability in a previous study (Skerrett and Moss-Morris, 2006).  
 
4.2.8 Cohen Perceived Stress Scale (CPSS) 
The CPSS (Cohen et al., 1983) was developed to examine the role of stress in disease (in the last 
month). It assesses perceived stressful situations and stress reactions on a cognitive and emotional 
level. The questionnaire contains 14 items and each item is scored from 0 to 4; a global score is 
then computed ranging from 0 to 56, with higher scores indicating greater perceived stress. A cut-
off of  >21 for high short-term perceived stress has been utilised with patients with CD (Langhorst 
et al., 2013). Rather than rating events or situations, it assesses how the individual globally 
perceives stress, thereby encompassing the general perceived predictability, controllability, and 
manageability of challenging situations, their personal impact and meaning, and each individual’s 
perceived capacity to cope with the challenges effectively (Targownik et al., 2015). This measure 
of perceived stress has shown greater predictive utility in models of health-care outcomes than 
have measures assessing the occurrence of recent negative life events or ratings of the perceived 
impact of these specific negative events (Vermeire et al., 2010).  
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4.2.9 Inflammatory Bowel Disease Distress Scale (IBD-D) 
The IBD-D  (Woodward et al., 2016) is a newly developed scale designed to identify and measure 
distress related to IBD. It assesses how IBD has made patients feel during the last 3 months. 
Patients are provided with a list of issues and have to rate whether these cause them distress on a 
6-point Likert scale, ranging from ‘Mildly distressing’ to ‘Highly distressing’. At the time of use 
for the PhD cross-sectional study, the measure was in the process of psychometric validation. The 
scale has now been validated and the publication is in press. It has content and construct validity, 
as the items were derived from interviews with people with IBD and by a steering group that 
included service users. Issues of psychological morbidity (anxiety and depression), emotional 
coping and psychosocial stress, do not appear to reflect the whole experience of people with IBD. 
Indeed, people may feel distressed about their condition without being depressed or anxious, 
feeling stressed or feeling like they are coping poorly (Woodward et al., 2016). Whilst disease-
related distressed is a widely used patient reported outcome measure in diabetes (Sturt et al., 2015, 
Dennick et al., 2017), the association between disease-related distress and IBD has only been 
shown utilising general distress indicators such as the Global Severity Index from the Brief 
Symptom Inventory. Despite still being in the process of validation at the time of use, the IBD-D 
was included in order to identify the association between IBD-fatigue and distressing factors 











5 Paper 3 - Cognitive behavioural therapy for the management of inflammatory bowel 
disease-fatigue with a nested qualitative element: study protocol for a randomised 
controlled trial 
 
This chapter includes the published protocol of the PhD intervention (Artom et al., 2017), 
published as Paper 3 of this PhD thesis. Before presenting the published paper, this chapter 
describes the process of intervention development. This includes a description of the process of 
initial adaptation of the CBT manual for MS-fatigue (van Kessel et al., 2008) to a manual for 
IBD-fatigue and the Patient and Public Involvement activity with patients and HCPs. The steps 
involved in improving the readability of the text, making the graphic design of manual more 
acceptable to patients and obtaining input from the therapists are presented. A copy of the 
intervention manual is presented in Appendix XI.  
 
After the published paper, this chapter presents a justification for the choice of a telephone 
intervention modality, and an additional description and justification for the methods chosen for 
the intervention protocol. This includes a further justification for the choice of feasibility, 
acceptability and initial estimates of efficacy outcomes of the pilot intervention study. Eligible 
patients were provided with a Patient Information Sheet (Appendix XII) explaining the nature 
and the aims of the study. Patients had the opportunity to fully consider their participation in the 
study for at least 48 hours. A signed Patient Consent Form (Appendix XIII) was returned with the 
baseline questionnaires by post. The study was granted ethical approval by the United Kingdom 
National Research Ethics Service - North West - Liverpool Central Committee (16/NW/0791, 
Appendix XIV). At the time of ethical approval, permission was granted also for questionnaire 
data collection at 6 and 12-months’ post-randomisation follow-up points. However, due to the 
limited time-frame of this PhD project, only the baseline and 3-months post-randomisation results 
of the pilot intervention study were analysed and reported in this thesis. A statement of the 
contribution of the PhD student to this paper appears at the end of the paper on Page 123. 
Amendments to the published paper suggested by the PhD examiners following the oral 
examination are presented in Appendix XIX. 
 
5.1 Fatigue-related commonalities between IBD and MS 
Quantitative (Jones et al., 2009, Kwakkenbos et al., 2015) and qualitative studies (Czuber-Dochan 
et al., 2013b), and systematic reviews (Czuber-Dochan et al., 2013a, Artom et al., 2016a) have 
shown similarities in the perceived experience of fatigue between IBD and other disease groups. 
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Across long-term conditions patients have described losing control of their body because of the 
intensity of the fatigue experience and/or the unpredictability of fatigue. Fatigue also made it 
difficult to plan activities ahead of time with a consequent reduction in participation to social 
events. Additionally, invisibility of fatigue and difficulty in expressing its severity and impact led 
to a perception of lack of understanding from others (Whitehead et al., 2016). Similarities across 
conditions are also reported in patients’ experiences of managing their fatigue. Most patients 
sought relief from fatigue by sleeping or resting. Likewise, they adjusted their activity levels to 
fit with their reduced capacity (Eilersten et al., 2015).  
 
Specifically, parallels exist between descriptions of IBD-fatigue and fatigue in MS, with both 
patient groups describing fatigue as lack or loss of energy and not being able to stay awake 
(Czuber-Dochan et al., 2013b). In a study comparing MS and ulcerative colitis (Bol et al., 2010), 
no significant differences were found in independent contributors to physical and mental fatigue 
between the two patient groups. Both MS and IBD are autoimmune, inflammatory, chronic and 
intermittent diseases. Furthermore, both MS and IBD are can have a significant negative impact 
on physical, mental and social well-being (Klevan et al., 2014, Lönnfors et al., 2014). It is 
therefore possible that similar immune system dysregulation processes could lead to fatigue in 
the two conditions. Based on the similarities in the experiences of fatigue and the likely similar 
mechanisms causing fatigue between MS and IBD, it was seen reasonable to adapt an existing 
successful MS-fatigue intervention rather than starting from scratch with intervention 
development.  
 
5.2 Adaptation of MS fatigue management intervention manual  
Permission was granted by Van Kessel and colleagues to utilise and modify their intervention 
manual for the management of MS-fatigue. A copy of the manual was obtained in digital format 
in June 2016. The manual entitled ‘Managing your multiple sclerosis fatigue: a cognitive 
behavioural therapy manual’ was composed of 100 pages in Microsoft Word in plain black and 
white text. The manual was structured with: an introduction section, an instruction section and 
eight intervention sessions. The intervention manual was read in full by the PhD student (MA) 
and the PhD supervisors (CN, JS, WCD). A series of preliminary steps were then undertaken by 
the PhD student to adapt the MS-fatigue manual to a manual for IBD-fatigue prior to the Patient 
and Public Involvement activities. First, the title of the intervention was changed. The acronym 
‘MODIFY Fatigue’ was drawn from the full name of the manual ‘Managing your Inflammatory 
Bowel Disease Fatigue’ to indicate the proposed intention of the intervention to modify the 
severity and impact of fatigue on patients’ daily activities. Second, the term ‘multiple-sclerosis’ 
was substituted with ‘inflammatory bowel disease’ throughout the manual. Third, all sections of 
the manual containing disease-specific information were either removed, modified or signposted 
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to be further addressed by HCPs during the stakeholder engagement activity. Modifications to 
sections of the manual relating specifically to IBD or IBD-fatigue were conducted based on 
evidence from previous quantitative, systematic review and qualitative studies conducted by 
Czuber-Dochan and colleagues (2013a,b); clinical IBD guidelines (e.g. European Crohn’s and 
Colitis Organisation, British Gastroenterology Society) and information provided by the national 
charity, Crohn’s and Colitis UK. Sections of the manual containing more specialised medical 
information, were deferred to the specialised knowledge of HCPs working with IBD. Fourth, the 
title page and instructions section of the manual (Using the Manual), was modified to reflect the 
MODIFY Fatigue intervention protocol. The process of adaptation of the MS-fatigue intervention 
to the IBD-fatigue intervention is similar to the one conducted by others in adapting this MS-
fatigue intervention (van Kessel et al., 2008) to cancer (Corbett et al., 2016) and renal fatigue 
(Picariello et al., 2018). 
 
5.3 Stakeholder HCPs engagement activity 
A stakeholder engagement activity was conducted with HCP working with patients with IBD. 
One IBD-nurse specialist and one gastroenterologist were asked to review the content of the entire 
manual, particularly focusing on sections relating to disease-specific information (e.g. IBD 
symptoms, medications, aetiology). When information was considered incorrect or insufficient, 
HCPs were encouraged to add further detail based on their medical knowledge and experience 
working with patients with IBD. All differences of opinion or queries were resolved through 
discussion with the supervisory team. The final version of the manual to be presented to the 
patients, was approved by both HCPs. 
 
5.4 Patient and Public Involvement activity 
A Patient and Public Involvement activity with patients with IBD was then undertaken to achieve 
face and content validity of the intervention. The Patient and Public Involvement activity was 
conducted in order to tailor the intervention to IBD-patients’ needs and determine which elements 
were relevant, acceptable and useful when adapting an intervention for the management of fatigue 
to patients with IBD. Next, nine IBD patients were invited to take part in a Patient and Public 
Involvement activity. Invited patients were either known to the supervisory team for having taken 
part in previous Patient and Public Involvement activities or were referred by Crohn’s and Colitis 
UK charity. Of these, 4 patients accepted to be involved and were sent a paper copy of the manual 
via post together with instructions on how to complete the activity and a structured feedback form 
(Appendix XV) to complete. In the instructions, the aims of the Patient and Public Involvement 
activity and of the study were explained. They were then asked to read the manual carefully, 
answer the questions on the feedback form and make annotations on the manual as they read it. 
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Completed feedback forms together with the annotated manuals were returned via mail prepaid 
return envelopes.  
 
The feedback form (Appendix XV) was 7 pages long and contained 30 open and Likert scale 
questions regarding: overall impressions of the manual, language and comprehension, format and 
organisation, usefulness of the manual and feasibility of the intervention tasks described in the 
manual. All participants commented on the size of the CBT manual, implying that receiving the 
manual as a single book may be overwhelming for patients with fatigue. A decision was therefore 
made to present the manual in a ring binder, with separate colours for each session. The ring 
binder allowed patients to move pages according to their preference. The separate colours were 
chosen to encourage patients to undertake each session individually instead of reading the manual 
as a whole. The participants found the language clear and understandable, however further 
readability assessment tests were conducted so the manual complied with the plain English 
guidelines (Plain English Campaign 2017). The format and organisation of the manual were not 
rated very highly. In particular, the need for more colour, pictures and bullet points was 
highlighted. The manual was also considered to be too text heavy and dense with information per 
page. In light of these comments on the formatting of the manual, a decision was made to engage 
a graphic designer to make the manual more user friendly.  
 
The content of the manual was perceived as useful and relevant in helping people with IBD to 
manage their fatigue. Indeed, participants reported acquiring new knowledge in relation to their 
fatigue as a result of reading the manual. In line with the therapeutic objectives of the intervention, 
information regarding monitoring and planning of activity, negative cognitive-behavioural 
responses to fatigue and sleep were considered particularly relevant to participants’ experience of 
fatigue. Having more information about these aspects of fatigue made them more aware of their 
own cognitive-behavioural patterns in relation to fatigue and ways in which they could be 
modified. These comments were consistent with the notion that cognitive-behavioural 
mechanisms related to fatigue may be comparable across conditions and that an adapted version 
of a manual for MS-fatigue could be applicable to patients with IBD-fatigue. However, 
participants highlighted the need for more IBD-specific examples of maladaptive cognitions and 
behaviours, to make the content more tailored to the IBD population. Indeed, tailoring the content 
of the intervention can enhance the relevance of the information presented and lead to greater 
desired changes in response to the communications (Hawkins et al., 2008). Consequently, whilst 
keeping the therapeutic content drawn from the CBT manual for MS-fatigue (van Kessel et al., 
2008), more examples and quotes specific to people with IBD from qualitative studies conducted 
by Czuber-Dochan and colleagues (2013b)  were incorporated in the IBD-fatigue manual. Lastly, 
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the intervention tasks were perceived to be feasible to complete with adequate organisation and 
motivation levels.   
 
5.5 Readability assessment 
The use of jargon-free language is recommended for all health-related content (Stableford and 
Mettger, 2007). Nonetheless, evidence shows that 43% of English population of working-age find 
health material containing text only, too complex to be able to understand and use (Rowlands et 
al., 2015). It is thus important to consider readability of the content when designing interventions, 
as the efficacy of interventions can be limited if materials cannot be read or understood by patients 
(Protheroe et al., 2017). The Flesch-Kincaid system (Farr et al., 1951) is the most widely used 
computerised method for assessing readability statistics for text (Paasche-Orlow et al., 2003). It 
is composed of the Flesch Reading Ease test and the Flesch-Kincaid Grade Level test. The Flesch 
Reading Ease test rates text on a 100-point scale. The higher the score, the easier it is to understand 
the document. The score is computed using the average number of syllables per word and words 
per sentence. Syllables-per-word is a measure of word difficulty. Words-per-sentence is an 
indicator of syntactic complexity. The Flesch-Kincaid Grade Level test rates text on a United 
States school grade level. The Flesch-Kincaid score has the advantage of measuring the 
readability of a document based on the minimum education level required for a reader to 
understand it. The Flesch-Kincaid system was chosen to test the readability of the manual for its 
excellent reproducibility and high correlation to other readability scales (Paasche-Orlow et al., 
2003).  
 
After incorporating the feedback from the Patient and Public Involvement activity, the Flesch 
Reading Ease test and Flesch-Kincaid Grade Level tests were run on the IBD-fatigue intervention 
manual utilising Microsoft Word. In order to have representative data for the whole manual, three 
sections from different sessions of the manual were selected. Flesch Reading Ease test scores 
were 37%, 64% and 61% for the three sections tested.  Flesch-Kincaid Grade Level test scores 
were grade 12, grade 9 and grade 9.  Based on these scores, the need to improve the readability 
of the intervention manual was recognised. Following the plain English guidelines (Plain English 
Campaign 2017), the aim was to enhance the Flesch Reading Ease scores to 70% and reduce the 
Flesch-Kincaid Grade Level scores to grade 8.  This was done by changing passive verbs to active 
verbs, shortening or breaking-up long sentences and paragraphs, using lists when appropriate, 
using pronouns such as ‘you’ and ‘we’ and reducing the density of complex words. This process 
was conducted in two stages: the PhD student initially enhanced the readability up to 60%, 
throughout the manual, and subsequently, a professional medical writer was employed to 
complete the process and bring the manual to the required readability level. All changes were 
made through track changes in Microsoft Word in order to allow for full transparency of the 
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process and facilitate a consensual agreement of the final text. All disagreements or queries were 
resolved through discussion. The final version of the manual (Appendix XI) was approved by all 
members of the supervisory team.  
 
5.6 Graphic design  
A graphic designer, working internally at King’s College London, was engaged to make the 
design more user friendly. All changes reflected feedback from the Patient and Public 
Involvement activity and were made in accordance with the supervisory team’s requests. The 
section headings were inserted to keep formatting consistent across sections and high contrast 
colour text was added to improve flow and readability. Aside from colour, font was kept as simple 
as possible to encourage easy reading. A picture of the windy road towards recovery was inserted 
on the front page of the manual to make it more visually appealing. In order to streamline access 
to the homework sheets, all homework tasks were moved to the end of the intervention manual 
as a separate homework booklet. Aside from homework sheets for each section, spare homework 
sheets were provided for patients who may have wished to complete additional tasks during or 
after the completion of the intervention. The manual was presented in a ring binder so as to 
enhance flexibility of use of the manual and encourage participants to move the order of its 
content according to their preference. Each session of the intervention was colour coded to 
facilitate communication with the therapist with reference to specific sessions. The colour of each 
session was also signposted in the contents page of the manual. At the end of the design editing 
process the manual was reviewed and approved by the supervisory team.  
 
5.7 Therapists’ input   
Once the content, language and formatting of the manual were approved by the research team, 
the final version of the manual was submitted for approval by the two therapists who would 
deliver the intervention. The therapists were asked to comment on the ease of use of the manual 
to deliver the therapy and to share their professional opinion on the cognitive-behavioural 
therapeutic aspects of the manual. Both therapists provided positive comments regarding the ease 
of use and therapeutic content of the manual. Clinical experience, grounded in daily trial-and-
error practice, contributes to making sense of ‘what works for whom’ (Roth and Fonagy, 2013) 
and therapists’ accumulated practice-based knowledge is considered a rich source of evidence 
regarding effective interventions (Westen et al., 2004). As such, the therapists’ positive comments 
were valuable in confirming the intervention manual. Only minor modifications to the language 
were suggested and inputted. The final version of the manual was provided to participants 
randomised to Group 1 of the intervention.  
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5.8 Control intervention  
Participants who were randomised to the control group received the Crohn’s and Colitis UK 
‘Fatigue in IBD’ Information Sheet (Appendix XVI) to be used without therapist help. The 
Fatigue in IBD Information Sheet was developed by CCUK together with the two members of 
the supervisory team (CN, WCD) to explain what fatigue is, what may cause it and possible ways 
of reducing. The Information Sheet was chosen as the control intervention as it provided valid 
and empirically tested information about fatigue to patients, without incorporating the principles 
of CBT. Studies testing CBT interventions for fatigue in other conditions such as cancer in the 
UK, have also utilised information booklets development by their national charities as their 




















5.9 Telephone intervention modality   
Conventional wisdom supports the idea that psychological therapies should be delivered face-to-
face. The central premise to this argument is that the effectiveness of such interventions depends 
upon on the development of a high quality therapeutic alliance between therapist and client. As 
the use of the telephone invariably eliminates cues and information transmitted through verbal 
and non-verbal channels, the telephone could potentially impact on the development of 
therapeutic alliance (Mohr et al., 2012, Sarkar and Gupta, 2012). However, in a study comparing 
therapeutic alliance in clients receiving CBT for depression by telephone or fact-to-face (Stiles-
Shields et al., 2014), there were no significant differences in client or therapist alliance on the 
Working Alliance Inventory and Working Alliance Inventory scores predicted depression end of 
treatment outcomes. Findings on the comparability of therapeutic alliance levels between 
telephone and face-to-face interventions have also been found for interventions for psychosis 
(Mulligan et al., 2014). In light of the above data, the decision to use the telephone as the modality 
of delivery was therefore taken.  
 
The choice of the telephone as the modality of delivery of the intervention was due to its 
widespread use and its ability to overcome potential geographical barriers. The telephone is the 
most widely used communication medium in the UK with 94% of adults personally owning/using 
a mobile phone (OfCom, 2017). Telephone-administered psychotherapy is now increasingly part 
of the mental health care landscape (Mohr et al., 2008). The telephone offers the opportunity to 
extend care to populations that are difficult to reach, such as rural populations, patients with 
chronic illnesses and disabilities, and individuals who otherwise have barriers to treatment (Mohr 
et al., 2005). Accordingly, the acceptability of delivering care over the telephone is growing. A 
survey of primary care patients found that nearly 19% of patients who desired behavioural and 
psychological care wanted telephone treatment and an additional 44% would consider it (Mohr et 
al., 2010). Furthermore, systematic review of evidence from nine RCTs (1093 participants) of 
telephone-delivered CBT in patients with long-term conditions reported a mean attrition rate was 
9.5% across all the studies (Muller and Yardley, 2011), which is significantly lower than the 
attrition rate in studies delivering CBT face-to-face (Salmoiraghi and Sambhi, 2010).  
 
5.10 Feasibility outcomes  
The MRC guidance (Craig et al., 2008) states that the purpose of the pilot and feasibility phase 
of the framework is to inform the design of a subsequent large, definitive trial assessing the 
effectiveness of the intervention. Pilot studies are a smaller version of the main study that test 
whether the components of the main study can all work together (Thabane et al., 2010). They are 
a requisite initial step in exploring a novel intervention (Whitehead et al., 2014) and resemble the 
main study in many respects, including the assessment of the primary outcome. Pilot studies are 
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done when an outline plan for the main study has been settled, in order to test whether it can be 
delivered smoothly and efficiently (Lee et al., 2014). Although, staging of studies is not as well 
defined in non-drug intervention development, when designing a pilot study it is always important 
to keep the next study in mind. The aims and methods of the pilot should be aligned with the goals 
of the subsequent study (Moore et al., 2011). Pilot studies can be subdivided into internal and 
external pilots. External pilots are independent pieces of work, which are designed and conducted 
separately from the main trial. Conversely, internal pilot studies are studies which are 
incorporated within the main trial (Charlesworth et al., 2013). The current study was an external 
pilot study. An external pilot was chosen as opposed to an internal pilot because it allowed for 
pre-testing of the feasibility of other factors related to the trial that could not have otherwise be 
determined if the pilot had been part of the main trial (Lancaster et al., 2001). Furthermore, at the 
time of planning of the pilot study, the full-scale effectiveness RCT was not yet funded.  
 
Van Teijlingen et al. (2001) and Van Teijlingen and Hundley (2001) summarise the reasons for 
performing pilot studies into four broad classifications: process, resources, management and 
scientific. Reasons in the process category assess the feasibility of the steps that need to take place 
as part of the large-scale trial. Reasons in the resources category assess time and budget problems 
that can occur during the large-scale trial. Reasons in the management category cover personnel 
and data management issues. Lastly, reasons in the scientific category deal with estimation of 
treatment effect, levels of response and treatment safety (Thabane et al., 2010). The feasibility 
outcomes of the pilot study were part of the process classification and had the purpose of assessing 
the potential successful implementation of the intervention in a large-scale trial and to reduce 
threats to the validity of the large-scale trial in the future (Tickle-Degnen, 2013). Collecting 
information relating to these feasibility outcomes reduces the likelihood of failure of a future 
large-scale trial due to poor design (Wilson et al., 2015). The feasibility outcomes for this pilot 
study were selected to be in line with the methodological issues that require piloting in the context 
of an RCT according to Shanyinde and colleagues (2011). These feasibility outcomes were to: 
• Assess the feasibility of recruiting eligible patients and assess the willingness of 
participants to be randomised; 
• Assess the completeness of the outcome data questionnaire booklets;   
• Evaluate the compliance rates of patients to the intervention; 
• Assess withdrawal rates during the intervention support sessions; assess the completion 
rates of the outcome measures at follow-up.  
 
Testing the acceptability of randomisation can determine the acceptability of the concept of 
randomisation to the participant and the best way of explaining the process to the patient before 
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eliciting informed consent. Likewise it is crucial to determine what the consent rate will be for 
patients enrolling in the trial as this will impact directly on planning the time needed to recruit 
enough participants to the trial, with consequent implications for funding. Moreover, failure to 
recruit the required number of participants reduces the statistical power, with consequent 
implications for determining effect sizes. Piloting of outcome data questionnaire booklets is 
especially important when the patient has to self-complete the questionnaires as this will ensure 
that the questionnaires are comprehensible and appropriate, and that the questions are clearly 
understood, well defined and presented in a coherent way (Lancaster et al., 2001). Lastly, 
compliance and withdrawal rates from the intervention need to be assessed as attrition rates have 
been found to be significantly associated with poor outcomes in low intensity psychological 
interventions (Delgadillo et al., 2014).  
 
Progress criteria for success were defined for the primary feasibility objectives of the study. These 
helped to interpret the results of the pilot study and determine whether it is feasible to proceed to 
a full-scale trial. Following Thabane and colleagues’ (2010) recommendations, the outcome of 
the pilot study was categorised into one of four options: i) Stop (main study not feasible) ii) 
continue, but modify protocol (feasible with modifications), iii) continue without modifications, 
but monitor closely (feasible with close monitoring), and iv) continue without modifications 
(feasible as is). The success of procedures and unanticipated problems were also carefully 
examined in order to obtain the best possible design for future large-scale trials of IBD-fatigue 
management (Shanyinde et al., 2011). Nonetheless, due to the small size of pilot studies it is 
advised never to use pilot study effect sizes alone to determine whether a full trial should be 
conducted. Other factors such as qualitative impressions from pilot study participants on how 
well the intervention worked in the field should also be evaluated. Indeed, if the results of the 
pilot study reflect promise in every aspect but the observed effect size, the progression to a large 
scale trial should be considered (Westlund and Stuart, 2016). Consequently, where outcomes fell 
short of a pre-defined progression criterion except there was a sufficient qualitative understanding 
of why this happened and how to improve it, the possibility of proceeding should be evaluated 
(O’Cathain et al., 2015).  
 
5.11 Acceptability outcomes 
Guided by a person-based approach to intervention testing (Yardley et al., 2015), acceptability 
outcomes were included to ground the development of the intervention in a thorough 
understanding of the perspective and psychosocial context of the individuals who will use it. 
Indeed eliciting and addressing the views and needs of the intended intervention users is a crucial 
part of effective intervention testing (Baker et al., 2014) to ensure the intervention is engaging 
and usable. Utilised to complement theory-based approaches, the person-based approach provides 
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guidance on the most effective ways of applying theory in the specific context of each intervention 
and the individuals who will use it. It provides insight into the ways in which participants perceive 
and utilise specific elements of the intervention and why certain elements may be particularly 
important to them (Yardley et al., 2015). The acceptability outcomes were to:  
• Evaluate patients’ experience of the intervention 
• Evaluate therapists’ views on the intervention delivery 
• Evaluate HCPs views on the intervention implementation 
 
5.12 Initial estimates of efficacy outcome measures  
A detailed description and justification for the use of the majority of the scales used to test initial 
estimates of efficacy in the pilot study was included in Chapter 4, Section 4.2 Study 
Questionnaires. For further information on: IBD-Fatigue Scale, United Kingdom Inflammatory 
Bowel Disease Questionnaire, Brief Illness Perceptions Questionnaire and Epworth Sleepiness 
Scale, please refer back to Sections 4.2.1 to 4.2.6. The study questionnaires were presented to 
participants grouped in a booklet (Appendix XVII). Instead of using the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond and Snaith, 1983), a decision was made to utilise two 
separate questionnaires for the measurement of depression and anxiety. The HADS is the most 
commonly utilised measure to assess depression and anxiety in IBD (Neuendorf et al., 2016) and 
has been extensively used in medical patients (Mikocka-Walus et al., 2016). However, it is yet to 
be validated in IBD and it has recently been shown to differentiate poorly between anxiety and 
depression (Cosco et al., 2012, Norton et al., 2013). Furthermore, a systematic review and meta-
analysis in rheumatoid arthritis (Dickens et al., 2002) showed significantly greater effect sizes for 
depression in patients using the HADS compared to other depression scales. Indeed, studies using 
the HADS found patients with rheumatoid arthritis to be more depressed. The HADS contains 
items such as “I feel slowed down”, “I can sit at ease and feel relaxed”, and “I still enjoy the 
things I used to enjoy” which may overlap with symptoms of patients’ physical illness, thus 
inflating their depression scores.  
 
5.12.1 Nine-item Patient Health Questionnaire (PHQ-9) 
The PHQ-9 (Kroenke et al., 2001) was firstly designed to be a diagnostic and severity instrument 
for depressive symptoms in patients in primary care. The questionnaire contains nine items, which 
are scored from 0 (not at all) to 3 (nearly every day), according to the frequency of their experience 
over the previous two-week period, with a total score range of 0 to 27. Major depression is 
diagnosed if five or more of the nine depressive symptom criteria have been present at least “more 
than half the days” in the past two weeks, and one of the symptoms is depressed mood or 
anhedonia. The scale correlates with other validated depression measures including: the Beck 
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Depression Inventory–II (Titov et al., 2011), the HADS (Kendel et al., 2010) and the Center for 
Epidemiologic Studies Depression Scale (Milette et al., 2010). The PHQ-9 has been widely 
applied in medical settings (Kroenke et al., 2010) and its different versions have been utilised for 
the assessment of depressive symptoms in studies with IBD patients (Cohen et al., 2014, Calloway 
et al., 2017).  
 
The scale has shown good sensitivity to change, with changes in the PHQ-9 score corresponding 
to changes in depression diagnostic status over time (Löwe et al., 2004a). Likewise, the PHQ-9 
has shown to be a reliable instrument to measure response to depression treatment (Löwe et al., 
2004b). It has therefore been deemed as a useful brief tool to be used in longitudinal studies and 
clinical trials. The PHQ-9 was chosen for the present intervention study as it consists of the actual 
9 criteria upon which the diagnosis of Diagnostic and Statistical Manual of Mental Disorders IV 
depressive disorders is based. Its exclusive focus on depressive disorders ensures accurate 
discrimination of depression from anxiety and general psychological distress. Furthermore, 
although it has comparable sensitivity and specificity (Amtmann et al., 2014), it is easy to use and 
half the length of other depression measures (Bombardier et al., 2004). Indeed, brief measures 
imply less patient burden and are more likely to ultimately be utilised in the busy setting of clinical 
practice  (Kroenke et al., 2001).  
 
5.12.2 Seven-item Generalised Anxiety Disorder Scale (GAD-7)  
The GAD-7 (Spitzer et al., 2006) was developed with a primary care population to identify 
generalised anxiety disorder. It asks participants how often during the last two weeks they have 
been bothered by each of the seven core symptoms of anxiety. Response options are ‘not at all’, 
‘several days’, ‘more than half the days’ and ‘nearly every day’, scored as 0, 1, 2 and 3, 
respectively. It has a minimum possible score of zero and a maximum possible score of 21. 
Systematic review evidence (Plummer et al., 2016) suggests a cut-off of eight or nine to optimise 
sensitivity. The GAD-7 has shown to have high levels of internal consistency and test-retest 
reliability (Löwe et al., 2008). It has been used in large-scale treatment studies (Clark et al., 2009) 
and has been shown to be more responsive to change following treatment compared to other scales 
(Dear et al., 2011). The GAD-7 is thus suitable to be used in brief clinical interventions.   
 
The GAD-7 was chosen for the present intervention study as it is based on Diagnostic and 
Statistical Manual of Mental Disorders IV criteria and it is easy to administer without undue 
burden on patients (Ruiz et al., 2011). The scale has previously been used to assess anxiety 
symptoms in patients with IBD (Byrne et al., 2017).  Furthermore, both the PHQ-9 and the GAD-
7 form part of the core Improving Access to Psychological Therapy outcome dataset and thus 
would enable comparison with national data in the future.  
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5.13 Study follow-up assessment times  
Psychosocial intervention studies targeting IBD-fatigue as a primary or secondary outcome have 
varied in their follow-up assessment times. Garcia-Vega and colleagues (2004) assessed the 
effects of stress-management post-treatment, at 6 and 12 months post-treatment. Vogelaar and 
colleagues (2011) assessed the effects of solution-focused therapy and problem solving therapy 
at 3 months post-treatment. Lastly, Vogelaar and colleagues (2014) assessed the effects of 
solution-focused therapy at 3, 6 and 9 months post-treatment. More broadly of the 21 studies 
included in a systematic review of psychological interventions (Timmer et al., 2011), 11 studies 
had a follow-up period of 12 months or longer, in four studies the last assessment was scheduled 
at 3 months and in the remaining studies data were reported for time intervals of 4 to 10 months 
or the exact time point was not specified. No study provided a justification for the choice of 
follow-up assessment times. It was thus difficult to determine the appropriate study follow-up 
assessment times based on evidence from similar trials.  
 
The success of RCTs is contingent upon adequate retention of research participants (Friedman et 
al., 1998) and it is increasingly recognised that performing long-term follow-up RCTs is 
challenging due to attrition. The likelihood of loss to follow-up increases with the duration of 
follow-up (Fewtrell et al., 2016). Attrition can be problematic in intervention studies as it can 
threaten the reliability and validity of the findings by: limiting analyses to a smaller and less 
representative sample and altering the composition of the intervention groups (Ahern and Le 
Brocque, 2005).  Nonetheless, the 12 months post-randomisation follow-up assessment time was 
chosen to assess the long-term durability of psychological treatment on IBD-fatigue. No 
intervention study has previously assessed the effects of psychological treatment on fatigue and 
QoL at one-year post-randomisation. It was therefore important to determine whether any effects 
of CBT were maintained over time. The longest follow-up time utilised by a study targeting 
fatigue as a primary outcome to date was 9 months. In the RCT assessing the efficacy of a 7-
session course of solution-focused therapy (Vogelaar et al., 2014), participants showed a greater 
reduction in fatigue and QoL compared to the care as usual group at 3-months. However at 9 














6 Paper 4 - Cognitive Behavioural Therapy for the Management of Inflammatory Bowel 
Disease-Fatigue: A Pilot Randomised Controlled Trial 
 
This chapter includes the findings from the pilot RCT, submitted as Paper 4 of this PhD thesis 
(Artom et al., 2018, submitted). Paper 4 has been submitted for publication in Trials and 
Feasibility journal and is currently under review. A statement of the contribution of the PhD 
student to this paper appears at the end of the paper on page 162. Amendments to the published 



















































































This chapter presents a summary of the key findings of this PhD project and the key findings in 
relation to the research questions and the wider and relevant literature. Some of the project phases 
are addressed simultaneously, reflecting an iterative process of intervention development as 
advised by the MRC framework. Furthermore, as these questions are intrinsically linked and 
answered by the same study, questions relating to the feasibility of the intervention and of the 
trial protocol will be addressed together in Section 7.2.4. Subsequently, the chapter covers 
critiques to the study, including strengths and limitations of the theoretical framework, the theory 
and the methods used. Implications for the findings overall are then discussed in Sections 7.4 
Implications for research and Section 7.5 Implications for practice. Future plans and conclusions 
are provided.  
 
7.1 Summary of key findings  
The systematic review study (Artom et al., 2016a; PhD Paper 1) identified eight interventions 
tested to address IBD-fatigue. Of these, only four were specifically designed to target fatigue: two 
psychosocial, one behavioural and one pharmacological intervention. There were promising, 
short-term effects for psychosocial and behavioural interventions, including solution-focused 
therapy, stress-management and exercise. Overall, a need for more interventions for the 
management of fatigue was established. IBD-fatigue was significantly associated with modifiable 
clinical and psychosocial factors including disease activity, depression, and anxiety and sleep 
difficulties. However, most studies were cross-sectional; thus the direction of causation remains 
unknown. Further exploration of the interplay between these physical and psychosocial factors 
utilising observational studies was suggested by the systematic review findings.  
 
In the cross-sectional study (Artom et al. 2016b; PhD Paper 2), disease activity was the only 
clinical factor consistently associated with severity and impact of fatigue and QoL. Emotional, 
cognitive and behavioural factors were associated with fatigue and QoL above and beyond the 
influence of sociodemographic and clinical factors. Negative fatigue perceptions were 
significantly associated with severity of fatigue. Negative fatigue perceptions, all-or-nothing and 
avoidance behaviours were significantly associated with impact of fatigue. Additionally, disease 
activity together with currently taking steroids were significantly associated with worse QoL. The 
study findings indicated that emotional and behavioural factors and patients’ negative fatigue 
perceptions, may be the key factors to be addressed to improve fatigue, possibly through 
psychological therapy.  
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For the pilot RCT study (Artom, 2018; PhD Paper 4), feasibility progression criteria assessing 
completeness of outcome measures and compliance were met, those of recruitment and retention 
were not fully achieved. Initial estimates of efficacy with per protocol analysis showed a reduction 
in fatigue scores and an improvement in QoL scores at 3-months post-randomisation. The 
difference in change in scores between the intervention the control group was significant for 
impact of fatigue on daily activities. The intervention was acceptable to participants and feasible 
for therapists to deliver. HCPs reported that the intervention would be broadly applicable but 
time, finance and training constraints may limit its implementation. Results of the pilot study 
indicated that a full-scale effectiveness RCT to test effectiveness and cost-effectiveness of CBT 
for IBD-fatigue was feasible and has a potential for improvement of fatigue with some changes 
to the protocol. Considering online interventions with therapist support sessions may have the 
potential to reduce demand on clinicians and lower costs whilst still maintaining a personalised 
approach to patients.  
 
7.2 Key findings in relation to the PhD research questions and the wider literature  
This study set out to develop a complex intervention for the management of fatigue and test its 
feasibility and potential efficacy in patients with IBD. To achieve the overall study aim, a series 
of questions were posed. In order to answer the study research questions, a systematic review 
study (PhD Paper 1), a quantitative cross-sectional study (PhD Paper 2), intervention 
development with a patient and public involvement activity and a pilot RCT (PhD Papers 3 & 4) 
were conducted guided by the development and the feasibility and piloting phases of the second 
version of the MRC framework (Craig et al., 2008) for complex interventions. Self-regulation 
theory (Leventhal et al., 1980) was utilised as the theoretical basis of the intervention.  
 
7.2.1 Which available interventions for the management of fatigue have been identified and 
previously tested in patients with IBD?  
The research question was answered by a systematic review of available interventions for the 
management of IBD-fatigue (Artom et al., 2016a; PhD Paper 1), which identified the evidence-
base and fulfilled Step 1 of the development phase of the MRC framework. Findings from the 
systematic review informed decision-making on the type of intervention to be developed and 
whether existing research could be replicated or adapted for the development of the PhD 
intervention. At the time of the review, eight interventions had been tested to address IBD-fatigue. 
Of these, only four were specifically designed to target fatigue: two psychosocial, one behavioural 
and one pharmacological intervention. The two psychosocial interventions tested solution-
focused therapy following pilot testing (Vogelaar et al., 2011) and at 6 months’ follow-up in a 
full-scale RCT (Vogelaar et al., 2014) and reported significant positive effects on fatigue and 
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QoL. However, the effects were not maintained at 9 months. The behavioural pilot RCT (McNelly 
et al., 2016) compared exercise advice, omega-3 fish oil, a dietary consultation and placebo and 
found that participants who received advice to initiate physical activity had lower fatigue levels 
measured by the IBD-F scale compared to those receiving exercise placebo at end of treatment. 
Lastly, in an open label pilot study (Costantini and Pala, 2013) assessing the effects of thiamine 
on fatigue, 10/12 patients had a complete remission of fatigue. Yet, extensive methodological 
limitations demanded caution in the interpretation of the findings. Overall, there was judged to be 
a need for more interventions for the management of fatigue. The promising outcomes of 
psychological therapy to improve fatigue contrasted with the lack of knowledge regarding the 
underlying physiological mechanisms of IBD-fatigue (Kreijne et al., 2015) and the 
methodological weaknesses of pharmacological interventions, warranted the exploration of a 
psychosocial intervention for the PhD project. Yet the lack of long-term effects of existing 
psychosocial interventions prompted the need to conduct further development work to add to the 
evidence-base prior to intervention design.  
 
More recent studies, published after the publication of the systematic review (Artom et al., 2016a) 
have left the landscape of interventions for the management of IBD-fatigue relatively unchanged, 
with a suggested potential advantage of psychosocial versus pharmacological interventions. 
Adding to the promising evidence for psychosocial interventions for IBD-fatigue, one non-
pharmacological open label study (Szigethy et al., 2016) assessed the effects of 2-4 sessions of 
brief behaviour therapy for sleep over 4 weeks (Phase 1) and maintenance therapy alone or with 
bupropion (unicylic, aminoketone antidepressant) added over 8 weeks (Phase 2). There was a 
significant decrease in fatigue measured by the Multidimensional Fatigue Inventory (MFI) 
following Phase 1 and a significant change over time of the MFI in the brief behaviour therapy 
for sleep + bupropion group after Phase 2. Conversely, pharmacological interventions for IBD-
fatigue are still in a developmental state with mixed findings (Kreijne et al., 2015). One 
pharmacological open label study (Goodhand et al., 2016) assessed the effects of ferrous sulphate 
(200 mg twice daily) in 43 adolescents and 45 adults with IBD and iron deficiency anaemia. After 
6 weeks of treatment with ferrous sulphate, there was no significant difference in fatigue level 
measured with the MFI scores. Similarly, in a randomised placebo controlled trial (Scholten et 
al., 2017) investigating the effect of surplus oral vitamin B12 supplementation on fatigue in 
patients with IBS or IBD there was no significant difference in scores of the Checklist Individual 
Strength subscale ‘subjective fatigue’ between the intervention group and the control group. 
Lastly, an observational study (Karlsen et al., 2017) investigated whether serum drug 
concentration or anti-drug antibodies of adalimumab influenced severity of fatigue. Assessing 
fatigue in 75 IBD patients with the Fatigue Severity Scale and in 87 IBD patients with the fatigue 
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Visual Analogue Scale, fatigue levels were not influenced by serum concentrations of 
adalimumab, nor by presence of anti-drug antibodies.  
 
The finding that ferrous sulphate does not significantly change fatigue scores (Goodhand et al., 
2016), is consistent with evidence from the PhD systematic review (Artom et al., 2016a) 
demonstrating no significant correlations between iron deficiency and fatigue. Indeed, this finding 
implies that although patients with IBD should be screened for iron-deficiency and non-iron-
deficiency anaemia, other non-anaemic causes of fatigue should always be considered (Hou et 
al., 2016). Contrariwise, the absence of significant effects of oral vitamin B12 (Scholten et al., 
2017) supplementation is somewhat conflicting with previous evidence. Indeed, it is known that 
vitamin B deficiency can cause fatigue (Butler et al., 2006), and evidence from both a small pilot 
study (Costantini and Pala, 2013) testing high-dose thiamine supplementation and an 
observational study (van Langenberg and Gibson, 2014) included in the PhD systematic review 
(Artom et al., 2016a) showed positive effects of vitamin B group supplementation on fatigue. 
Nonetheless, the study (Scholten et al., 2017) used <150 pmol/L as cut-off point when there is no 
consensus on the optimum cut-off  for B12 deficiency (Battat et al., 2014). It may therefore be 
possible that Scholten and colleagues (2017) utilised a too lenient cut-off for B12 deficiency, thus 
not achieving significant changes as a result of the B12 supplementation intervention. 
Furthermore, prevalence of vitamin B12 deficiency has been shown to be low in IBD (Bager et 
al., 2011). Taken together these findings support the notion that nutrient status should be restored 
if necessary through dietary modification and use of supplementation (Kreijne et al., 2015), yet 
there is a considerable proportion of patients for whom fatigue will not respond to 
pharmacological treatments for biochemical conditions (e.g. anaemia) or to disease-modifying 
medication. For these patients the development of other forms of intervention targeting non-
biochemical factors associated with fatigue is necessary, further justifying continued study of 
psychosocial factors and interventions in IBD-fatigue.   
 
7.2.2 Which potentially modifiable physical and psychosocial factors are associated with 
fatigue in patients with IBD?  
The research question was answered by a systematic review assessing targets for health 
interventions in IBD-fatigue (Artom et al., 2016a; PhD Paper 1) and a cross-sectional study 
assessing the contribution of clinical and psychosocial factors to fatigue (Artom et al. 2016b; PhD 
Paper 2). Setting-out to identify the evidence-base to fulfil Step 1 of the development phase of the 
MRC framework, the systematic review (Artom et al., 2016a) evaluated modifiable physical and 
psychosocial factors associated with fatigue in patients with IBD which could be targeted in the 
PhD intervention. Subsequently, aiming to identify components of the intervention and 
appropriate theory to fulfil Steps 2a & 2b of the development phase of the MRC framework, the 
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cross-sectional study (Artom et al. 2016b) addressed the need for further exploration of 
modifiable cognitive (i.e. illness perceptions, symptom focus) and behavioural factors (i.e. 
avoidance, all-or-nothing behaviours) associated with IBD-fatigue which were lacking in the 
systematic review (Artom et al., 2016a) and their interrelation with physical factors. Indeed, there 
is increasing recognition regarding the importance of cognitive and behavioural factors in the 
perpetuation and maintenance of fatigue symptoms in chronic conditions above and beyond the 
role of socio-demographic and clinical factors (Skerrett and Moss-Morris, 2006, Donovan et al., 
2007). Drawing from interventions in other long-term conditions such as cancer, MS and 
rheumatoid arthritis (Gielissen et al., 2006, van Kessel et al., 2008, Hewlett et al., 2011), evidence 
shows that primary disease factors trigger the initial symptoms and how people respond to their 
fatigue cognitively, behaviourally and emotionally may then perpetuate or worsen fatigue. The 
cross-sectional study (Artom et al. 2016b) was thus undertaken to evaluate the relationship 
between fatigue and primary disease factors and the relationship between fatigue and cognitive, 
behavioural and emotional factors in order to corroborate the appropriateness of developing an 
intervention based on self-regulation theory principles in IBD.  
 
Physical factors  
In line with models of fatigue developed in other long-term conditions based on self-regulation 
theory (Skerrett and Moss-Morris, 2006), a consistent positive association was found between 
fatigue and IBD disease activity in both the systematic review  (Artom et al., 2016a) and the cross-
sectional study (Artom et al. 2016b). The relationship between IBD-fatigue and disease activity 
was also established by other observational studies (Tew et al., 2016, Williet et al., 2016, 
Huppertz-Hauss et al., 2017, Jonefjäll et al., 2017, Ratnakumaran et al., 2017) published after the 
systematic review (Artom et al., 2016a). Patients with higher disease activity levels measured by 
standard clinical indices reported higher levels of severity of fatigue and/or impact of fatigue on 
daily activities. Moreover, the relationship between fatigue and active disease has also been 
shown in other inflammatory, relapsing and remitting conditions including: rheumatoid arthritis 
(Singh et al., 2014), MS (Patejdl et al., 2016) and systemic lupus erythematosus (Jump et al., 
2005). The established association between IBD-fatigue and disease activity, confirms the notion 
that primary disease factors may trigger initial symptoms of fatigue in patients with IBD. Fatigue 
may therefore be part of a sickness behavioural response evoked by pro-inflammatory cytokines 
to inflammatory and danger signals from an activated immune system (Dantzer et al., 2008). 
Targeting the underlying inflammatory disease as a first line strategy with pharmacological 
treatment may thus decrease inflammation and in turn reduce fatigue. Likewise, patients with 
active disease should not be included in psychosocial interventions for IBD-fatigue management 
as the targeting of perpetuating psychosocial factors will not be effective if the active disease 
triggering their fatigue is left untreated.  
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Nonetheless, across studies, disease activity has been assessed by different criteria, cut-offs and 
combinations including: i) faecal calprotectin; ii) standard clinical indices; iii) endoscopic, 
radiological, and/or haematological investigations (Artom et al., 2016a) and findings may vary 
according to measurements used. Indeed, in contrast to studies utilising standard clinical indices, 
others have shown no difference in fatigue scores according to faecal calprotectin (Ratnakumaran 
et al., 2017, Huppertz-Hauss et al., 2017) or C-reactive protein (Huppertz-Hauss et al., 2017). It 
is surprising for Simple Clinical Colitis Activity Index (SCCAI) (Walmsley et al., 1998) scores 
and not faecal calprotectin to be associated with fatigue, as the SCCAI has previously shown to 
correlate well with activity measures (Higgins et al., 2005). Conversely, poor correlation between 
the Harvey Bradshaw Index (HBAI) (Harvey and Bradshaw, 1980) and mucosal inflammation 
(Gracie et al., 2016, Peyrin-Biroulet et al., 2016a) may explain in part why subjectively perceived 
disease activity and objective inflammation markers have different relationships with fatigue in 
CD. It has been suggested that standard clinical index scores of disease activity may be influenced 
by psychological comorbidities (Gracie et al., 2016) and that in turn psychological comorbidities 
may also be associated with the reporting of higher levels of fatigue (Ratnakumaran et al., 2017). 
Caution is therefore applied in the interpretation of findings utilising standard clinical indices 
only. In order to unravel this problem further, future studies should therefore consider the 
inclusion of a faecal calprotectin measurement and/or an endoscopic evaluation to be used in 
addition to standard clinical indices. 
 
Psychosocial factors  
The systematic review showed a significant association between fatigue and depression, anxiety 
and sleep difficulties across studies. These findings have subsequently been confirmed by studies 
published after the PhD systematic review (Artom et al., 2016a), where a significant association 
between fatigue, depression, affective spectrum disorders and mental co-morbidity was present 
(Bager et al., 2017; Coates et al., 2017, Huppertz-Hauss et al., 2017). The positive relationship 
between sleep problems and fatigue was also confirmed (Hashash et al., 2017, Huppertz-Hauss 
et al., 2017). Additionally, addressing a gap identified by the systematic review (Artom et al., 
2016a), the cross-sectional study (Artom et al. 2016b) showed a significant association between 
fatigue and cognitive factors such as perceptions of fatigue. Mirroring other conditions (Skerrett 
and Moss-Morris, 2006, Chilcot et al., 2016), more negative fatigue perceptions were 
significantly associated with fatigue severity. Additionally, more negative fatigue perceptions, 
avoidance and all-or-nothing behaviours were significantly associated with impact of fatigue on 
daily activities. Further substantiating the applicability of self-regulation theory for the 
understanding of IBD-fatigue, the established associations between IBD-fatigue and psychosocial 
factors adds support to the notion that how people respond to their fatigue cognitively, 
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behaviourally and emotionally may then perpetuate or worsen fatigue across conditions (Van 
Kessel and Moss-Morris, 2006). People who are depressed or anxious, may have a more negative 
emotional representation of their fatigue and consequently initiate negative coping procedures 
directed at emotion management. The adoption of maladaptive sleep patterns in response to their 
fatigue may lead to the exacerbation of symptoms. Furthermore, those with more negative 
perceptions about their fatigue may develop more maladaptive cognitions and behaviours (i.e. 
avoidance and/or all-or-nothing behaviour) in relation to their fatigue, with consequent worsening 
of the impact of fatigue on their lives (Hagger et al., 2017).  
 
Added support for the relevance of fatigue-related cognitions in the IBD population comes from 
a qualitative study by Jordan et al. (2017). The study explored the experience of people with IBD 
and moderate-severe symptoms of anxiety/low mood to identify psychological processes which 
could be targeted in interventions. Interviews found that when participants had negative 
perceptions about the consequences of their IBD and their IBD-fatigue they described all-or-
nothing behavioural responses, where they cycled between periods of excessive occupational 
activity followed by periods of retreat. This entailed working extended hours and taking on more 
whilst feeling well, to compensate in advance for future periods of reduced functioning due to 
illness. In turn this boom-or-bust behaviour was described by participants as having negative 
consequences in that it led to further tiredness or fatigue and underperformance at work. Adopting 
all-or-nothing behavioural responses may therefore be unhelpful for people with IBD in that it 
may precipitate or maintain fatigue which could perpetuate concerns and maintain anxiety levels.  
 
Overall, these findings are in line with a transdiagnostic cognitive-behavioural perspective 
(Harvey, 2004) which proposes that similar cognitive-behavioural treatment can be used across 
different conditions and that fatigue may respond to similar treatment approaches regardless of 
the specific diagnosis or the trigger of disease-related factors. By adopting this view, which is 
already established in symptoms such as chronic pain (Crowe et al., 2017), core individual clinical 
precipitating factors underling symptoms are addressed first and common processes that 
perpetuate and maintain symptoms are subsequently addressed through CBT (Chalder and Willis, 
2017). Quantitative (Jones et al., 2009, Kwakkenbos et al., 2015) and qualitative studies (Czuber-
Dochan, 2015), and systematic reviews (Czuber-Dochan et al., 2013a, Artom et al., 2016a) have 
shown similarities in the perceived experience of fatigue between different disease groups. 
Likewise, a recent study (Ali et al., 2017) demonstrated comparability in symptom-related 
cognitions and behaviours across autoimmune rheumatic diseases and chronic fatigue syndrome. 
The overlap of cognitive, behavioural and emotional factors associated with fatigue between IBD 
and other long-term conditions found by the cross-sectional study (Artom et al., 2016b) thus 
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implies that targeting unhelpful beliefs across conditions may be a viable therapeutic objective 
for the management of fatigue for patients in disease remission.  
 
7.2.3 Which mechanisms of change are relevant, acceptable and useful when developing an 
intervention for the management of fatigue to patients with IBD? 
Building on the findings from the previous phases of the PhD study, the research question was 
answered by a Patient and Public Involvement activity. The Patient and Public Involvement 
activity aimed to use patient and HCPs perspectives to inform the adaptation of an intervention 
for MS-fatigue to IBD-fatigue, fulfilling step 3 of the development phase of the MRC framework. 
A cognitive-behavioural intervention for MS-fatigue (van Kessel et al., 2008) was chosen as the 
basis for the intervention, based on the results of the PhD systematic review (Artom et al., 2016a) 
and the PhD cross-sectional study (Artom et al. 2016b) which highlighted the importance of 
cognitive, behavioural and emotional factors in association with IBD-fatigue. The process of 
adaptation of the MS-fatigue intervention to the IBD-fatigue intervention is similar to the one 
conducted by others in adapting this MS-fatigue intervention (van Kessel et al., 2008) to cancer 
(Corbett et al., 2016) and renal fatigue (Picariello et al., 2018). The MS intervention had 
promising results in reducing levels of MS-fatigue (van Kessel et al., 2008) and incorporated in-
depth mediation analysis (Knoop et al., 2012) demonstrating the significance of changing 
perceptions of fatigue in decreasing the severity of fatigue. Following a logic model (Figure 6, p. 
58) focused on changing negative emotions and unhelpful cognitions and behaviours in relation 
to fatigue, the PhD intervention therefore aimed to break the vicious cycle of fatigue, ultimately 
reducing its severity and impact on QoL. Findings from the Patient and Public Involvement 
activity informed the adaptation of a CBT intervention for the management of IBD-fatigue, of 
which the protocol is published as Paper 3 (Artom et al., 2017) and the results are presented as 
Paper 4 (Artom, 2018; submitted).  
 
Iterative work with both patients and HCPs who work with patients with IBD was then conducted 
in order to tailor the intervention to IBD patients. By conducting this process with Patient and 
Public Involvement groups, intervention manual development is not conceptualised as a single 
event but as a series of progressive stages in which the manual is refined to fit users’ needs 
(Carroll and Nuro, 2002). Findings from the Patient and Public Involvement activity showed that 
the content of the manual was perceived as useful and relevant in helping people with IBD manage 
their fatigue. Specifically, in line with the therapeutic objectives of the intervention, information 
regarding cognitive-behavioural mechanisms of fatigue were considered particularly relevant to 
participants’ experience of IBD-fatigue. Consistent with a transdiagnostic approach to fatigue 
management, it was therefore postulated that mechanisms of change based on modification of 
cognitive-behavioural factors related to fatigue in MS (Van Kessel and Moss-Morris, 2006) were 
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relevant, acceptable and useful to patients with IBD. Aside from adding more IBD-specific 
examples, participants suggested no changes to the therapeutic content of the manual.  
 
7.2.4 What is the feasibility of an intervention for the management of fatigue in patients with 
IBD? & What is the feasibility of a trial protocol for delivering a full pragmatic RCT of 
an intervention for the management of fatigue in patients with IBD?  
The research questions were answered by a pilot intervention study with a nested qualitative 
component (Artom, 2018; submitted; Paper 4) which aimed to test procedures and estimate 
recruitment and retention, covering the  feasibility and piloting phase of the MRC framework. 
Progression criteria for continuation to a full-scale RCT relating to the feasibility of the 
intervention and feasibility of the trial protocol were set. Feasibility progression criteria assessing 
completeness of outcome measures and compliance were met, with a low proportion of missing 
item responses in questionnaires and 90% reported compliance rates to reading the intervention 
manual. Progression criteria of recruitment and retention were not fully achieved, with 44% of 
eligible participants consenting for participation, a withdrawal rate during treatment of 23% and 
a loss to follow-up rate of 29%. The intervention was acceptable to patients and feasible for the 
CBT therapists to deliver. However, HCPs identified potential barriers to the feasibility of 
implementation of the intervention in clinical practice. Overall these findings suggested a full-
scale effectiveness RCT testing CBT for IBD-fatigue is feasible with some changes to the 
protocol.  
 
The high level of completeness of the outcome measures suggested that the measures used were 
acceptable to patients (Brédart et al., 2002). Evidence shows that involving patients can be 
beneficial in assessing the appropriateness, wording and timing of research instruments (Brett et 
al., 2014). As such, the development of the questionnaire booklets together with Patient and 
Public Involvement may have enhanced the acceptability of the outcome measures. Likewise, the 
high levels of compliance for participants who started the intervention, indicated the acceptability 
of the intervention tasks. The choice of adapting an existing CBT intervention for MS-fatigue 
(van Kessel et al., 2008) which has already proven to be an acceptable treatment option for 
patients with MS-fatigue, may have aided in increasing participant compliance with the 
intervention tasks. Further confirmation of the acceptability of the intervention to patients was 
evidenced from interviews with participants in the CBT intervention group. Participants reported 
having a positive experience of taking part in the intervention, providing encouraging views on 
the intervention manual and the modality of communication of the therapy sessions. Similarly, at 
the end of the intervention delivery the therapists stated that they would use this intervention for 
the management of IBD-fatigue in the future, implying the feasibility of delivery of the 
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intervention. Indeed, the use of a treatment manual may have been beneficial in helping the 
therapists feel more guided and supported in delivering the treatment (Langer et al., 2011).  
 
Clinical trials are harder to recruit for than observational studies due to the greater commitment 
from participants in terms of time (Newington and Metcalfe, 2014). The lower than expected 
consent for participation highlighted that time commitment required for the intervention may be 
a potential barrier to the uptake of a full-scale CBT trial for IBD-fatigue (Moss-Morris et al., 
2010). Indeed, CBT takes on a collaborative stance that encourages patients to work together with 
the therapist on changing how they feel by applying what they have learned. Aside from reading 
the intervention manual and undertaking the sessions with the therapist, CBT often requires 
patients to spend additional time completing tasks related to the intervention. As change is 
assumed to take place in between therapy sessions, homework is important in enabling that 
change (Williams and Garland, 2002, Bannink, 2017). For a predominantly young, working 
population of patients with IBD-fatigue, spending time undertaking the intervention tasks on top 
of their daily commitments may be very difficult. Qualitative research (Czuber-Dochan et al., 
2013b, Beck et al., 2013) has shown that IBD-fatigue limits patients’ in their everyday lives and 
patients spend their energy on activities of high importance to them (i.e. family and work). If 
participants perceive that the study would not sufficiently benefit them, they may not be motivated 
to prioritise participation over their daily activities (Locock and Smith, 2011). 
 
Other reasons for the slightly lower than expected recruitment rates may be related to the 
characteristics of the study population. In a study exploring the characteristics of non-responders 
to self-reported questionnaires in an IBD-cohort study (Multone et al., 2015), age > 50, female 
gender and longer disease duration were identified as factors inversely associated with non-
response. Reported signs and symptoms of depression were also a risk factor for non-response. 
The latter finding is in line with evidence showing that patients with mood disorders (Mein et al., 
2012) are at higher risk of non-response in studies. Unfortunately, due to ethical reasons, socio-
demographic and clinical data for those who did not consent to participate could not be recorded 
in the PhD intervention study. Nonetheless, the baseline characteristics of those who consented 
(i.e. 65% female gender, mean age of 38, median time since diagnosis of 16 years), suggest 
different socio-demographic subgroups of the population may have been more willing to 
participate. Furthermore, with a high comorbidity between IBD-fatigue and depression (Artom et 
al., 2016a) and high levels of depression reported in this intervention study (mean PHQ = 10.87), 
it is possible that their depressive symptoms may make patients with IBD-fatigue a particularly 
difficult group to recruit. Strategies to improve recruitment in future trials could include: having 
a dedicated research nurse for recruitment at each site, recruiting through charity networks such 
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as CCUK and engaging participants at the start of the programme by better highlighting the 
benefits of the research in its early stages (Donkin and Glozier, 2012).  
 
Despite not achieving the pre-defined progression criteria, findings relative to retention of 
participants are comparable to or higher than other pilot psychosocial studies in IBD across 
different modalities of intervention delivery (Vogelaar et al., 2011, Mikocka-Walus et al., 2015, 
Schoultz et al., 2015). A study testing individual, face-to-face, psychological interventions (i.e. 
solution-focused and problem-solving therapy) for IBD-fatigue (Vogelaar et al., 2011), reported 
a during treatment withdrawal rate of 21%. Investigating the efficacy of online CBT for managing 
anxiety and depression in IBD, Mikocka-Walus et al. (2015), reported a 33% loss to follow-up 
rate at 6 months and a 56% loss to follow-up at 24 months. In a trial comparing group 
mindfulness-based cognitive therapy vs. wait-list control for depressive symptoms and stress in 
IBD (Schoultz et al., 2015), the during treatment withdrawal rate was 45% and the loss to follow-
up rate was 41%. It is hence possible that the progression criteria for retention in the PhD 
intervention were set unrealistically high.  
 
Alternatively, one participant who dropped out at session 4 reported feeling that the intervention 
was not suitable to him as his fatigue was not severe enough. Therefore, low retention rates may 
have been due to the threshold for fatigue at enrollment being set too low. Additionally, other 
reasons could also explain low retention rates. Participants may have had unrealistic perceptions 
around the benefits of the intervention (McDonald et al., 2006). Similarly, participants may not 
have fully comprehended the impact of psychotherapy at the start of the intervention and thus 
have been reluctant to further participate after the first sessions (Vogelaar et al., 2011). 
Furthermore, if participants perceived contact with staff to be insufficient during the study, they 
may not feel supported enough to remain engaged in the trial (Mikocka-Walus et al., 2017). 
Lastly, participants may not have persisted with the intervention because they believed that the 
research was not important enough or were not invested in participating in the research from the 
start. Indeed, evidence shows that people who participate in research trials are more likely to view 
research more favourably (Madsen et al., 2002). Strategies to improve retention may include: 
outlining the exact time requirements of participation in the invitation materials so that 
participants are more aware of what to expect, offering more flexible appointment times (Attwood 
et al., 2016) and the use of web-based data collection which reduces time associated with study 
participation (Akmatov et al., 2017).  
 
HCPs found a broad applicability and usefulness of the intervention to their IBD patient group. 
Indeed, consistent with previous qualitative (Czuber-Dochan et al., 2014b) and quantitative 
research (Dibley et al., 2017), HCPs reported struggling to help patients with IBD-fatigue. The 
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intervention was thus seen as a promising addition to the limited array of interventions 
recommended by HCPs to manage IBD-fatigue. However, no current member of the IBD team 
was seen to have enough time and adequate training to deliver the intervention in its current 
format. Doctors were unlikely to have capacity to deliver the intervention and availability of 
financial resources to employ an external therapist to deliver the CBT intervention was also 
perceived as limited. The identified lack of resources is consistent with the knowledge that the 
UK NHS is currently under-funded and overstretched. Eighty-five percent of physicians believe 
that the current health funding is insufficient to meet the rising demand for health services, the 
number of medical and nursing students has fallen and NHS staff increasingly feel like collateral 
damage in the battle between rising demand and squeezing budgets. Even the most useful and 
effective intervention will be worthless if it cannot be implemented into clinical practice, and 
inadequate training of practitioners and lack of funding are among the two principal factors which 
contribute to the limited translation of evidence-based approaches (Glasgow and Emmons, 2007). 
As such, despite the positive views of HCPs regarding the use of the intervention, identified 
barriers to implementation need to be addressed prior to the progression of the study to a full-
scale RCT. This should be done by integrating an economic evaluation in the full-scale RCT to 
demonstrate cost-effectiveness (Glasgow and Emmons, 2007) and finding less resource intensive 
modalities of delivery of the intervention such as online interventions (Griffiths et al., 2010).   
 
Barriers to implementation of the intervention were similarly identified in the original MS-fatigue 
trial (van Kessel et al., 2008). Despite promising results of the face-to-face CBT for MS-fatigue, 
few MS services have access to a CBT therapist. Consequently, a mixed method pilot RCT of an 
internet-based version (Moss-Morris et al., 2012) of the therapist-delivered CBT intervention for 
MS-fatigue (van Kessel et al., 2008) was trialed. The online intervention consisted of eight, 
interactive, tailored weekly sessions. Participants received three telephone support sessions of 
between 30–60 min, while they worked through the programme. Large between group treatment 
effects were found for the primary outcomes of fatigue severity (d = 1.19) and impact (d = 1.02). 
The online CBT group also reported significantly greater improvements in anxiety, depression 
and quality-adjusted life years. Internet delivery of the intervention was acceptable to most 
participants and cost-effective. Additionally, this internet-based version was subsequently piloted 
in New Zealand (van Kessel et al., 2016) to compare use of the website only (MSInvigor8-Only) 
with use of the website plus email-based therapy support (MSInvigor8-Plus). The MSInvigor8-
Plus condition resulted in significantly greater reductions in fatigue severity and impact compared 
with the MSInvigor8-Only condition. Large between-group effect sizes for fatigue severity (d = 
0.99) and fatigue impact (d = 0.81) were found. These findings therefore suggest that online CBT 
interventions for the management of fatigue may be feasible, potentially effective and cost-
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effective. Yet providing regular support alongside the website may have added benefits in terms 
of adherence to the programme and improvements of fatigue outcomes.  
 
7.2.5 What are the initial estimates of efficacy of an intervention for the management of fatigue 
in patients with IBD? 
The research question was answered by a pilot intervention study with a nested qualitative 
component (Artom et al., 2017; PhD Papers 3&4). There were greater improvements at 3-months 
post-randomisation in severity and impact of fatigue and QoL for the intervention group 
compared to the control group, yet these differences were significant only for impact of fatigue. 
Preliminary efficacy analysis from the study thus indicates that changing IBD-patients’ feelings, 
cognitions and behaviours in relation to fatigue may improve the impact that fatigue has on their 
lives. Consistent with results of CBT interventions in other conditions such as MS (van Kessel et 
al., 2008), rheumatoid arthritis (Hewlett et al., 2011) and cancer (Gielissen et al., 2006, 
Goedendorp et al., 2010), results of the intervention suggest that CBT is effective in targeting 
perpetuating factors of fatigue in IBD-patients in remission. Once modifiable primary disease and 
clinical factors shown to trigger IBD-fatigue in the systematic review (Artom et al., 2016a) have 
been managed through pharmacological interventions, modifiable psychosocial factors shown to 
perpetuate IBD-fatigue in the cross-sectional study (Artom et al. 2016b) can be managed through 
non-pharmacological interventions based on cognitive-behavioural models.  
 
Utilising sections I and II of the IBD-Fatigue scale (Czuber-Dochan et al., 2014a), the intervention 
study (Artom et al., 2017) aimed to determine the effects of CBT on both the severity of, and 
impact of, fatigue. Impact is not the same as fatigue severity and the inclusion of measures of 
perceived severity and impact of fatigue on daily life is advised to better elucidate intervention 
effects on fatigue (Joseph et al., 2015). Indeed, fatigue severity does not reflect a person’s 
perception and appraisal of the fatigue and measuring only fatigue severity can fail to capture 
differences in the experience of fatigue. If a decrease is seen in fatigue severity and the impact of 
fatigue remains high, it can imply that a patient still suffers and is disabled due to fatigue. The 
patient is thus not fully recovered (Knoop et al., 2007). Differences in improvements at 3-months 
post-randomisation for the intervention compared to the control group were significant for impact 
of fatigue but not severity of fatigue. The extent to which patients perceive fatigue to impact on 
their daily activities is individual and may be seen in the context of personal attributions (Sirois, 
2009). Consequently, the significant effect of CBT on impact of IBD-fatigue on daily activities 
is in line with the notion that CBT can change subjective psychological factors which determine 
how patients experience symptoms.  
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Multiple explanations can be advanced for the lack of significant effects on severity of fatigue. 
This may be a result of the complex, multidimensional and multifactorial aetiology of fatigue in 
IBD (Dittner et al., 2004). Indeed, although psychological factors have been shown to perpetuate 
IBD-fatigue (Graff et al., 2013), inflammatory disease-related processes may still play a role in 
causing fatigue even when IBD is quiescent (Czuber-Dochan et al., 2013a). As such, if these 
inflammatory disease-related processes are not fully controlled, CBT may help to improve the 
impact of fatigue on patients’ daily activities yet not necessarily have an effect on its severity to 
the same degree. Another explanation is that the sample was too small to detect meaningful 
differences. Alternatively, as tiredness is common in the general population, it may be difficult 
for patients to discriminate where experiencing fatigue as a sign of illness ends and the experience 
of normal daily activities (Gielissen et al., 2007). Lastly, as suggested for a CBT intervention for 
MS-fatigue (Thomas et al., 2014) where improvements were only shown 4 months after the 
intervention ended, it may be that changes may take longer to have an impact because behavioural 
changes are only slowly adopted in daily life. Therefore, it is possible that the effects on fatigue 
severity may require longer time to be evidenced compared to those on fatigue impact.  
 
Building on the quantitative data indicating efficacy for CBT on impact of fatigue, qualitative 
interview data from the intervention (Artom et al., 2017) showed that participants experienced a 
change in the negative way they thought and felt about their fatigue. Participants highlighted that 
having more positive thoughts about fatigue had helped them feel better about it, ensure it had a 
lesser impact on their lives and ultimately manage it more effectively. Furthermore, participants 
identified negative behavioural strategies through the homework tasks and then modified them as 
a result of the CBT. In line with recent qualitative evidence in IBD (Jordan et al., 2017), all 
participants talked about the negative all-or-nothing behavioural patterns they had been adopting 
before the trial, and how the intervention had taught them to better pace their activity levels 
through self-monitoring, introducing breaks, planning their time effectively and learning to say 
no. This is consistent with self-regulation theory (Leventhal et al., 1980) which states that the way 
people think about their illness can have a significant impact on the way they feel about, behave 
in relation to and cope with their symptoms. In absence of mediation analysis this causal 
mechanism between changes in cognitions and changes in fatigue cannot be confirmed at this 
stage (Windgassen et al., 2016). However, drawing from mediation analysis conducted in the 
original MS-fatigue trial (Knoop et al., 2012), it may be implied that the intervention helped to 
break the vicious cycle of cognitive, behavioural and emotional responses to symptoms which 
interact with clinical factors to maintain IBD-fatigue. Future studies should therefore include 
mediation analysis to determine these causal mechanisms.  
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The non-significant effect of the intervention on IBD-specific QoL is somewhat surprising. 
Nonetheless, QoL scores improved in both the CBT intervention and control group, with the 
intervention group showing a greater increase from baseline to follow-up compared to the control 
group. This is consistent with other pilot studies assessing the effects of psychosocial 
interventions for IBD-fatigue (Vogelaar et al., 2011), depression and anxiety (Schoultz et al., 
2015) and distress (Mikocka-Walus et al., 2015) where change in QoL scores did not mimic 
change in other outcome measures for all patients as expected. One of the possible explanations 
is that sample sizes in these studies was too small to detect any significance (McCombie et al., 
2013). Another, is that psychotherapy may only improve QoL of life for a subgroup of patients 
more ‘in need’ (i.e. with high scores on mental health subscales), thus implying that 
psychotherapeutic interventions should be targeted at this group rather than the general IBD 
population (Mikocka-Walus et al., 2015). Lastly, it may be suggested that the CBT intervention 
was not as effective in improving QoL as it was at improving impact of fatigue because the 
intervention was designed specifically to improve fatigue, and improvements in QoL are a likely 
consequence of symptom improvement. Indeed, similar results have been found in a meta-
analysis of CBT for eating disorders (Linardon and Brennan, 2017), where improvements in QoL 
were smaller compared to changes in improvements in eating disorders.  
 
7.3 Critiques of the study 
Strengths and limitations of the individual studies are described in the discussion section of each 
of the four published papers. Findings from the studies should be interpreted in light of these. 
Reflecting on this PhD project overall, critiques to the theoretical framework, the theory and the 
methods applied to each phase of the MRC framework to answer the research questions are 
discussed below.  
 
7.3.1 Critiques of the theoretical framework 
A number of strengths of the use of the MRC framework (Craig et al., 2008) to guide the 
development of the PhD intervention were identified. The use of the development phase of the 
MRC framework was firstly helpful in identifying the components and mechanisms that would 
underpin the PhD intervention in advance of piloting its efficacy. Indeed, the identification of the 
intervention components and mechanisms of change was key in then selecting an MS-fatigue 
intervention (van Kessel et al., 2008) to adapt for the management of IBD-fatigue (Haji et al., 
2014). The use of the MRC framework supported the grounding of the intervention development 
process in a theoretical framework. Furthermore, by including a feasibility and piloting phase, 
the risk of evaluating an unfeasible intervention in a large-scale effectiveness RCT was reduced. 
The MRC’s guidance to incorporate qualitative methods within RCTs ensured that the PhD 
intervention was more appropriate and relevant to the needs of the target population. The MRC 
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framework’s guidelines to publish piloting work, allowed for useful data from the intervention 
pilot to be disseminated for wider use (Reelick, 2011). The recommendation of the MRC 
framework to explain the decision-making process in each phase, aided in adopting a more 
reflective and critical approach to intervention development (Craig and Petticrew, 2013). 
 
Limitations of the MRC framework for this PhD project were mainly related to its application. 
Although numerous papers reporting the utilisation of the MRC framework as guidance for the 
development of complex interventions were identified, examples in which the step-by-step 
application of the framework was described were rare (Hurley et al., 2016). Accounts of how 
different research methods can be utilised in intervention development were found (i.e. systematic 
reviews to identify and evaluate the evidence-base, quantitative studies to help to draw 
conclusions about likely intervention effects and potential effect modifiers, qualitative studies to 
provide an in depth understanding of relevant issues) (O'Brien et al., 2016). Nonetheless, there 
was a lack of clarity over the methods to be applied to each MRC phase, making it difficult to 
make fully informed decisions on the methods to use during the development of the PhD 
intervention.  
 
A posteriori, in order to gain a better understanding of which methods have been applied by other 
researchers, studies which used the MRC framework were reviewed (Appendix XVIII). As a 
comprehensive and recent review of the evidence had already been conducted, the studies were 
drawn from two reviews (Corry et al., 2013, Levati et al., 2016). The systematic review by Corry 
and colleagues (2013) aimed to review published guidelines for intervention development and to 
examine how researchers have used guidelines when developing interventions. Of the 14 papers 
included in the review which reported the development of interventions, the 9 papers which 
referred to the MRC framework were included. The scoping review by Levati and colleagues 
(2016) aimed to identify and synthesise the available evidence relating to the strategies and 
methods used to optimise interventions at the pre-trial stage. Of the 27 papers included in the 
review, the 17 papers which referred to the MRC framework were included. Seven of the papers 
overlapped between the two reviews, with a total of 20 papers remaining. For each study the 
version of the MRC framework (Campbell et al., 2000, Craig et al., 2008) utilised and the methods 
applied for each phase were specified.  
 
Overall, the brief review showed a wide variation in the ways in which studies applied the MRC 
framework. To identify the evidence-base most studies conducted single or multiple, systematic 
or non-systematic reviews. The methods utilised for the other steps of development were very 
different according to each study. For instance, to identify/develop theory methods included: 
additional literature searches, qualitative interviews, focus groups, questionnaire surveys, analysis 
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of registry data, content analysis of available interventions and non-participatory observation. 
Likewise, to model processes and outcomes qualitative interviews, focus groups, economic 
modelling, Delphi studies and consensus processes and non-participatory observation were used. 
As such, it can be hypothesised that to date investigators have no conclusive path to follow for 
choosing the methods to apply to each phase of the MRC framework. A further refinement of the 
second version of the MRC framework  (Craig et al., 2008) or the integration of other frameworks 
such as the Steps for Quality Intervention Development proposed by Wight et al. (2015) may be 
helpful in filling this important methodological gap.  
 
7.3.2 Critiques of the theory 
The use of self-regulation theory (Leventhal et al., 1980) as the basis of the intervention was 
chosen as a result of the PhD systematic review (Artom et al., 2016a; PhD Paper 1) and 
subsequently tested  by the PhD cross-sectional study (Artom et al. 2016b; PhD Paper 2). Self-
regulation theory is a patient-centred and dynamic theory, in which individuals’ perceptions of 
their illness and symptoms are constantly evolving (McAndrew et al., 2017). Its use was therefore 
helpful in developing an intervention which recognised patients’ capacity for change through self-
management. In the development phase, self-regulation theory was beneficial in selecting which 
psychosocial variables should be manipulated by the PhD intervention in order to produce the 
desired change in fatigue (Eccles et al., 2005). The theory was also a steppingstone in the choice 
of a cognitive-behavioural therapeutic modality for the intervention. The compatibility between 
self-regulation theory and cognitive behavioural techniques and theory has previously been 
demonstrated (McAndrew et al., 2008). As self-regulation theory incorporates cognitive and 
behavioural concepts, it is intuitive for cognitive and behavioural skills from CBT to be used to 
modify behaviour and challenge maladaptive cognitions which maintain poor self-regulation. In 
line with these tenets, it was thus postulated that CBT could be effective in modifying illness 
perceptions and coping responses, which in turn influence outcomes (i.e. lower to higher levels 
of fatigue). Finally, in the modelling phase, the use of self-regulation theory aided in enhancing 
the process of intervention development by drawing on effective interventions in other conditions 
based on cognitive-behavioural principles (Gielissen et al., 2006, van Kessel et al., 2008, Hewlett 
et al., 2011) without ‘reinventing the wheel’ (Lippke and Ziegelmann, 2008). 
 
Grounding this PhD project in self-regulation theory was valuable to understand how people self-
manage and cope with symptoms, however it is not a stand-alone approach for addressing 
symptoms in complex interventions (McAndrew et al., 2017). RCTs which have used self-
regulation theory alone in an attempt to influence the process of self-regulative illness 
management are sparse (Hagger et al., 2017) and self-regulation theory is generally used as an 
adjunct with other therapeutic modalities (Corbett et al., 2015). Although the PhD intervention 
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incorporated some principles of self-regulation theory, the theory was not overtly addressed 
within the treatment manual or the sessions. Indeed, participants filled out the Brief Illness 
Perceptions Questionnaire (Broadbent et al., 2006) as part of the outcome measure booklet, yet 
their perceptions of fatigue were not elicited directly by the therapist. By adapting an existing 
manual for the management of MS-fatigue (van Kessel et al., 2008) the therapeutic content of the 
intervention could not be significantly altered. Mimicking research conducted in cancer fatigue 
(Corbett et al., 2015, 2016), in the future however, the theory could be incorporated more 
explicitly in both the development phase and the CBT therapeutic process in order to help the 
therapists develop a treatment plan more tailored to their patients’ needs. By eliciting the patients’ 
perceptions about their fatigue for instance, the therapist could then identify the perceptions which 
are key to improving self-management, and subsequently work with them to negotiate a shared 
set of more helpful fatigue perceptions (McAndrew et al., 2017).  
 
7.3.3 Critiques of the methods 
The systematic review (Artom et al., 2016a; PhD Paper 1) identified modifiable factors which 
had already been or could be targeted by health interventions to reduce IBD-fatigue. A systematic 
review study was considered appropriate to explore available interventions and potentially 
modifiable factors associated with IBD-fatigue, as it enabled collection of all available empirical 
evidence on these aspects (Higgins and Green, 2011). Indeed, the systematic review (Artom et 
al., 2016a) was useful in systematically evaluating the effects of existing interventions for IBD-
fatigue. Nonetheless, results of a systematic review are dependent on the quality of the studies 
used as the primary data source (Smith et al., 2016). Although 79% of the included studies in the 
systematic review (Artom et al., 2016a) were high or medium quality, no studies were excluded 
on the basis of quality. Consequently, findings should be carefully appraised before reaching 
definitive conclusions. Furthermore, due to the limited number of interventions available, no clear 
pattern of results favouring one particular intervention type emerged. Likewise, although effects 
were found for psychosocial interventions, it was unclear which behaviour change techniques in 
the psychosocial interventions were responsible for the observed changes in fatigue. In order to 
overcome these barriers, in the future the application of a taxonomy of behaviour change 
techniques (Abraham and Michie, 2008) could help to identify what made an intervention more 
effective than another. Evaluating the effectiveness of the individual behaviour change 
components of the interventions rather than the interventions as a whole, would enhance the value 
of the systematic review by enabling a more informed selection of intervention components 
during intervention development process (Michie et al., 2009).  
 
The cross-sectional study (Artom et al. 2016b; PhD Paper 2) evaluated the potential relationship 
between modifiable cognitive-behavioural factors and IBD-fatigue. A cross-sectional study was 
190 
considered appropriate to explore potentially modifiable factors associated with IBD-fatigue, as 
it allowed for multiple clinical and psychosocial outcomes potentially associated with IBD-
fatigue to be studied at the same time (Mann 2003). Furthermore, the study enabled the 
assessment of fatigue in a relatively large and diverse sample of IBD patients, and across multiple 
hospital sites. However, causation could not be determined from data collected only at one point 
in time and cross-sectional studies do not provide an explanation for their findings (Price and 
Murnan, 2004). Since data on exposure and outcome were obtained at the same time, the direction 
of the association could not be established with certainty (DiPietro, 2010). Conversely, a 
longitudinal design would have allowed for more robust temporal associations between clinical 
and psychosocial factors to be assessed, together with an analysis of mediating factors. In order 
to overcome limitations of cross-sectional study design, 12 and 24-months’ follow-up points were 
included in the design of the quantitative study and in the ethical approval application. Due to the 
limited time-frame of this PhD project, only the baseline results of the longitudinal study were 
analysed and included in this thesis. At the time of writing-up of the present chapter, 24-months’ 
follow-up data are being collected. Analyses and dissemination of the longitudinal study research 
will follow. As fatigue has been demonstrated to be very variable, with fluctuations over time 
(Schwartz et al. 2000), upcoming follow-up assessment time-points will provide a more complete 
picture of patterns of fatigue in patients with IBD. 
 
A Patient and Public Involvement activity informed the adaptation of a CBT intervention for MS-
fatigue to IBD-fatigue. Involving end-users in the development process was useful in making the 
intervention more responsive to IBD-patients’ needs. However, the Patient and Public 
Involvement activity was limited in its scope. Indeed, participants annotated comments on the 
intervention manual and completed a structured feedback form at only one point in time. The 
inclusion of more iterative phases, moving between participants’ feedback and changes to the 
intervention, may have been helpful in providing detailed information on specific aspects of the 
intervention. Furthermore, in depth qualitative techniques for including Patient and Public 
Involvement could have been used to improve the intervention development process. Think-aloud 
interviews for instance, ask people to give their immediate reactions to every element of the 
intervention and allow researchers to also observe how it is used (Van den Haak et al., 2007). 
They can be important in identifying problems experienced by people when carrying out the 
intervention and allow modification of the intervention accordingly. Alternatively, retrospective 
semi-structured interviews can be valuable to evaluate people’s experiences after completion of 
either a part of or the whole intervention. Semi-structured interviews can be complementary to 
think-aloud interviews because they provide information about how people use interventions in 
absence of the researcher, who might otherwise influence their experiences (Bradbury et al., 
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2014). Additionally, diaries can enable people to keep a longitudinal record of aspects of the 
intervention they found helpful or unhelpful, easy or hard to use and relevant or irrelevant.  
 
In the future, the evaluation of the PhD intervention in a full-scale RCT as an online platform 
could permit more comprehensive Patient and Public Involvement work with patients to be 
conducted with a lower expenditure of resources. In online intervention development, users are 
involved iteratively throughout the entire process. Initially users can help to identify the 
intervention objectives and key features of the intervention needed to achieve each objective. 
Once a prototype is created, users can test it to gain insight on whether the intervention is 
acceptable, interesting easy to use and feasible for people to adhere to. As user feedback is 
collected, changes can be made to the intervention and further Patient and Public Involvement 
can be conducted to determine whether the implemented changes are suitable. Lastly, after the 
prototype is refined users can be encouraged to use the intervention on their own in order to try 
behavioural changes supported by the intervention. Indeed, online interventions are typically used 
independently by users, and so they must be designed with an understanding of how people do 
this (Yardley et al., 2015). Furthermore, the application of a prioritisation method such as the 
MoSCoW analysis (Bradbury et al., 2014), could streamline the process of incorporating user 
feedback to the online intervention development. The method ranks content changes into: ‘Must’ 
– essential change, ‘Should’ – important but not critical content change, ‘Could’ – desirable 
content change and ‘Would’ – change that could improve user experience but by no means 
essential.  
 
The pilot RCT (Artom, 2018; submitted; PhD Paper 4) assessed the feasibility and initial 
estimates of efficacy of a CBT manual with 8, weekly therapist telephone sessions vs. a fatigue 
information sheet without therapist help. The undertaking of a pilot study prior to a full-scale 
effectiveness RCT was useful in evaluating the feasibility, acceptability and efficacy of the 
intervention prior to rolling it out across a wide range of settings. Changes to the protocol can 
now be conducted in order to make the intervention trialled in the full-scale evaluation more 
implementable in the NHS (Craig and Petticrew, 2013). Moreover, the inclusion of a nested-
qualitative study within the RCT allowed for the patient, therapist and healthcare professionals’ 
perspectives to be embedded in the future intervention. These perspectives led to the 
understanding of which components of the intervention worked to improve fatigue and potentially 
the reasons why. However, the small external pilot design of the study prevented the possibility 
of conducting mediation analysis to confirm the causal mechanisms between changes in 
cognitions and changes in fatigue. As such, mediation analysis should be included in the full-
scale RCT for the advancement of psychological theory and refinement of clinical practice. By 
pinpointing mediating psychological mechanisms, therapeutic processes may be refined to focus 
192 
on specific aspects of therapy that lead to improvements in outcomes, with the possibility of 
discarding aspects that are less relevant. Uncovering mechanistic processes can also lead to more 
effective delivery of therapy and can be useful for development and enhancement of treatments 
that can be used transdiagnostically across different conditions, tackling a range of outcomes 
simultaneously (Windgassen et al., 2016).  
 
Additionally, ethical approval permissions were not sought for the inclusion of fidelity 
assessments in the pilot RCT. Intervention fidelity refers to the extent to which the core 
components of the intervention are delivered as intended by the protocol (Bond et al., 2000). 
Intervention fidelity can impact both the internal validity and the external validity of these studies 
and has implications for the ability to attribute symptom changes to the intervention and to 
replicate and disseminate treatments (Perepletchikova et al., 2007). Consequently, audio-
recording and fidelity coding of a subset of the sessions should be included in the full-scale RCT 
in order to give providers corrective feedback when the intervention is ongoing and identify 
potential fidelity-outcome associations at the end of the intervention (Miller and Rollnick, 2014).   
 
7.4 Implications for research 
The results of this PhD project have a number of implications for research:  
• Psychosocial factors (emotional, cognitive and behavioural) are consistently associated 
with IBD-fatigue. Further longitudinal research can help to unravel the relationship 
between psychosocial and clinical factors in IBD-fatigue.  
• Cognitive-behavioural factors maintaining and/or perpetuating fatigue are similar across 
conditions. Drawing from other conditions to develop interventions utilising a 
transdiagnostic approach can be helpful to develop effective interventions without re-
inventing the wheel.  
• Cognitive-behavioural interventions can contain complex language. The average reading 
age for a standard CBT intervention is 17 years (Flesch–Kincaid grade 12) (Williams and 
Garland, 2002). Existing interventions need to be evaluated together with patients in order 
to make the language appropriate to their needs.  
• Patient and Public Involvement is useful in making the intervention relevant to patients’ 
needs. More time should be planned for intervention development in order for patients to 
be involved iteratively throughout the intervention development process.  
• In depth qualitative research is important when developing complex interventions to 
ensure that interventions are usable and engaging (Yardley et al., 2015). Qualitative work 
should be included in the intervention development phase.  
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• CBT is a feasible and effective therapeutic modality for the management of IBD-fatigue. 
Therefore test CBT in a full-scale RCT with some adaptations to the protocol.  
• Low satisfaction rates were experienced in control group receiving Fatigue Information 
Sheet. The use of a comparison instead of a control group, e.g. in which intervention time 
is kept constant across the two groups may help to minimise the effect of patients’ 
expectancy on attrition. The use of validity checks to test the validity of the control 
condition may also be beneficial. Alternatively, a different trial design such as a stepped 
wedge RCT which involves sequential roll-out of an intervention to participants over a 
number of time periods, would allow all participants to receive the CBT intervention. 
Indeed, this design is particularly relevant where it is predicted that the intervention will 
do more good than harm (Brown and Lilford, 2006).  
• The telephone is an acceptable modality of delivery of support sessions. Use telephone 
rather than face-to-face support sessions in a full-scale RCT (Freedland et al., 2011).  
• Manualised CBT with therapist support sessions may not be feasible to implement in 
NHS IBD services. Ways to increase the feasibility of implementation need to be 
identified. These could include testing the CBT manual without therapist support or the 
translation of the paper CBT manual to an online intervention platform.  
• Interventions will only be implemented in the NHS if they are cost-effective. In depth 
economic analysis to calculate costs and assess potential cost-effectiveness should be 
included in the full-scale RCT.  
 
7.5 Implications for practice 
The results of this PhD project also have implications for practice:  
• Fatigue is a prevalent and burdensome symptom for patients with IBD. Fatigue should 
thus be recognised and discussed and addressed in clinical practice. Likewise, care 
pathways for the management of fatigue should be put in place.  
• High levels of psychological distress in IBD patients were identified throughout this PhD 
project. Having a dedicated psychologist within IBD services may be beneficial in 
addressing psychological issues experienced by patients with IBD and improve their 
QoL. This is in line with findings on HCPs views on how to best reshape existing IBD 
care worldwide (Mikocka-Walus et al., 2014), which suggest that an ideal IBD service 




7.6 Future plans  
Additional publications stemming from this PhD project will be completed following submission 
of this thesis incorporating publications. These include: analysis of the 12 and 24-months’ 
longitudinal data evaluating physical and psychosocial predictors of IBD-fatigue, and the 6 and 
12-months post-randomisation data analysis of the pilot CBT intervention for IBD-fatigue. A 
secondary qualitative analysis of the qualitative interviews with patients conducted as part of the 
pilot RCT is also being conducted. Furthermore, being part of a larger research team at King’s 
College London conducting work  related to fatigue and IBD-symptom management has allowed 
me to be involved in projects related to IBD-fatigue which are not part of my PhD. Participation 
in these projects demonstrates my interest in IBD-fatigue and my desire to pursue further work 
on this topic in the future. In 2014-15 I took part in an international collaboration for a Cochrane 
review on interventions for fatigue in IBD. The protocol has been published (Farrell et al., 2015b), 
the full review will be finalised in 2018. In 2017 I co-applied with my supervisor (WCD), and 
obtained a European grant to translate and cross-culturally validate the IBD-Fatigue scale in seven 
languages. The project is now in its final phase. Funding for a 5-year National Institute for Health 
Research programme grant to improve the well-being of patients with IBD by reducing the burden 
of fatigue, pain and incontinence has been obtained by the research team in April 2016. The 
programme has commenced in January 2018 and in line with Internet-based work conducted in 
MS (Moss-Morris et al., 2012), it will include a full-scale evaluation of an online self-
management intervention, health economics and process evaluation. The outcomes of the 
qualitative interviews included in the PhD intervention will be used to inform the development of 
the full-scale RCT. Having successfully obtained the position of Research Associate on the 
programme, my role will be to help on the development of the online intervention.   
 
7.7 Reflection 
Reflection refers to the process of thinking retrospectively on an event in order to learn from it 
(Mezirow, 1998); reflexivity is an active process of dynamic self-awareness which takes place as 
an event is happening (Downing, 2006). In qualitative research, reflexivity has emerged as a way 
to manage how personal understanding, knowledge and perspectives of the researcher can 
influence the research itself (Finlay and Gough, 2008). Although, this is not predominantly a 
qualitative PhD the opportunity to reflect retrospectively on the process of conducting the PhD 
research can be valuable in interpreting its conclusions. The principles of reflection were 
incorporated throughout this PhD and in the process of writing this chapter.  
 
I believe that making the decision to write a thesis incorporating publications has influenced my 
experience of undertaking this PhD project. Having the opportunity to disseminate my work 
throughout the PhD, enabled me to receive external feedback on my research by experts in the 
195 
field from its earliest stages. Benefitting from feedback from reviewers, alongside guidance from 
by supervisory team, aided me to benchmark the quality of my work against what is expected 
within my discipline, and to better understand the nature of academic research. Publishing my 
research for a broader audience, fostered my sense of achievement during the course of my project 
and improved my motivation in progressing from one stage to the next. Additionally, having 
published in gastroenterology-specific journals allowed me to become an expert reviewer and 
attend medical conferences on IBD. Both of these experiences have been valuable in learning 
more about research and clinical practice in IBD. Publications are increasingly used in universities 
to measure performance and as a criterion for achieving academic promotion and competitive 
research funding. As such, it is possible that the publication of my research papers may have 
helped me in obtaining employment as a Post-doctoral Research Associate.  
 
Prior to commencing my PhD, I undertook an undergraduate degree and an MSc in Psychology. 
With no previous medical or nursing background, I was conscious of my need to acquire 
knowledge on IBD from the early stages of my PhD. IBD is a complex physical illness and an 
understanding of its symptoms and medical management is crucial in being able to appreciate the 
impact of IBD on patients’ QoL. Throughout my PhD I therefore took part in weekly GI 
multidisciplinary team meetings at one of the hospitals where I recruited for my cross-sectional 
and intervention studies. Taking part in these meetings allowed me to develop an awareness of 
the condition as a whole and better appreciate how fatigue is managed in clinical practice. 
Furthermore, it is possible that having formed a positive relationship with the clinical team may 
have helped me in engaging HCPs in my study, thus achieving better recruitment outcomes. 
Additionally, being embedded within the IBD clinical team, I was able to give a voice in the 
psychological aspects of IBD, ultimately helping to make the availability of psychological 
management a priority for the hospital directorate. Contributing to service development, I aided 
in setting-up a psychological screening programme and submitting a business case for an 
integrated psychological service for IBD patients.  
 
7.8 Conclusions 
This PhD provides an original contribution to the body of knowledge on feasible and effective 
treatments for the management of IBD-fatigue. Studies in this PhD addressed the primary need 
for the development of a theoretically-driven intervention to improve fatigue in patients with IBD. 
A number of physical and psychosocial factors which could potentially be modified through 
targeted health interventions and improve fatigue in IBD were identified, emphasising the 
importance of conducting research on factors potentially amenable to modification. Cognitive and 
behavioural factors, known to perpetuate fatigue in other conditions, were found to be associated 
with IBD-fatigue, indicating a potential for the development of transdiagnostic cognitive-
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behavioural fatigue management interventions. Drawing from a theory-based, effective CBT 
intervention for MS-fatigue and incorporating Patient and Public Involvement activities, this PhD 
integrated current best evidence across conditions, patient experience and clinical expertise. The 
resulting intervention was the first to test the applicability of CBT treatment models for fatigue 
with proven effectiveness in other long-term conditions to patients with IBD. Findings for the 
pilot intervention indicate feasibility and potential for efficacy of CBT for the management of 
IBD-fatigue. A large-scale RCT is needed to investigate the size and longevity of treatment gains 
and the cost-effectiveness of the therapy. Incorporating changes to the protocol and developing 
an online intervention may be an effective way to overcome the barriers to implementation 
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Aims of the study Design Sample Fatigue 
tool(s) 
Main Findings Study 
Quality  
Pharmacological and non-pharmacological intervention studies  
Costantini 
(2013) (58) 
To assess effectiveness of 
1200 mg/day thiamine 









CFS Scale  -Ten/12 patients showed complete regression of fatigue (score 0); 2/12 nearly 
complete regression of fatigue (score 3 & 5). One patient treated with 1200 
mg/day of thiamine showed a mild tachycardia that completely regressed by 






To assess effectiveness of 
stress management technique 
in reducing  disease activity 
and improving psychosocial 
functioning in CD patients 





- The self-directed stress management reported as significantly reducing  
tiredness post-treatment and at 6 and 12 months post-treatment 
- Medical treatment plus psychological treatment seems to be more effective 




Assess effect of infliximab 
on quality of life  in patients 




83 CD -IBDQ - Placebo and actively treated patients reported symptom improvement  




Evaluate effects of 
adalimumab maintenance 
therapy on HRQoL in 





854 CD  FACIT-F 
IBDQ 
SF-36 
- At baseline patients’ mean fatigue scores were 22.9 points 





Measure effect of infliximab 
on fatigue, clinical disease 





14 CD  MFI 
IBDQ  
- Baseline fatigue prevalence 86% 
- Fatigue was significantly reduced by administration of a single dose of 
infliximab (patients with fistulae received one extra dose of infliximab 4 





To test effects of (i) 
individual advice to increase 
physical activity (PA) and/or 
(ii) supplementation with 











- There was a significant deterioration in FACIT-F score with the 
supplementation of omega-3 fish oil  
- There was no significant difference on FACIT-F scores between those 
receiving and not receiving exercise advice. Fatigue was significantly reduced 





To assess feasibility and 
effect of psychological 
interventions in the 
management of fatigue  
RCT, pilot 
study 
29 CD CIS -SFT: fatigue level improved in 6/10 patients, in PST group - 3 of patients 
improved fatigue scores, and in the CAU group – 3/7 patients improved 
fatigue from baseline to 3 months follow up 
-SFT had a positive effect on fatigue, better quality of life and fewer visits to 




To assess effectiveness of  
SFT compared with CAU  on 
fatigue and QoL in 
individuals with IBD fatigue   




CIS-fatigue -At 3 and 6 months, scores were significantly better in the SFT group than in 
the CAU group. Significantly more individuals in the SFT group had a CIS-
fatigue score below the cut-off point of 35 compared with individuals in the 
CAU group. The effect was no longer significant at 9 months 
High  
Longitudinal population based and outpatient studies 
Banovic 
(2010) (54) 
Assess fatigue, disease 
activity, depression and 
anxiety, sleep disturbances, 
and subjective QoL 
Longitudi
nal study  
 
52 CD  MFI - Age and gender did not influence fatigue 
Longitudinal data  
- Disease was inactive and there was no difference in fatigue score 
- No significant difference between the two visits on the assessments of 




To evaluate psychological 
and biological factors in 





318 CD MFI -72%with active and 30% with inactive disease reached (clinical) threshold 
for fatigue 
-Disease activity, poor sleep (but not hours of sleep) and perceived stress 








To assess fatigue 
longitudinally to determine 
the course of fatigue in IBD 
and the contributors to 









MFI at 12, 
24 months 
follow-up 
Longitudinal data  
-Fatigue was higher over time when disease was consistently active 
-Poor sleep quality, distress, and lower psychological well-being, were 
significantly associated with changes in fatigue over time. Women and those 
who were younger were more likely to report higher fatigue 
- Perceived stress was not statistically significant after the Bonferroni 







et al. (2014) 
(9)  
To evaluate patient-reported 
outcomes in a cohort of 
patients with IBD and their 
associations between disease 
activity indices and IBD 
QoL  
Longitudi

















-Shorter disease duration, active disease, prednisone and having a pouch were 
associated with worse fatigue 
- Patients with fatigue had significantly lower levels of quality of life 
Longitudinally patients with worsening disease activity had worse fatigue and 
those with improving disease had improved fatigue scores. Older patients, 





To investigate the prevalence 
and severity of fatigue and 












- MFI-20 dimensions general fatigue and physical fatigue were significantly 
worse in CD compared to UC and IBDU 
- Disease activity and anaemia were positively related with the level of 
fatigue  
- In CD, patients using medication were significantly more tired than patients 
using no medication. Gender, age, length of follow-up, anaemia, and the use 
High 
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of infliximab did not determine the level of fatigue. In UC female gender was 
associated with higher fatigue scores, resulting in a worse score. Age, length 




To evaluate prevalence and 
severity of fatigue in CD 
(compared with UC and 
healthy controls) and to 
identify potentially 
























- Current corticosteroid, immunomodulator and biologics were significantly 
associated with higher fatigue scores. In CD disease activity was associated 
with fatigue 
Multivariate logistic regression analyses 
- Current active, sleep quality, depression, limited employment, smoking and 
vitamin B group supplement use were associated with fatigue 
- Small magnitudes of change were observed, mean changes in score = + 0.9 




To explore frequency of 
fatigue in two different 
hospitals, explore the factors 
related to the risk for fatigue, 
and investigate differences 
between disease phenotype 
in CD patients of a referral 








CIS-fatigue -Patients in disease remission were less fatigued compared to patients with 
active disease 
Follow-up multivariate analyses 
- Women were significantly more fatigued than men. A longer disease 
duration was associated with significantly less fatigue for men. More disease 
activity was associated with more fatigue. Patients using 5-ASA at baseline 
showed less fatigue, but when 5-ASA caused side-effects, fatigue levels were 
higher at baseline 
- Anti-TNF use at baseline associated with a higher fatigue level, maintaining 
anti-TNF through the follow-up year associated with a decreased fatigue 






To investigate prevalence, 
characteristics and 





437 IBD MFI - Fatigue scores were not significantly different between the UC and CD 





To identify diagnostic 
variables of IBD-fatigue 




118 (26 UC/92 
CD)  
 
MFI -Depressive mood, trait-anxiety and daytime sleepiness were the most 





To determine relationships 
between personality and the 
perception of IBD-fatigue 








MFI - No significant relationship between level of fatigue and duration of disease, 
number of relapses, number of flare ups, number of quiescent periods, 
number of hospitalizations 
Univariate analysis 
- Significant relationship between level of fatigue and cumulative severity of 
intestinal resection, anxiety, daytime sleepiness and self-directedness 
Multivariate analysis 
- Forty-five percent variance in fatigue (MFI) was explained by the value of 





To evaluate well-being in 
patients with primary 
sclerosing cholangitis with 
focus on fatigue in 
comparison with IBD alone 








in the UK and 
one in Sweden  






To study disease specificity 
of fatigue in multiple 
sclerosis and comparing its 
level with UC 
Cross-
sectional 
study   
 
76 UC &  
88 MS 
 
MFI - Physical fatigue in both MS and UC patients significantly correlated with 





Cejas et al. 
(2013) (5) 
To define applicability of 
three questionnaires and to 
define which had better 
application characteristics.  
To determine the impact of 
fatigue on health perception 














Phase 137 (70 






- There was a significant correlation of QoL with the three fatigue 
questionnaires. There was a positive significant relationship between the 
degree of disease activity and the level of fatigue in the three questionnaires 
Questionnaire administration phase  
-There were no statistically significant differences between CD and UC.  
-There was a significant relationship between clinical disease activity and 




To report the prevalence of 
fatigue in a cohort of newly 
diagnosed IBD individuals. 
To explore the relationship 
of fatigue with QoL, 







FACIT-F - No significant differences in fatigue prevalence between CD and UC 
- CD individuals with active disease were significantly more likely to have 
fatigue than those with inactive disease (not significant in UC). Significantly 
more women met fatigue criteria than men 
- Fatigue was significantly associated with disease specific (IBDQ) and 
general (SF-36, EQ-5D) quality of life 
-Those with fatigue had significantly worse valuations of their current health 
state and were significantly more impaired in their daily activities. Working 
individuals fatigue had significantly higher, overall work impairment, work 
impairment and absenteeism (CD only). Depression was significantly greater 




To investigate the 
relationship between iron 
deficiency and fatigue in 









MFI - 49% of individuals with iron deficiency had high fatigue, 45% of individuals 
without iron deficiency had high fatigue (MFI > 13) 
-No mean differences in types of fatigue or fatigue outcomes between iron-
deficient and iron-sufficient groups. Those with high fatigue had lower mean 
Hb than those without fatigue, but the difference was not significant. 




To describe the prevalence 
and degree of fatigue in 
newly diagnosed and 




81 (60 UC/21 





Univariate analysis  
-No significant associations between fatigue and disease activity, CRP or 
faecal calprotectin. fVAS scores were associated with CRP, ferritin and 




between fatigue, depression 
and disease activity. 
Multivariate analysis 
- HADS-D and age were significantly associated with fatigue. CRP, ferritin, 
calprotectin and gender were not significantly associated with fatigue 
Hauser 
(2005) (46) 
To identify determinants of 
fatigue in IBD-outpatients in 





37 UC with 








-Fatigue had significant predictive value for reduced physical and social 
functioning. Fatigue in UC patients was independent from objective disease 
measures in quiescent disease. Disease activity and depression were 





Estimate level and frequency 
of fatigue among patients 
with mild to moderate IBD 














- Age, gender, employment, nor education had statistically significant impact 
on fatigue 
- IBD symptoms, Hb levels, and altered sleep patterns were significant 





To investigate influence of 
chronic fatigue on generic 









-  Fatigue was associated with increased IBD symptoms, smoking and Hb 








To examine impact of 
fatigue on disease-related 









-Increased levels of worrying were associated with increased fatigue levels 







To investigate occurrence of 
fatigue among IBS positive 




140  (92 UC, 
48 CD)  
 
 





Assess potential relation 
between fatigue and 
gastrointestinal symptoms in 








13/28), 286 HC  
FIS 
SF-36  
- Fatigue has a negative impact on QoL  
- Fatigue was significantly associated with Anti-TNF/immunomodulator 
therapy, depression and anxiety. Fatigue was not associated with age, gender 





To assess the prevalence and 
severity of fatigue in IBD 




80 IBD MFI 
 






To assess 3 fatigue 
assessment scales in IBD and 





605 (164 UC, 







- Females, CD patients (IBD-F, MFI), individuals with higher levels of 
anxiety and depression had significantly higher levels of fatigue. IBDQ total 
scores were strongly associated with fatigue. Those working part-time and 
those not working had higher physical fatigue compared to individuals 
working full time (IBF-F, MFI, MAF) 
Multivariate analysis 
- IBD-F: 45% of variability of fatigue was predicted by female gender, 
depression, CD and poorer QoL. MAF: age, depression and IBDQ score were 
High  
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all independently associated with fatigue, 48% of fatigue was attributable to 
these factors. MFI: gender, depression and IBDQ were all independently 
associated with fatigue, 42% of the variability in general fatigue could be 
attributed to these factors 
Opheim 
(2014a) (25) 
To examine fatigue 
interference with daily living 
in IBD individuals and to 
explore relationships 
between severe fatigue 
interference and socio-
demographic and clinical 









FSS-5 -Female gender, CD diagnosis and active disease were significantly 
associated with higher fatigue.  
Univariate analysis 
-Female gender, CAM use, active disease, the presence of at least one 
comorbid condition were significantly associated with fatigue in UC. Disease 
activity, adverse drug reaction were significantly associated with fatigue in 
CD. Patients who were working, had a higher education level or income were 
less likely to report severe interference 
Multivariate analysis  
- CAM use and disease activity remained factors independently associated 
with fatigue in UC. Current smoking and having an active disease remained 








To explore associations 
between socio-demographic, 
disease-related and personal 







FSS-5 -Mean FSS-5 score was higher in CD patients compared to UC patients.  
-In UC, FSS-5 was negatively associated with lower scores on all 3 SOC sub 







Pellino et al. 
(2014) (55) 
To assess patient-reported 





16 IBD and 16 
Controls  
FIS -Patients with IBD had more severe overall fatigue compared to non-IBD 
controls. When considering IBD patients with mild to low active disease (n = 





To investigate the prevalence 
of IBS-like symptoms in CD 
patients in remission and 
impact of IBS-like symptoms 





CD, 40 IBS and 
20 healthy 
subjects 
FIS - There were significant correlations between the severity of symptoms and 





To assess the prevalence and 
possible determinants of 




117 CD & 55 
UC  
PFS -64% reported fatigue regardless of clinical activity; 40% in clinical remission 
(HBI≤5) reported fatigue 
-None of the studied determinants of fatigue were significantly correlated 




Evaluate factors of 
importance for fatigue in 
patients with chronic 











- Patients with IBS and IBD were more fatigued than controls 
- Patients with IBS were more fatigued than patients with IBD 
- Psychological well-being, sleep disturbances and employment status were 





Elucidate factors  influencing 
perception of difficulties of 
life and psychological well-










- Emotive coping, low social support and high difficulties in life influence the 





To validate the FACIT-F 
scale in IBD 
Cross-
sectional 
study   
209 IBD FACIT-F - Disease activity was significantly positively associated with fatigue levels 
- Fatigue was not significantly associated to CRP. There were no significant 




et al. (2014b) 
(48) 
To measure and compare 
self-reported fatigue with 
skeletal muscle fatigue in 
CD subjects and healthy 
controls, and to identify 
associated factors that may 






and 22 matched 
HC  
(part of the 
same sample as 
(13) 
FIS - The rate of muscle fatigue was significantly greater in the CD patients 
compared to controls. Maximal force production was not significantly 
different between the CD and control group 
- There was a significant negative correlation, between subjective physical 
fatigue and objectively measured rate of muscle rate of muscle fatigue. Those 
reporting greater fatigue via survey tended to demonstrate greater muscle 





To assess level of physical 
fitness and daily physical 
activity in IBD patients and 
whether fatigue is associated 
with impaired physical 





10 IBD patients 
with fatigue 




CIS-fatigue  - Fatigued patients showed a significantly lower intensity of daily physical 
activity (motility) and an impaired physical fitness compared with non-
fatigued patients  
- Clinical characteristics such as surgery, disease activity, age at diagnosis, 
disease type, disease type, body composition, medication use and side effects 
to medication were not significantly different between fatigued and non-
fatigued patients 
High  
Yoo et al. 
(2014) (37) 
To investigate fatigue level 
and fatigue-related factors 
among Korean IBD patients 
Cross-
sectional 
study   
128 (68 UC/60 






-There was no difference in fatigue according to disease type  
-In FACIT-F and all sub dimensions of BFI except walking ability, both UC 
and CD patients showed significantly increased fatigue symptoms compared 
to controls. In CD, ESR and disease activity were significantly correlated with 
global BFI in the unadjusted regression analysis. But after adjustment none of 
the factors were statistically significant 
- Anaemia was a significant determinant of both global BFI and FACIT-F. 
ESR significantly correlated with FACIT-F  
Med 
Key: anti-TNF- anti-tumour necrosis factor; BFI - Brief Fatigue Inventory; CAM - complementary and alternative therapies; CAU - care as usual; CD- Crohn’s disease; CFS – Chalder Fatigue Scale; CIS - Checklist 
Individual Strength – fatigue; CRP- c-reactive protein; DFIS - Disease Fatigue Impact Scale: EQ5D - Euro Quality of Life; ESR- Erythrocyte sedimentation rate; FACIT-F - Functional Assessment of Chronic 
Illness Therapy-Fatigue scale; FIS - Fatigue Impact Scale; FQ - Fatigue Questionnaire; FSS - Fatigue Severity Scale; FSS-5 - Five-Item Fatigue Severity Scale; fVAS - Fatigue visual analogue scale; GSCL (fatigue) - 
Short Form Giessen Subjective Complaints List; Hb- haemoglobin; HRQoL –Health-related quality of life, IBD-F - Inflammatory Bowel Disease- Fatigue; IBDQ - Inflammatory Bowel Disease Questionnaire; IBDU- 
inflammatory bowel disease unclassified; HC - healthy controls; MAF - Multidimensional Assessment of Fatigue; MFI - Multidimensional Fatigue Inventory; MFIS - Modified Fatigue Impact Scale; MS- multiple 
sclerosis; PFS - Piper Fatigue Scale; PBT – Problem solving therapy; PSC- primary sclerosing cholangitis; PSHI- Post Surgical Handicap Index; PST- problem solving therapy; QoL - quality of life; SBS- short bowel 
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Bager (2012)  + ve 0.05  
(HBI >4, SSCAI >4)  
  N.S.   + ve 0.05  
CD male 
          
Banovic (2010)  N.S.≠ (CDAI>150)                
Banovic 
(2012a)  
    N.S.   N.S.          
Bjornnsson 
(2004)  
+ ve 0.001  
(GSRS) 
              +ve 0.001 
Bol (2010)  + ve 0.01  
(CAI) 
               
Castillo (2013) + ve 0.001  
(HBI>3, CAI>6) 
               
Cohen (2014) + ve 0.002*  
(HBI >5, SSCAI >5) 
               
Goldenberg 
(2013) 
+ ve 0.001(HBI ≥5, 
Powell-Tuck ≥5)   
   N.S.  N.S.            
Graff (2011)  + ve 0.001 (HBI ≥5, 
Powerll-Tuck ≥5) 
  N.S.   N.S.            
Graff (2013)  + ve 0.001 (HBI ≥5, 
Powell-Tuck ≥5) 
  N.S.  N.S.           
Grimstad 
(2015) 
N.S. ¥(HBI ≥5, MS>2)   N.S.  N.S. N.S.           
Hauser (2005)  + ve 0.03  
(CAI≥4) 
        - ve 
0.05 








 + ve 
0.012 




     +ve 0.05 N.S.          
Kalaitzakis 
(2008)  




       -ve 0.038         
Loftus (2008)        -ve 0.0001         
Kappelman 
(2014) 
+ ve 0.001 
(SCDAI>150, SCCAI 
≥4) 
     +ve 
0.001 
         
Minderhoud 
(2003)  




       - ve 0.05         
Opheim (2014a)  + ve 0.001  
(HBI ≥4, SCCAI >3) 
     N.S. N.S.       +ve 
0.09** 
 
Piche (2010)  + ve 0.0005 
(CDAI>150) †   
               
Romberg-
Camps (2010)  
     + ve 0.05 
# 
          
Simren (2008)  + ve 0.0001~  N.S.  N.S.    + ve 
0.0001 
     + ve 
0.01 
    
Tinsley (2011) + ve 0.001(HBI ≥5, 
SCCAI ≥5) 




+ ve 0.001(HBI , 
SCCAI) 
     +ve 
0.003 
+ve 0.03 -ve 
0.001 






          +ve 
0.05 
     
Vogelaar (2013) + ve 0.001 (HBI ≥5)       +ve 0.002          
Vogelaar (2015)          +ve 
0.037 
      
Yoo et al. 
(2014)  





  p = .005#            
Key: anti-TNF- tumour necrosis factor; CAI – Clinical Activity Index; CDAI – Crohn’s Disease Activity Index; CRP- C - reactive protein; ESR- erythrocyte sedimentation rate; GSRS- Gastrointestinal Symptom 
Rating Scale; Hb- haemoglobin; HBI – Harvey Bradshaw Index; MS – Mayo Score; N.S.- non-significant; SCCAI- Simple Clinical Colitis Activity Index; SCDAI – Short Crohn’s Disease Activity Index;**only for 
CD individuals; #only for UC individuals, ¥ disease activity measured with calprotectin; †  disease activity measured with endoscopic, radiological and/or haematological investigations (i.e. Crohn’s Disease Endoscopic 
Index Score, small bowel enterclysis, inflammatory markers [haemoglobin, CRP, ESR, platelets and albumin], ~ disease activity measured with  haematological investigations (CRP, albumin, haemoglobin and platelets), 
+ ve, positive association at p < 0.05; - ve, negative association p < 0.
250 
Appendix III: Systematic review search strategy example 
 
EMBASE 1974 to 2015 
1. exp Crohn disease/ or crohn*.mp. 
2. (colitis and ulcerat*).mp. or exp ulcerative colitis/ 
3. (inflammatory bowel disease* or IBD).mp. 
4. 1 or 2 or 3 
5. exp fatigue/ 
6. (energy OR tired* OR sleep* OR drows* OR letharg* OR exhaust*).mp. 
7. (lack OR loss OR lost) adj (energy OR vigo* OR vitality).mp.  
8. 5 or 6 or 7   
9. 4 and 8  
10. limit 9 to (human and english language and yr="2012 -Current" and (adult <18 
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Country Intervention MRC 
version  
MRC phase/step  Methods  











2008 1a.  Identifying the evidenced base  
 
− Systematic review of studies of depression management 
in the UK 
− Interviews with healthcare professionals to determine 
preferences for the future intervention 
− Interviews with patients with CHD and depression needs 
for the future intervention 
1b.  Identifying/developing theory  
 
− Multidisciplinary project group and independent steering 
group meetings to integrate findings  
− Iterative evidence review to support choices for the 
intervention content   
1c.  Modelling the process and 
outcomes 
 
− Focus groups  to determine the potential acceptability of 
the intervention to patients with CHD and depression 
and to identify whether any changes were necessary 
2. Feasibility and piloting  Not reported  
3. Evaluation   Not reported 










unit (ICU)  
2000 0. Pre-clinical phase 
 
− Literature review to identify key components of 
intervention  
− Review of theories of change and behavioural 
management to identify factors critical for change  
1. Modelling phase  
 
− Observation of patients where intervention was to be 
introduced  
− Semi-structured interviews with ICU consultants to  
identify aids and barriers to developing weaning 
protocols and their introduction to practice 
− Questionnaire survey for ICU nurses to determine 
knowledge and attitudes towards weaning  
2. Exploratory phase  
 
− Exploratory trial employing quasi-experimental, non-
equivalent group design 
439 
3. Definitive RCT phase  Not reported  
4. Long-term implementation 
phase  
Not reported 
Burr et al.  
(2011) 
UK Intervention for 
glaucoma 
screening  
2008 1a.  Identifying the evidenced base  
 
− Semi-structured interviews with eye-care providers, 
policy makers and health service commissioners to elicit 
their experiences and perspectives about the main  
− properties of a potential intervention for a national 
glaucoma screening trial 
1b.  Identifying/developing theory  Not reported   
1c.  Modelling the process and 
outcomes 
 
− Economic modelling incorporating data collected from 
the interviews.  
− All the potential screening components put forward by 
the interviewees were summarised in tabular form for 
consideration in the economic model. New screening 
strategies were then ordered according to the potential 
that they would be cost-effective  
2. Feasibility and piloting  Not reported  
3. Evaluation   Not reported 




UK Intervention to 
improve shared 
care for patients 
with long-term 
mental illness 
2000 0. Preclinical phase 
 
− Literature search to gain an understanding of prevailing 
attitudes and identifying and overcoming obstacles to 
change 
− Focus groups with HCP to define how to develop a 
system of shared care  
1. Modelling phase  
 
− Proposed conceptual framework for shared care and 
toolkit were then developed by integrating the data from 
the focus groups with the literature and ideas from 
practical experience 
− Focus groups with HCP and local experts in primary 
mental health to review toolkit 
− Revised toolkit 
2. Exploratory phase 
 
− Piloting of toolkit in 3 practices  
− Brief questionnaire with fixed and free text responses to 
evaluate practitioners’ perceptions of the different 
components of the intervention 
440 
− Semi-structured and in-depth interviews with all 
involved  
− Reflection of the research team on their experiences of 
using the model  
− Further modification based on feedback  
3. Definitive RCT phase  Not reported 
4. Long-term implementation 
phase   
Not reported 
Byrne et al. 
(2006) 






2000 0. Preclinical phase  
 
− Literature search relating to secondary prevention of 
CHD 
− Discussion of research team on key findings regarding 
successful interventions and identification of findings 
deemed appropriate to the setting 
− Looked at theories on health behaviour (theories on 
lifestyle/behaviour change) 
1. Modelling phase  
 
− Focus groups with patients from 4 GP practices to 
evaluate experiences and attitudes towards key 
intervention components identified in literature  
2. Exploratory phase  
 
− Training of practitioners and evaluation of training  
− Pilot testing of the preliminary intervention 
− Semi-structured interviews and focus groups to evaluate 
patients’ experience of the intervention  
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   Not reported 








2008 1a. Identifying the evidence base 
 
− Two systematic reviews to identify effective components 
and characteristics of pain management courses and 
predictors, mediators and moderators of outcome in pain 
management courses  
− Phenomenological qualitative interview (with chronic 
pain self-management course participants) and focus 
group (with experts from those who had recently 
published in this field and tutors of local Expert Patients 
Programme providers) study to address what the 
intervention should focus on  
441 
1b. Identifying or developing 
theory  
 
− Literature search and spoke to experts on behavioural 
change theory and models of persisting pain. Considered 
different theories 
1c. Modelling the process and 
outcomes 
 
− Mapping of behavioural change theories  
− Created a consensus group (patients, HCPs, researchers 
and commissioners) to agree on the outcomes we wanted 
the intervention to affect and the appropriate 
measurement tools 
2.    Feasibility and piloting  
 
− Uncontrolled pilot study approach to test the feasibility 
of delivering the intervention and the receipt of the 
intervention 
3. Evaluation  Not reported  
4. Implementation  Not reported  
Clyne et al. 
(2013) 





older people  
2000 and 
2008 
1a.  Identifying the evidence base 
 
− Literature review to identify potentially inappropriate 
prescribing criteria and the empirical and theoretical 
evidence relating to intervention research and altering 
prescribing practice  
1b.   Identifying or developing 
theory  
Merged with previous step  
1c.   Modelling the process and 
outcomes 
 
− Consensus based methodology with experts in the field 
(GPs, pharmacists, specialist in clinical pharmacology 
and medicine for the elderly) to decide which criteria to 
include in the study  
− Patient case identification to test intervention materials 
compiled in consensus methodology completing 
specifically designed evaluation sheets  
− Focus groups with GPs to evaluate materials  
− Compiling of information from evaluation sheets and 
focus groups to further refine intervention  
2. Exploratory phase  
 
− Proposed intervention tested by five GPs  
− Qualitative interviews with GPs to inform the 
development and implementation of the intervention for 
the main RCT  
3. Definitive RCT phase  − Cluster large-scale RCT to assess effectiveness and 
acceptability of the intervention 
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− Qualitative interviews at the end of the RCT  with 
patients and GPs to provide insight into the intervention 
delivery and acceptability of the intervention 
4. Long-term implantation phase   Not reported 
Ettema et al. 







2008 1a.  Identifying the evidenced base  
 
− Systematic review to identify studies describing 
interventions for preparing older patients for a hospital 
admission for cardiac surgery and the methods that have 
been used to evaluate these interventions 
1b.  Identifying/developing theory  
 
− Literature review looking at possible relationships 
between the preadmission characteristics of older 
patients and the occurrence of postoperative 
complications   
− Analytical (observational) study to model preadmission 
patient characteristics related to postoperative 
complications by collecting data from patients in clinic. 
Comparison of patients having complications and not 
having complications 
− Prognostic study using a scorecard to predict 
postoperative complications in the same sample as the 
analytical study  
1c.  Modelling the process and 
outcomes 
− Patient in-depth interviews exploring perceived needs 
before and during hospital admission  
− Survey study with cardiac nurses asking their opinion on 
the prevention, diagnosis and treatment of postoperative 
complications  
− Expert round with Dutch national leading experts to test 
face validity of the content of the intervention  
− Clinical expert round  with cardiac surgeons and cardiac 
surgery nurses to test the clinical applicability of the 
intervention  
2. Feasibility and piloting  Not reported 
3. Evaluation   Not reported 
4. Implementation  Not reported 
UK Palliative 2000 0. Preclinical phase  
 
- Qualitative study of lung cancer and COPD patients’ 
experience of breathlessness  
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- Developed pilot intervention 
1. Modelling phase  
 
- Qualitative interviews with patients and relatives who 
had used the newly formed pilot palliative breathlessness 
service and clinicians who had referred to it to evaluate 
the service 
- Refined intervention  
2. Exploratory phase  
 
- Mixed method pilot pragmatic single-blind fast track 
RCT of the re-developed breathlessness service vs. 
standard care to test the feasibility of the proposed mixed 
method trial  
- Collection of quantitative data (response rates, protocol 
completion rates and field notes) to evaluate feasibility 
of intervention  
- Qualitative interviews with patients, carers, referrers and 
providers of the intervention to evaluate acceptability of 
the intervention  
- Further refinement of intervention 
3. Definitive RCT phase  - Plan for mixed method pragmatic single-blind fast track 
RCT trial of the re-developed breathlessness service vs. 
standard care integrating: a qualitative topic-guided 
interview with quantitative outcome measures for 
patients and carers; a concurrent qualitative interview 
study with referrers to the service; and sequential 
qualitative interviews with service providers. This will 
be conducted to determine the effectiveness of the 
intervention, reasons for success or failure and reasons 
for variation.  
4. Long-term implantation phase   Not reported  
Faes et al. 
(2010) 
Netherlands Intervention for 
complex fall 
prevention 
2000 1a.  Identifying the evidenced base  
 
− Descriptive analysis of the characteristics of the cohort  
− Literature reviews to understand pathways that cause and 
sustain falls in frail community; of interventions to 
prevent falls and fear of falling   
1b.  Identifying/developing theory  
 
− Semi-structure interviews with frail older patients who 
experienced falls and primary family caregivers  
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− Literature reviews of behavioural change theories to 
reduce fear 
− Focus group with project team and experts  
− Non-participatory observation of CBT group and 
individual therapy to reduce fear  
1c.  Modelling the process and 
outcomes 
− Second focus group with experts  
− Semi-structured interviews with experts  
− Semi-structured interviews with patients and caregivers  
− Delphi study with specialists  
− Second non-participatory observation of  session for 
physical therapists, who were trained to deliver a fall 
prevention intervention for non-frail older persons  
− Literature review on the available evidence regarding the 
recruitment and adherence of older persons in aging 
research 
− Third non-participatory observation of physical training 
sessions for demented older persons conducted by 
physiotherapists 
2. Feasibility and piloting  − Test feasibility of the recruitment process, intervention 
and measurement  
3. Evaluation   − Focus group with patients, caregivers, instructors, and 
researchers 
− Focus group with researchers and instructors 
− Questionnaires administered to patients, caregivers, and 
instructors evaluating the performance of the 
intervention according to protocol 
− Third focus group with experts  
4. Implementation  Not yet performed  
Gray et al. 
(2013) 
 
UK Intervention for 
weight loss in 
adult men  
2000 0. Preclinical phase  Not reported  
1. Modelling phase  
 
- Pilot intervention development by expert 
multidisciplinary working group (psychologists, health 
social scientists, nutritionist, men health’s nurse, 
representative of Scottish Premier League)  
- Scoping review to identify optimal target population: 
summarising existing evidence on men’s motivation to 
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lose weight and improve their lifestyles, the potential 
health benefits of wright loss and increased physical 
activity and current weight management and physical 
activity guidance 
2. Exploratory phase  
 
- Piloting of intervention  
- Process evaluation to explore programme delivery from 
participant and coach viewpoints (feedback form 
completion and observation of sessions)  
- Feasibility trial to investigate recruitment, retention and 
potential weight loss in preparation for subsequent RCT 
- Semi-structured focus groups with men who completed 
intervention and telephone or face-to-face interviews 
with non-completers to explore acceptability, utility of 
components, suggestions for changes  
- Semi-structured interviews with those delivering the 
intervention  
- Triangulation of data to produce detailed description to 
inform the redevelopment of the programme  
3. Definitive RCT phase  - Two members of the programme development working 
group used the BCT taxonomy to map the content of the 
intervention onto specific behaviour change techniques  
- RCT not reported  
4. Preclinical phase  
 
Not reported  












1a.  Identifying the evidenced base  
 
- Review and synthesis of existing qualitative studies for 
the need of psychological support after a stroke  
- Review of the literature to identify systematic reviews of 
post-stroke psychological needs and effectiveness of 
interventions addressing these needs  
- Identification of theories to illuminate possible effective 
mechanisms and actions aimed at promoting 
psychosocial well-being during the stroke recovery 
process  
- Development of intervention aimed at promoting 
psychosocial wellbeing  
1b.  Identifying/developing theory  Merged with previous step 
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1c.  Modelling the process and 
outcomes 
- Evaluation and critique of the proposed intervention by 
patient and relative representatives, clinical experts and 
researchers during several expert group meetings 
- Refinement of intervention  
2. Feasibility and piloting  Not reported  
3. Evaluation   Not reported  
4. Implementation  Not reported  
Lewis et al. 
(2013) 
 
UK Guided self-help 
(GSH) 
intervention for 








0. Preclinical phase  Not reported  
1. Modelling phase  
 
- Identification of existing evidence to create a portfolio of 
information for key stakeholders  
- Portfolio presented to stakeholders and their opinions 
and suggestions gathered through a series of focus 
groups and semi-structured interviews 
- Creation of prototype one  
- Results of qualitative analysis used to create initial 
prototype GSH programme  
2. Exploratory phase  
 
- Pilot of prototype one  
- Interviews with participants to elicit their experiences of 
the program  
- Focus groups with stakeholders to discuss findings and 
refine programme  
- Creation of prototype two  
- Pilot of prototype two  
- Interviews with participants to elicit their experiences of 
the program  
- Focus groups with stakeholders to discuss findings and 
finalise programme  
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   Not reported  
Lovell et al. UK GSH 2000 0. Preclinical phase  Not reported  
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primary care  
 
1. Modelling phase  
 
− Quantitative systematic review and meta-regression to 
synthesise available evidence of the effectiveness of 
RCTs with populations suffering from depression  
− Qualitative meta-synthesis to identify key factors that 
may moderate effectiveness  
− Consensus process with experts to interpret the evidence 
and deal with ambiguities. Questions related to the 
number, duration and time period of the intervention, 
how to incorporate and manage issues such as the patient 
being the agent of change and regaining control, the 
delivery mode of the guidance, the health technology, 
and the training and role of health professional 
delivering the intervention 
− Matrix of results to combine results of the three  
− Used matrix for discussion with trial team and derive 
final intervention  
2. Exploratory phase  
 
− Exploratory randomised controlled trial examining: 
fidelity using analysis of taped guided self-help sessions, 
acceptability to patients through semi-structured 
qualitative interviews, preliminary estimation of effect 
size through comparison of outcomes in patients 
receiving intervention and those in usual care 
3. Definitive RCT phase  Not reported 
4. Long-term implantation phase   Not reported  








2000 0. Preclinical phase  
 
Merged with modelling phase  
1. Modelling phase  
 
− Broad ranging iterative literatures review on melanoma, 
with further focus on intervention development to inform 
specific aspects of the final design  
− Steering group (researchers, GPs and hospital specialists 
working patients with melanoma) meetings to identify 
possible intervention models  
− Semi-structured telephone interviews with patients with 
melanoma and GPs about their thoughts on the 
intervention 
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2. Exploratory phase  
 
− Intervention piloted by two GPs (one urban and one 
rural) to assess feasibility and identify problems and 
deficiencies 
− Brief semi-structured interviews with patients who 
underwent the intervention to understand participants’ 
practical experiences and views on how to optimize the 
intervention  
3. Definitive RCT phase  − Funding for large-scale RCT in place 
− Parallel qualitative study to provide more information to 
inform further intervention development if this is 
necessary 
Not reported 
4. Long-term implantation phase   Not reported  











cancer patients  
2000 0. Pre-clinical phase − Selected most robust  tool for risk assessment and best 
guideline by looking at a meta-analysis of trials and 
cohort study 
− Review of historical registry and audit data from the 
centre 
1. Modelling phase - Identification of training needs for staff, planning and 
implementation of training schemes and development of 
transferable competencies and training material  
- Mapping patient pathways and flow  
- Production of key documentation and Standard 
Operating Procedures for the delivery of the service 
2. Exploratory phase  Not reported   
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   - Pathway implemented  
- Audit of new pathway 
Redfern et al. 
(2008) 
 





2000 0. Preclinical phase  
 
− Systematic review to evaluate the effectiveness of 
interventions to improve risk factor management for 
CHD and stroke  
− Statistical analyses of data collected in the stroke register 
to identify local patterns of secondary prevention 
management  
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− Exploratory qualitative interviews to investigate 
patients’ understanding of secondary prevention of 
stroke and experiences of managing risk factors  
− Non-participant observations at two hospital stroke 
outpatient clinics to investigate how prevention advice is 
given and received  
− Content analysis of currently available patient 
information literature addressing secondary prevention 
(data extracted by two researchers using a structured 
matrix) 
1. Modelling phase  
 
− Compiling of 48 key issues arising from pre-clinical 
phase and presentation of key issues to all study 
investigators  
− Discussion by research team to decide which factors 
should be addressed in intervention  
− Presentation of findings to steering group of experts 
(clinicians, researchers, patients and their family) 
− Modification of register data collection tools  
− Testing of new questions on patients and minor 
modification following feedback  
− Development of secondary prevention package. 
Checking by specialist, SMOG test for readability, 
feedback from patients  
2. Exploratory phase  
 
− Pre-trial evaluation of intervention components by 
testing the complete intervention process  
− No randomisation 
− Documentation of all problems encountered 
− Semi-structured interviews with patients and 
professionals following the intervention  
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   Not reported  
Robinson et al. 
(2005) 
UK Intervention to 
facilitate coping 
skills in new 
2000 0. Preclinical phase  
 
- Literature review to identify the needs of carers of 
people with stroke  
- Development of intervention based on CBT model and 
coping theory  
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 carers of stroke 
patients  
1. Modelling phase  
 
− Semi-structured interviews to explore carers’ 
experiences of caring and their views on the proposed 
theoretical intervention  
− Refinement of course following interviews  
2. Exploratory phase  
 
− Feasibility testing of the course 
− Interviews conducted with course participants to explore 
views about content, appropriateness and delivery of the 
course 
− Second feasibility testing of course, completion of 
feedback questionnaires  
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   Not reported  
Smith et al. 
(2012) 
 
UK Intervention to 
reduce time to 
presentation 
with lung cancer 
symptoms  
2008 1a.  Identifying the evidenced base  - Meetings of expert multidisciplinary group 
(psychologists, sociologist, GPs, respiratory physician, 
researcher) to: define the problem of patient behaviour 
leading to late presentation of lung cancer symptoms, 
identify target group, identify behavioural and social 
models from health psychology, map theory and 
evidence on to concrete behaviour change techniques, 
quantify the potential benefit of the intervention  
- Synthesis of identified techniques into a first draft of the 
intervention  
1b.  Identifying/developing theory  
 
Merged with prior phase  
1c.  Modelling the process and 
outcomes 
- Focus groups with GPs, high risk patients and patients 
with lung cancer to comment on the summary of the 
intervention 
- Individual interviews with patients with lung-cancer to 
comment on the summary of the intervention 
- Refinement of intervention based on data from focus 
groups and interviews  
- Meetings with GPs who had agreed to pilot interventions 
to identify potential barriers  
- Coding of manual using 84 behaviour change techniques 




2. Feasibility and piloting  Not reported  
3. Evaluation   Not reported  
4. Implementation  Not reported  








type 2 diabetes 
2000 0. Preclinical phase  
 
- Literature analysis and review of findings from parallel 
studies 
- Needs analysis of patient diabetes educational needs  
- Re-validation of Dutch 20-item type 2 Diabetes Self-
Efficacy Scale in the UK 
1. Modelling phase  
 
- Small uncontrolled trial of the intervention to evaluate 
feasibility, identify appropriate outcome measures for 
future trials and improve components 
2. Exploratory phase  
 
Not reported  
3. Definitive RCT phase  Not reported  
4. Long-term implantation phase   Not reported  
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Appendix XIX: Amendments to published papers following oral examination  
 
• Paper 1, page 64: Add sentence in Methods section stating: ‘The search was completed 
in June 2015.’  
• Paper 2, page 89: Original sentence stating: ‘Questions in Section 2 are scored on a 0-4 
Likert scale, with the possible total score ranging from 0 to 20.’ Correct sentence in 
Methods section stating: ‘Questions in Section 1 are scored on a 0-4 Likert scale, with 
the possible total score ranging from 0 to 20.’ 
• Paper 2, page 92: Original sentence stating: ‘In addition, faecal calprotectin (r = 0.47, P 
< 0.001) and platelets (r = - 0.15, P < 0.03) were significantly associated with QoL.’ 
Correct sentence in Results section stating: ‘In addition, faecal calprotectin (r = - 0.47, P 
< 0.001) and platelets (r = - 0.15, P < 0.03) were significantly associated with QoL.’ 
• Paper 2, page 93: In Table 2, the subheadings should be corrected and presented in the 
order: B (95% CI), P- value, ∆R2. 
• Paper 2, page 95: In Table 3, the subheadings should be corrected and presented in the 
order: B (95% CI), P- value, ∆R2. 
• Paper 2, page 96: Please find below the missing NS data to be added to Table 4, Columns 
2 and 3.  
IBF-F1 (Column 2)  
Distress = 0.14 (-0.01-0.02), p = 0.65 
Stress = 0.05 (-0.05-0.12), p = 0.45 
All-or-nothing = 0.10 (-0.03-0.21), p = 0.14 
Avoidance = 0.02 (-0.10, 0.13), p = 0.75 
 
IBD-F2 (Column 3)  
Female gender = -0.006 (-4.71, 4.08), p = 0.87 
Daytime sleepiness = 0.07 (-0.15, 0.88), p = 0.16 
 
• Paper 4, page 156: In Table 4, the legend should be corrected to p <.05 from p < .005. 
• Paper 4, page 147: In Table 2, percentage of patients with previous surgery in Group 1 
should be corrected to 6.6%.  
• Please find below completed and corrected references. Reference 48 should be deleted 
and substituted with 41 in text.  
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10. Williet, N., Sarter, H., Gower-Rousseau, C., Adrianjafy, C., Olympie, A., Buisson, A., 
Beaugerie, L. and Peyrin-Biroulet, L., 2017. Patient-reported outcomes in a French nationwide 
survey of inflammatory bowel disease patients. Journal of Crohn's and Colitis, 11(2), 165-174. 
12. Casellas, F., Herrera-de Guise, C., Robles, V., Navarro, E. and Borruel, N., 2017. Patient 
preferences for inflammatory bowel disease treatment objectives. Digestive and Liver 
Disease, 49(2),152-156. 
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coexistent psychopathology have significant impact on fatigue burden in patients with 
inflammatory bowel disease. Journal of Clinical Gastroenterology, 52(5), 423-430. 
39. McNelly, A.S., Nathan, I., Monti, M., Grimble, G.K., Norton, C., Bredin, F., Czuber-Dochan, 
W.J., Berliner, S., Gay, M.A., Darvell, M. and Terry, H., 2016. The effect of increasing physical 
activity and/or omega-3 supplementation on fatigue in inflammatory bowel 
disease. Gastrointestinal Nursing, 14(8), 39-50. 
41. Szigethy, E., Mcauliff, K., Strassburger, M., 2016. Brief behavioral therapy and bupropion 
for sleep and fatigue in adolescents and young adults with inflammatory bowel disease. Journal 
of the American Academy of Child and Adolescent Psychiatry, 55(10), S210 
49. Czuber-Dochan, W.J., 2016. Exploring fatigue in Inflammatory Bowel Disease as 
experienced by individuals: a descriptive phenomenological study (Doctoral dissertation, King's 
College London). 
50. Artom, M., Czuber-Dochan, W., Sturt, J. and Norton, C., 2016. Targets for health 
interventions for inflammatory bowel disease-fatigue. Journal of Crohn's and Colitis, 10(7), 860-
869. 
60. Timmer, A., Preiss, J.C., Motschall, E., R³cker, G., Jantschek, G. and Moser, G., 2011. 
Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database 
Systematic Reviews, (2), CD006913. 
105. Christensen, H., Griffiths, K.M. and Farrer, L., 2009. Adherence in internet interventions for 
anxiety and depression. Journal of Medical Internet Research, 11(2), e13-e13. 
116. Ratnakumaran, R. Warren, L., Gracie, D., Sagar, R., Malin, J., et al., 2018. Fatigue in 
inflammatory bowel disease reflects mood and symptom-reporting behavior rather than 







• Please find below table with effect sizes to be added to Paper 4, page 156 in the last 




Outcome  Group Baseline  3-months follow-up     Change Scores  
  Mean SD  Mean SD N Mean  SD MD (CI) Effect 
size  
IBDF-1 Group 1 
 
11.57 3.60  7.29 3.95 7 -4.29 5.28 
-3.10                               
(-7.10, 0.86)                                 
-0.8  
Group 2 10.64 4.25  9.45 4.55 11 -1.18 2.68  
IBDF-2 Group 1 56.71 32.53  25.71 15.64 7 -31.00 25.72 -26.89                              
(-51.39, -
2.39)*                            
-1.2
Group 2 51.44 33.23 47.33 31.12 9 -4.11 20.08  
IBDQ Group 1 87.60 13.64  95.89 10.58 9 7.33 11.56 
3.33                                        
(-6.21, 12.88)                                          
0.3  
Group 2 91.70 9.80  95.70 10.54 10 4.00 8.04 
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Fatigue is a prevalent concern for patients with IBD, which can have a significant negative impact 
on patients’ quality of life (QoL) (Cohen et al., 2014). Symptoms of fatigue limit patients in their 
everyday lives, both physically, socially and at work (Beck et al., 2013). Accordingly, the 
management of fatigue is an important clinical priority in patients with IBD. Despite the high 
prevalence of fatigue, the causes of fatigue in IBD are not well understood by either patients 
(Czuber-Dochan et al., 2013b) or health-care professionals (HCPs) (Czuber-Dochan, 2014b); and 
this far only four non-pharmacological interventions (Vogelaar et al., 2011, 2014, McNelly et al., 
2016, Artom et al., 2017) have been targeted for this problem.  
 
While proving excellent prevalence data, the dominance of cross-sectional, population-based 
studies has limited the exploration of the pathogenesis of fatigue in the IBD clinical population 
(Artom et al., 2016a). To date, only three studies (Banovic et al., 2010, Graff et al., 2013, Van 
Langenberg et al., 2014) have looked at longitudinal predictors over time. One study (Graff et al., 
2013), found that higher disease activity, emotional distress, lower psychological well-being and 
poor sleep quality predicted an increase in fatigue over 24 months. Additionally, looking at factors 
improving fatigue in Crohn’s disease over time, Van Langenberg and colleagues (2014) reported 
that reduction in depression and commencement of a regular exercise programme led to 
improvements in physical fatigue. Older age, improvement is sleep quality and cessation of 
immunomodulator therapy were associated with improvements in cognitive fatigue.  
 
A cross-sectional study by our research team (Artom et al., 2016b) found that emotional, cognitive 
and behavioural factors were associated with fatigue and QoL above and beyond the influence of 
sociodemographic and clinical factors. Negative fatigue perceptions were significantly associated 
with severity of fatigue. Negative fatigue perceptions, all-or-nothing and avoidance behaviours 
were significantly associated with impact of fatigue. However, the direction of association 
between these factors is still unclear, as are the exact mechanisms of interplay over time. To 
develop and test treatment models specific to this population, it is therefore important to view 
fatigue within a biopsychosocial model of care and consider how different clinical, 
sociodemographic and psychosocial factors interact with each other to predict IBD-fatigue. The 
aim of current the study was thus to determine the longitudinal course of fatigue in IBD and the 





Study design and population  
The study followed a 12-months longitudinal design assessing clinical, socio-demographic and 
psychosocial predictors of fatigue. Participants were recruited between September 2015 and 
March 2016 from the IBD services (out-patient clinics and biologic infusion units) at three tertiary 
referral hospitals in London. Patients with a documented diagnosis of IBD, aged 18 and over, 
with sufficient command of written and spoken English to complete self-report questionnaires 
were considered eligible for inclusion. Exclusion criteria were known cognitive impairment, 
currently on intravenous iron therapy, pregnancy or childbirth within the last 6 months. The 
baseline data from the study are reported in Paper 2. All participants recruited at baseline were 
sent follow-up questionnaires 12-months after baseline response. Questionnaires were sent via 
postal mail with a prepaid envelope and patients were asked to return the completed 
questionnaires to the research team within 7 days from the day of receipt. Non-responders to the 
follow-up questionnaire were sent a reminder letter via postal mail at 4 weeks after the surveys 
were disseminated.  
 
Sociodemographic, clinical and psychological data collection 
Sociodemographic, clinical and psychological data collection were the same as the baseline study 
and are presented in Paper 2.  
 
Ethical considerations  
The study was approved by the United Kingdom National Research Ethics Service – London 
Bridge Committee (15/LO/1081). At baseline, eligible patients were provided with a Patient 
Information Sheet explaining the nature and the aims of the study. Signed informed consent was 
returned with the study questionnaire by post. Following completion of the consent form at 
baseline, continued consent for the study was implied by the return of the completed 
questionnaires at follow-up.  
 
Statistical methods  
Statistical analyses were performed using SPSS version 22. Factors associated with the outcomes 
in univariate analysis at baseline were included in multivariate regression analyses to identify 
independent predictors of fatigue at 12-months follow-up. Multiple imputation was not used to 
address missing data and multivariate analysis at 12-months follow-up was conducted on 
complete cases only. Variables were entered in two regression models (IBD-F1 and IBD-F2) 
using a two-block variable entry method hierarchical method. Block 1 was adjusted for 
sociodemographic and clinical predictors of the outcome variable (fatigue at 12-months follow-
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up); in block 2, psychosocial variables were added (i.e. adjusted for block 1, sociodemographic 
and demographic variables). 
 
Results 
A total of n = 414 patients were approached at baseline for inclusion in the study. Of these 182 
patients provided informed consent and returned the completed questionnaires via post (44% 
response rate). Of these 182, 100 responded at 12-months after one reminder (54.9% response 
rate). Fifty-one percent were female, 49.5% worked full-time and their median age was 44.5 years 
(range 20-83 years). The majority (64.2%) of participants had CD. Of the 62.4% of patients taking 
medication, 42% were on biologic medication (anti-TNFs or vedolizumab), and one participant 
had a stoma. 
 
Factors associated with severity of fatigue (IBD-F1) 
Significant factors in univariate analyses in respect to severity of fatigue at baseline (p <0.10) 
were examined in a two-block regression model for the IBD-F1 at 12-months follow-up (Table 
1). Female gender, divorced/widowed marital status and baseline disease activity significantly 
predicted fatigue at 12-months follow-up, explaining 17% of the variance in severity of fatigue 
scores. The emotional, cognitive and behavioural variables that were added in the second block 
explained 24% of the variance in fatigue severity scores at 12-months follow-up. However, they 
did not significantly improve the predictive validity of the model, Finc (13, 52) = 1.46, p = 0.16. 
More negative fatigue perceptions significantly predicted greater IBD-F1 scores at 12-months 
follow-up. After adjusting for psychosocial variables, divorced/widowed marital status (b = 0.29, 
p = 0.02) and baseline disease activity still significantly predicted greater IBD-F1 scores at 12-
months follow-up. Female gender (b = 0.21, p = -0.10) was no longer significant.   
 
Factors associated with impact of fatigue (IBD-F2) in individuals’ lives 
Significant factors in univariate analyses in respect to impact of fatigue at baseline (p <0.10) were 
examined in a two-block regression model for the IBD-F2 (Table 2). Education up to 18 
negatively predicted impact of fatigue, where patients with higher levels of education had 
significantly lower levels of fatigue impact at 12-months follow up (p = 0.03). Baseline 
sociodemographic and clinical variables explained 10% of the variance in impact of fatigue scores 
at 12-months follow-up. The emotional, cognitive and behavioural variables that were added in 
the second block explained 12% of the variance in impact of fatigue scores at 12-months follow-
up, not significantly improving the predictive validity of the model Finc (13, 50) = 1.60, p = 0.12. 
None of the emotional, cognitive and behavioural variables added in the second block 
significantly predicted impact of fatigue at 12-months follow-up (p> 0.05).  
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Table 1: Hierarchical regression of sociodemographic, clinical and psychosocial baseline and 





























Figures in bold are statistically significant at p < 0.01; IBD-F1 Fatigue severity 
Key: ΔR2 - Adjusted R Square; Anti-TNF- anti-tumour necrosis factor; ASA- aminosalicylates; CI – confidence interval; IBD-F – 





 Baseline IBD-F1  12-months IBD-F1 
 B(95% CI) 
P-
value 




STEP 1   .21    .17 
Sociodemographic        
 Education to 16   0.62 (-1.90, 3.13)  0.63   -0.03 (-3.80, 3.05) 0.82  
 Education to 18    1.67 (-0.45, 3.80) 0.12   -0.20 (-5.40, 0.44)  0.09  
 Retired  -1.83 (-4.48, 0.82)  0.17   -0.01 (-3.32, 2.98) 0.91  
 Not working   1.22 (-0.72, 3.15)  0.22   -0.1 (-5.27, 0.83) 0.15  
 Female gender   1.61 (0.15, 3.07)  0.03   0.26 (0.25, 4.60) 0.03  
 Single/S parent  -0.44 (-2.00, 1.12)  0.58   0.01 (-9.65, 10.67) 0.92  
 Divorced/Widowed  0.75 (-3.57, 5.07)  0.73   0.25 (0.62, 11.39) 0.03  
Clinical         
 Disease activity   0.27 (0.07, 0.46)  0.01   0.28 (0.04, 0.73) 0.03  
 Exercise <30 minutes  0.66 (-0.84, 2,16) 0.38   -0.12 (-3.26, 0.94) 0.27  
 Smoking current  0.36 (-2.86, 3.58)  0.82   0.02 (-4.12, 4.89) 0.86  
 Smoking ex 0.21 (-1.50, 1.91)  0.81   0.03 (-1.97, 2.47) 0.82  
 Thiopurines  -1.17 (-2.60, 0.27) 0.11   0.14 (-0.96, 3.63) 0.25  
STEP 2      .54    .24 
Emotional         
 Anxiety  0.04 (-0.17, 2.56) 0.68   0.08 (-0.33, 0.52) 0.66  
 Depression -0.09 (-0.32, 0.14) 0.44   -0.04 (-0.60, 0.46) 0.79  
 Distress  0.01 (-0.01, 0.01)  0.67   -0.10 (-0.03, 0.02) 0.57  
 Stress -0.06 (-07, 0.19)  0.39    -0.10 (-0.03, 0.02) 0.54  
Cognitive         
Negative fatigue 
perceptions 
 0.28 (0.20, 0.36)  <0.001   0.43 (0.08, 0.39)  0.01  
 Catastrophising  0.01 (-0.19, 0.21)  0.92   0.14 (-0.18, 0.54) 0.32  
 Damage beliefs  0.08 (-0.11, 0.26)  0.40   0.09 (-0.27, 0.49) 0.57  
 Embarrassment  -0.08 (-0.22, 0.05)  0.20    -0.04 (-0.32, 0.25) 0.80  
 Fear avoidance -0.07 (-0.21, 0.08)  0.37    -0.03 (-0.31, 0.24) 0.82  
 Symptom focus  0.08 (-0.08, 0.25)  0.34   0.20 (-0.17, 0.57) 0.28  
Behavioural         
All-or-nothing  0.07 (-0.07, 0.22)  0.31   -0.08 (-0.42, 0.23) 0.57  
 Avoidance  0.11 (-0.05, 0.26)  0.17    0.11 (-0.41, 0.21) 0.52  
 Daytime sleepiness 0.14 (0.01, 0.28)  0.04   0.05 (-0.24, 0.35) 0.73  
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Table 2: Hierarchical regression of sociodemographic, clinical and psychosocial baseline and 































Figures in bold are statistically significant at p < 0.01; IBD-F2 Fatigue impact on daily activities  
Key: ΔR2 - Adjusted R Square; Anti-TNF- anti-tumour necrosis factor; ASA- aminosalicylates; CI – confidence interval; IBD-F – 
Inflammatory Bowel Disease-Fatigue Scale 
 
Discussion  
The current study aimed to investigate factors predicting severity and impact of fatigue in patients 
with IBD. Specifically, it investigated whether modifiable emotional, cognitive and behaviour 
 Baseline IBD-F2  12-months IBD-F2 
 B(95% CI) 
P-
value 
ΔR2  B(95% CI) P-value  ΔR2 
STEP 1   .32    .01 
Sociodemographic        
 Education to 16 -3.95 (-17.64, 9.74) 0.57   0.12 (-10.15, 25.82) 0.39  
 Education to 18   2.36 (-8.73, 13.44) 0.67   -0.29 (-31.47, -1.54) 0.03  
 Retired  -4.33 (-17.57, 8.90)  0.52   -0.03 (-18.08, 14.11) 0.81  
 Not working 12.95 (2.88, 23.01) 0.01   -0.17 (-26.24, 4.68) 0.17  
 Female gender 5.32 (-2.25, 12.88) 0.17   0.01 (-10.87, 11.70) 0.94  
Clinical         
 5-ASA  -2.29 (-10.55, 5.97) 0.58   0.10 (-7.81, 17.25) 0.45  
 Anti-TNF   11.30 (3.53, 19.07) 0.01   0.12 (-5.69, 15.96) 0.35  
 Disease activity   2.17 (1.21, 3.13)  < 
0.001 
  0.14 (-0.81, 2.80) 0.27  
 Exercise <30 
minutes 
1.98 (-6.01, 9.96)  0.62   -0.07 (-14.00, 7.58) 0.55  
 Steroids  12.72 (-1.32, 
26.76)  
0.75   -0.13 (-50.27, 15.94) 0.30  
STEP 2   .73    .12 
Emotional         
 Anxiety -0.45 (-1.35, 0.45)  0.32   0.02 (-2.36, 2.11) 0.91  
 Depression  0.75 (-0.24, 1.74)  0.13   0.13 (-1.5, 3.57) 0.43  
 Distress  0.06 (0.01, 0.11)  0.02   -0.30 (-0.23, 0.04) 0.17  
 Stress  0.65 (0.09, 1.21)  0.03   0.11 (-1.06, 1.94) 0.56  
Cognitive         
Negative fatigue 
perceptions 
 0.55 (0.12, 0.78)  0.01   0.18 (-0.33, 1.26) 0.25  
 Catastrophising  0.49 (-0.36, 1.34)   0.26   0.28 (-0.33, 3.67) 0.10  
 Damage beliefs -0.17 (-0.93, 0.59)  0.65   -0.52 (-2.15, 1.57) 0.75  
 Embarrassment   0.06 (-0.49, 0.62) 0.82   0.18 (-0.73, 2.11) 0.33  
 Fear avoidance  0.13 (-0.49, 0.75)  0.68   0.18 (-0.68, 2.23) 0.29  
 Symptom focus -0.16 (-0.88, 0.55)  0.65   0.05 (-1.72, 2.18) 0.82  
Behavioural         
All-or-nothing   0.86 (0.25, 1.48) 0.01   0.02 (-1.70, 1.91) 0.90  
 Avoidance  
 1.31 (0.65, 1.98) < 
0.001 
  0.04 (-1.69, 1.91) 0.87  
 Daytime sleepiness  0.27 (-0.30, 0.84)  0.35    0.07 (-1.13, 1.85) 0.63  
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factors shown to be associated with fatigue cross-sectionally (Artom et al., 2016b), also predicted 
fatigue longitudinally at 12-months follow-up. The results of the study showed that baseline 
cognitive factors predicted severity of fatigue at 12-months follow-up. Negative fatigue 
perceptions, i.e. feeling of not having control over their fatigue or perceiving fatigue as having 
more negative consequences, at baseline significantly predicted severity of fatigue over time. 
However, no emotional, cognitive or behavioural factors significantly associated with impact of 
fatigue at baseline predicted impact of fatigue at 12-months follow-up.  
 
The main strength of this study was the longitudinal design assessing predictors of fatigue over 
time. Prior cross-sectional studies cannot readily address the direction of relationships between 
fatigue and other disease and psychological factors. However, the findings of the study should be 
considered in light of some limitations. The significant correlations between the psychological 
measures included in the regression models may indicate a cross-validation between overlapping 
measures, further analysis is therefore needed in order to reach more definitive conclusions on 
the fatigue pathways. The moderate sample size at baseline and the additional loss to follow-up 
at 12-months precluded the exploration of differences according to diagnosis type, potentially 
limiting the generalisability of the study. The missing data and the lack of use of multiple 
imputation methods to handle it at follow-up may have affected the robustness of the regression 
models.  
 
The fact that some psychological factors predicted severity of fatigue in IBD over time support 
the utility of approaching fatigue multidimensionally, utilising a biopsychosocial approach. When 
fatigue is evidently related to a flare of IBD or other clinical factors, medical or surgical therapy 
should be the first line of intervention. However, when there is no apparent explanation for 
fatigue, exploring psychosocial factors contributing to the onset and maintenance of fatigue may 
be of value. The study identified novel and potentially modifiable factors associated with fatigue 
in IBD providing future opportunities for further investigation and clinical application. 
Ultimately, further prospective interventional studies testing psychological interventions targeted 
at IBD-fatigue specifically are needed to confirm these findings. 
 
 
